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This thesis outlines a study of the identification and characterisation of antimicrobials from two 
primary sources; the Lactobacillus genus and the microbiome of fish. Through the incorporation of a 
wide variety of techniques, this study successfully demonstrates how a variety of methods can be 
used for the identification and production of novel antimicrobials.  
Chapter 1 gives an overview of the variety of different antimicrobials which can be produced by 
the lactic acid bacteria (LAB) which can play an important role in a number of processes, such as the 
preservation of fermented foods. These antimicrobials can vary from organic acids, such as lactic and 
acetic acid, to antimicrobial peptides known as ‘bacteriocins’.  
Chapter 2 outlines the identification of a novel bacteriocin known as ‘formicin’ through 
traditional colony isolation and screening methods. Formicin was identified from Bacillus 
paralicheniformis APC1576, an antimicrobial producing strain isolated from the intestine of a fish. 
Using a combination of mass spectrometry and genomic screening, formicin was found to be a two-
peptide lantibiotic, displaying antimicrobial activity against a broad range of Gram positive microbes. 
In Chapter 3, through a combination of in silico and lab-based screening of the Lactobacillus 
pangenome, it was possible to determine the extent and diversity of bacteriocins encoded and 
produced by the genus. This study shows that bacteriocin production may not be as prevalent as 
previously believed, however of the bacteriocins which were identified from within the genomes, 
many were found to be novel. By screening the strains identified as harbouring bacteriocin-related 
genes, five novel active bacteriocins were identified. 
Many strains of lactobacilli were found to encode bacteriocins, however upon analysis, these 
failed to display in vitro antimicrobial activity. Often the regulation of bacteriocin operons, or the 
loss of key bacteriocin-associated genes, results in the failure of these strains to produce 




particular class of bacteriocins, the Class IIa ‘pediocin-like’ bacteriocins. Here, using an expression 
designed for Class IIa bacteriocins, it was possible to produce eight novel bacteriocins identified from 
genomic data.  
In Chapter 5 shotgun metagenomic sequencing is used to characterise the compositional and 
functional properties of the intestinal microbiome of deep sea fish. Here it can be seen how bacteria 
have adapted to live in this environment by encoding systems to relieve the stress associated with 
life at higher pressures. The study also outlines the diversity of the potential antimicrobials which 
may be produced within the microbiome of such fish whilst also highlighting an apparent lack of 
genes associated with known mechanisms of antibiotic resistance.  
Overall, the results of this work demonstrate the effectiveness of a variety of methods for 
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The antimicrobial activity of lactic acid bacteria (LAB) has been utilised throughout 
recent human history. The fermentation of foods is an ancient method of preservation and 
often relies on the production of antimicrobials from bacteria such as LAB to inhibit the 
growth of spoilage microbes and pathogenic strains. Such antimicrobials include 
bacteriocins, organic acids, hydrogen peroxide and ethanol; these can be particularly useful 
for industrial use due to their potent activity and low toxicity. As consumers move away 
from the use of synthetic preservatives and food treatments, bacteriocins and organic acids 
represent obvious natural alternatives for food preservation. Similarly in the medical field 
where antibiotic resistant superbugs are becoming an increasing concern, antimicrobials 
from LAB represent potentially novel treatments for infections where classical antibiotics 
may no longer be effective in the future. This chapter will outline the different 
antimicrobials produced by LAB and discuss their potential applications in the food 






Lactic acid bacteria (LAB) are a non-sporulating group of Gram-positive bacteria found in 
environments ranging from food to the GI tract. LAB have been utilised for millennia due to 
their ability to preserve food and are key to the production of many fermented foods such 
as yoghurt, cheese, sourdough bread, fermented vegetables such as sauerkraut and 
fermented meats. The metabolites produced by the LAB from the breakdown of the original 
substrate (i.e. milk, meat or vegetable carbohydrates and proteins) both may alter the 
properties of the product whilst potentially inhibiting the growth of competing spoilage 
microbes (Ross et al., 2002). A range of antimicrobial metabolites can be produced by LAB 
(Figure 1), primarily in the form of organic acids such as lactic acid, which acidifies the 
product thus inhibiting the growth of competing microbes (Peréz-Dıaz et al., 2013). Many 
LAB have also been shown to produce antimicrobial peptides known as bacteriocins which 
target and kill sensitive competing microbes .  
The World Health Organization (WHO) estimated that 600 million food-borne illnesses 
occurred in 2010, leading to an estimated 420,000 deaths (World Health Organization 
(2015)). The implementation of systems to improve food safety is of high importance. 
Antimicrobials produced by LAB have been shown to inhibit a wide range of food spoilage 
bacteria and the addition of bacteriocins such as nisin to food can effectively reduce the 
levels of pathogens in a variety of products (O’Sullivan et al., 2002). 
Another major issue is the escalating crisis of antimicrobial resistant pathogens, already 
a cause of an estimated 700,000 deaths per year, a figure predicted to rise to 10 million 
deaths per year by 2050 (O’Neill, 2014). Coupled with this is a paucity of new antibiotics to 




LAB show potential for applications in the medical sector, with many shown to effectively 
inhibit multi-drug resistant strains (Okuda et al., 2013). Whilst much research has focused 
on the use of these antimicrobials in food, further work needs to be done to realise their 
potential in medicine (Cotter et al., 2013). This chapter reviews the range of antimicrobials 
produced by LAB, outlining their potential applications in industrial and medical settings. 
Bacteriocins 
Bacteriocins are heat stable antimicrobial peptides produced by bacterial cells and, 
unlike traditional antibiotics, are gene-encoded and ribosomally synthesised. The 
antimicrobial spectrum of these bacteriocins can vary, ranging from broad spectrum 
targeting a wide range of bacterial species to narrow spectrum inhibiting only closely related 
bacterial specie. LAB are recognised as prominent bacteriocin producers (Zacharof and 
Lovitt, 2012). Whilst a wide variety of bacteriocins exist, a common genetic architecture is 
found in many of the associated gene clusters. The structural gene in bacteriocin operons 
encodes the active peptide, this usually contains an N-terminal leader sequence with 
important functions during bacteriocin production. When translated within the cell the 
leader sequence reduces or abolishes the antimicrobial activity of the bacteriocin, 
preventing the cell from being killed by its own antimicrobial. In certain bacteriocins the 
leader can also be recognized by modification enzymes which can then direct the post 
translational modification of the active bacteriocin peptide. The leader is also crucial for 
bacteriocin secretion whereby dedicated ATP-binding cassette (ABC) bacteriocin 
transporters recognize the leader sequence and cleave it at a specific motif (i.e Gly-Gly) as it 
is being exported from the cell, thus releasing an active bacteriocin (Oman and van der 




operon, which can consist of single or multiple ABC transporters. These transporters also 
often include protease domains for cleavage of the bacteriocin signal sequence (Havarstein 
et al., 1995). Some bacteriocin have been shown to be secreted via the Sec translocase 
system (Herranz and Driessen, 2005). Bacteriocin operons also encode genes encoding 
immunity proteins which prevent the strains being killed by their own bacteriocins (Draper 
et al., 2012). Bacteriocin production can also be under tight regulation in producer cells due 
to the presence of a two component regulatory system within the operon which has an 
important role in quorum sensing (Rohde and Quadri, 2006, van der Ploeg, 2005). Certain 
bacteriocins also have key genes encoding modification and accessory proteins; however 
the presence of these depends on the class of bacteriocin. 
LAB produce a wide variety of different bacteriocins which can be grouped into classes 
based on their structure, genetics and mode of action (Table 1). Many classification systems 
for bacteriocins have been proposed, but we will follow the system outlined by Cotter et al. 








Class I bacteriocins undergo enzymatic post translational modification. Such 
modifications have important structural and functional roles for these bacteriocins. Class I 
bacteriocins can be further broken down into subclasses based on how the peptides are 
modified. For this chapter we will only discuss the classes which contain LAB derived 
bacteriocins.  
Lantibiotics 
The lantibiotics are the largest group of modified bacteriocins, and are produced by a 
range of LAB. These bacteriocins are termed lantibiotics due to the presence of lanthionine 
and methyllanthionine bridges within the peptides. Serine and threonine residues can be 
dehydrated to form 2,3-didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb). Dha 
and Dhb can then react with the thiol group on cysteine resides within the peptide, forming 
internal thiother crosslinks known as lanthionine and methyllanthionine bridges, 
respectively (Willey and van der Donk, 2007). These dehydration and cyclisation reactions 
are catalysed by modification enzymes encoded within the bacteriocin operon. These 
modifications can be carried out by two separate enzymes (LanB and LanC) in type 1 
lantibiotics, or a single enzyme (LanM) in type 2 lantibiotics (Marsh et al., 2010). Type 3 and 
4 lantibiotics also exist but these are much less common. 
Nisin is a type I lantibiotic produced by strains of Lactococcus lactis and represents one 
of the more well-known and commercialised bacteriocins. Nisin is a 34 amino acid 
lantibiotic, containing 5 (methyl)lanthionine ring structures along with three dehydrated 
residues (two Dha and one Dhb) (Hooven et al., 1996). Nisin interacts with lipid II in sensitive 




the linear C-terminal tail of nisin inserts into the bacterial membrane which results in the 
formation of a pore complex. This pore causes leakage of cytoplasmic material from the 
bacterial cell which leads to cell death (‘t Hart et al., 2015).  
TOMMs 
The thiazole/oxazole-modified microcins (TOMMs) are another member of the class I 
post-translationally modified bacteriocins. TOMMs all contain heterocycles derived from 
cysteine, serine, and threonine residues (Cox et al., 2015). Linear azol(in)e-containing 
peptides (LAPs) are a group of TOMMs produced by LAB. Streptolysin S from Streptococcus 
pyogenes is one such LAP however, unlike typical bacteriocins, it is a potent cytolytic toxin 
and virulence factor. Streptolysin modification is carried out by a complex of three key 
enzymes encoded within the operon. SagC is a cyclodehydratase which then removes 
hydrogens from these modified amino acids resulting in the formation of thiazoline, 
oxazoline and methyloxazoline rings. SagB is a dehydrogenase which coverts the thiazoline 
and (methyl)-oxazoline residues into thiazole, oxazole and methyloxazole heterocycles, 
respectively. SagC is a cyclodehydratase which then removes hydrogens from these 
modified amino acids resulting in the formation of thiazoline, oxazoline and methyloxazoline 
rings. A third protein, SagD, aids in the formation of the SagBCD complex (Lee et al., 2008). 
Despite a lack of characterised LAPs from other LAB, operons have been found in some 
Lactobacillus, Lactococcus and Oenococcus strains (Collins et al., 2017, Alvarez-Sieiro et al., 
2016).   
Thiopeptides are another family of TOMM bacteriocins, in addition to azoline and azole 
residues these can also contain Dha and Dhb residues due to the dehydration of Ser and Thr 




2013). In a recent in silico screen of the human microbiome metagenomic data a novel 
thiopeptide called ‘lactocillin’ was identified and characterised from a Lb. gasseri strain. This 
is active against a range of pathogens and represents a potential novel antimicrobial 
compound for the treatment of vaginal infections (Donia et al., 2014). 
Glycocins 
The glycocins are a family of post-translationally modified bacteriocins characterised by 
the glycosolation of amino acid residues on the peptide. The glycocins are a relatively small 
family of bacteriocins; however several have been isolated from LAB. Glycocin F is a 43 
amino acid bacteriocin produced by Lb. plantarum KW30 (Norris and Patchett, 2016) and is 
one of the more studied of these bacteriocins. It is composed of two α-helices held together 
by two disulphide bonds followed by a C-terminal tail. The peptide contains two β-linked N-
acetylglucosamine moieties attached to the oxygen and sulphur residues on Ser18 and 
Cys43 respectively, this S-glycosolation on the Cys residue is very rare (Venugopal et al., 
2011, Brimble et al., 2015).  
Class II 
Class II bacteriocins differ from class I in the fact they do not undergo extensive post-
translational modification. These bacteriocins are further classified based on their 
composition and structure. 
Class IIa  
The class IIa or ‘pediocin-like’ bacteriocins are single unmodified peptides with 
characteristic anti-listerial activity. These bacteriocins all contain a highly conserved N-




disulphide bridge, the peptides contain a less conserved hydrophobic C-terminus. An 
accessory protein encoded within the bacteriocin operon ensures correct disulphide bond 
formation and peptide folding (Oppegard et al., 2015). These peptides work by initially 
binding to the cell using the extracellular loop of the mannose phosphotransferase sugar 
uptake system as a receptor (Kjos et al., 2010). Once bound to the cell, the more 
hydrophobic C-terminus penetrates the cell membrane where it then forms a pore complex, 
thus causing leakage from the cell and eventual cell death (Papagianni and Anastasiadou, 
2009).  
Class IIb 
The class IIb bacteriocins are two-peptide unmodified bacteriocins where both peptides 
are generally required in equal amounts for optimum antimicrobial activity. These 
bacteriocins are typically encoded by adjacent genes in the bacteriocin operon.(Nissen-
Meyer et al., 2011). Despite being composed of two quite different peptides, these 
bacteriocins interact to act as a single antimicrobial entity. Most of these two-peptide 
bacteriocins contain GxxxG motifs which are involved in helix-helix interactions; this may 
allow the two peptides to interact and form a single functional unit (Fimland et al., 2008, 
Nissen-Meyer et al., 2010). These permeabilize the membrane of sensitive target cells to 
small molecules which results in cell death (Nissen-Meyer et al., 2010). Many of the class IIb 
bacteriocins which have been identified are produced by LAB, and appear to be the most 
prevalent type of bacteriocins encoded by lactobacilli (Collins et al., 2017) 
Class IIc 
Class IIc bacteriocins are circular peptides, linked by N-terminal to C-terminal covalent 




these peptides and helps confer resistance to proteolytic enzymes. These bacteriocins act by 
inducing ion permeation in the membrane of sensitive cells resulting in a loss in membrane 
potential and cell death (Hemu et al., 2016, Gálvez et al., 1991). Many of the class IIc 
bacteriocins which have been discovered are produced by LAB. The mechanism of peptide 
circularisation is still unclear and the enzymes involved have yet to be identified. 
Class IId 
The class IId bacteriocins are a group of single peptide, non-pediocin like bacteriocins. 
They bear no homology to pediocin-like bacteriocins and are not modified, acting as a 
heterogeneous group of peptides which don’t fit in other classes. Many diverse bacteriocins 
from LAB are found within this class. Bactofencin is one such bacteriocin, it is a small 
unmodified cationic bacteriocin produced by Lb. salivarius DPC6502 (O'Shea et al., 2013). 
One interesting subgroup of these bacteriocins is a group displaying homology to the 
bacteriocin lactococcin 972. Lactococcin 972 is bacteriocin produced by Lc. lactis subsp. 
lactis IPLA 972 and acts as a homodimer. This is a growing group of bacteriocins, several of 
which are encoded by LAB, with a unique mode of action and may warrant separate 
classification in the future (Collins et al., 2017, Letzel et al., 2014).  
Bacteriolysins (Formerly Class III Bacteriocins) 
Bacteriolysins are large heat sensitive antimicrobial proteins and due to their size and 
structure these proteins they are no longer considered bacteriocins. Several such peptides 
have been shown to be produced by LAB, such as enterolysin A (Nilsen et al., 2003), zoocin A 
(Heath et al., 2004), millericin B (Beukes et al., 2000) and helveticin J (Joerger and 
Klaenhammer, 1990). Bacteriolysins work by degrading the cell wall of sensitive cells. The N-




degrading enzymes, the C-terminus then contains a potential cell wall binding domain 
(Nilsen et al., 2003, Heath et al., 2004).  
Bacteriocin Applications 
The antimicrobial activity of bacteriocins coupled with their low toxicity makes them 
attractive compounds for industry and the fact that they are naturally produced by GRAS 
organisms may also render them more acceptable to health conscious consumers. A limited 
number of bacteriocins are already in use in the food industry such as  nisin (Younes et al., 
2017) and carnocyclin A which is marketed as Micocin® (Liu et al., 2014). However, the 
potential exists to widen the scope of applications, particularly as antimicrobials in the 
medical field (Cotter et al., 2013). Indeed, research into bacteriocin applications is 
increasing: the granting of bacteriocin-related patents increased by 66% between 2010-
2015 compared to the previous five years, covering a range of applications from biomedical 
research to nanotechnology (López-Cuellar et al., 2016).   
Food Preservation and Safety 
The use of bacteriocins in the food industry has primarily focused on food 
biopreservation and safety. Bacteriocins offer a natural alternative to the addition of 
chemical preservatives to food and have been shown to improve the flavour of certain 
fermented foods (Younes et al., 2017, O'Sullivan et al., 2002). Due to the peptide nature of 
bacteriocins they are generally digested in the gut upon ingestion, thus eliminating potential 





Bacteriocins themselves are used in food manufacture in at least three ways (Figure 2), 
the first of which is the addition of partially purified bacteriocins to the food product 
(Chikindas et al., 2018). Nisaplin® (Danisco), a dried powder containing 1.82% nisin is one 
such product (Gough et al., 2017). Nisin was awarded generally regarded as safe (GRAS) 
status by the FDA in 1988 and has been approved by the World Health Organization as a 
food additive and was also assigned the E number E234 (Younes et al., 2017). Nisin is one of 
the most commonly used bacteriocin food preservatives, its broad spectrum of activity, heat 
stability and history of effectiveness making it an attractive option for the food industry. The 
addition of Nisaplin® to cottage cheese was shown to effectively control levels of Listeria 
monocytogenes (Ferreira and Lund, 1996). Nisaplin® was also shown to immediately reduce 
L. monocytogenes levels by 3 log CFU/g in queso fresco, a non-fermented cheese (Lourenço 
et al., 2017).  
The second method by which bacteriocins may be added to food is as crude fermentates 
containing the active bacteriocins. One such example is ALTA® 2351 (Kerry Bioscience) a 
pediocin containing fermentate which has been shown to reduce L. monocytogenes 
numbers in raw sausage batter over 60 days (Knipe and Rust, 2009). Another popular 
example is microGARDTM (Danisco), a product of the fermentation of skimmed milk by LAB. 
This is extensively used in industry and has been shown to inhibit the spoilage of dairy 
products such as cottage cheese and yoghurt (Makhal et al., 2015, Salih et al., 1990).   
The third approach is to use bacteriocin-producing strains as starter or protective 
cultures in fermented foods. One advantage of this is that in situ production of bacteriocins 
by starter cultures reduces the need for the addition of external preservatives. The use of 




variety of foods such as fish (Gómez-Sala et al., 2016), meat (Diaz-Ruiz et al., 2012), 
vegetables (Settanni and Corsetti, 2008) and dairy products (Mills et al., 2017). One such 
example is the use of the nisin producer Lc. lactis subsp. lactis IFO12007 in the production of 
miso, a fermented soybean paste. The strain was used as a starter culture and was shown to 
inhibit the growth of Bacillus subtilis, even when this spoilage bacteria is inoculated at a 
concentration of 106 cells/g (Kato et al., 1999). The combination of a nisin and lacticin 3147 
producing Lc. lactis strain with a plantaricin producing Lb. plantarum strain served as a 
protective culture in cheese production causing a reduction of Listeria numbers to 0.3 log 
CFU/g compared to 2.9 log CFU/g in the non-bacteriocin producing control (Mills et al., 
2017). This study highlighted how bacteriocin-producing cultures can be used to stack 
bacteriocins in a food system thus creating multiple antimicrobial hurdles. 
Bacteriocins are useful as part of a hurdle technology in combination with other 
methods for food preservation (Hsiao et al., 2016). The use of other compounds and 
treatments together with the addition of bacteriocins may also lead to synergistic 
antimicrobial activity. Organic acids for example can help increase the net charge of 
bacteriocins at low pH, thus aiding in bacteriocin translocation through the cell wall. This 
potential interaction is particularly useful in LAB which often produce these acids and 
bacteriocins concurrently (Mills et al., 2011). The role of organic acids as antimicrobials will 
be discussed later in this chapter. The use of outer membrane permeabilizing agents such as 
EDTA can also extend the range of activity of these bacteriocins to include Gram-negative 
bacteria such as E. coli O157:H7 in food (Ananou et al., 2005). The combination of lacticin 




to inhibit the growth of pathogenic Cronobacter species up to 12 hours after rehydration of 
the milk formula (Oshima et al., 2012).  
Packaging and materials 
Another potential use for bacteriocins is their incorporation into packaging and other 
materials such as nanofibers. In cases where food comes into contact with the antimicrobial 
packaging, bacteriocins diffuse from the packaging thus inhibiting the growth of surface 
microorganisms. The antimicrobial packaging thus serves as an extra hurdle in food 
processing to improve safety, prevent food spoilage and extend product shelf life. The 
incorporation of bacteriocins into packaging can have advantages over direct bacteriocin 
addition to food through the reduction of non-specific binding of the bacteriocins to food 
components rather than the targeted bacterial strains, and by reducing the risk of 
bacteriocin degradation and inactivation in the food matrix (Laridi et al., 2003).  
There are several ways in which bacteriocins can be incorporated into such materials. 
Bacteriocins can be simply coated or absorbed onto a polymer or incorporated directly into 
the polymer matrix for packaging (Deshmukh and Thorat, 2013). Numerous studies on a 
range of foods have shown the effectiveness of nisin incorporated into food packaging (Irkin 
and Esmer, 2015). For example, the use of packaging containing immobilised nisin was 
shown to reduce Listeria innocua and Staphylococcus aureus levels as well as those of other 
microbes in sliced cheese and ham in modified atmosphere packaging, thus improving shelf 
life (Scannell et al., 2000). 




Probiotics are defined as live microorganisms, which when consumed in adequate 
amounts, confer a health benefit on the host (Pineiro and Stanton, 2007).Bacteriocin 
production can be considered an important probiotic trait due to the potential of such 
strains to inhibit pathogenic bacteria in the GI tract (Dobson et al., 2012). An example of this 
was demonstrated by Corr et al. who showed that the bacteriocin-producing Lactobacillus 
salivarius UCC118 strain displayed the ability to protect mice against infection with L. 
monocytogenes whilst a non-bacteriocin-producing mutant failed to show the same effect 
(Corr et al., 2007). Millette et al. also demonstrated that the nisin Z producing Lc. 
lactis MM19 and pediocin PA-1 producing P. acidilactici MM33 reduced vancomycin-
resistant enterococci (VRE) in infected mice (Millette et al., 2008). Bacteriocins may also 
help strains establish themselves in a complex environment by helping them out-compete 
the resident microbiota in a particular niche (Dobson et al., 2012). The production of the 
bacteriocins blpMN by Str. pneumoniae was shown to aid the establishment of the strain in 
the mouse nasopharynx (Dawid et al., 2007). The administration of an E. faecalis strain 
harbouring the bacteriocin 21 encoding plasmid pPD1 was able to colonize and outcompete 
VRE lacking pPD-1in infected mice, thus indicating the role bacteriocin production may play 
in the establishment producing strains in the host (Kommineni et al., 2015). Bacteriocins 
may also act as useful signalling peptides between the bacteria themselves and also with 
the host. The production of plantaricins by Lb. plantarum WCFS1 for example was shown to 
be linked to a change in the levels of the cytokines interleukin 10 and 12 from peripheral 
blood mononuclear cells which may offer protection against colitis (van Hemert et al., 2010, 
Foligne et al., 2007). The benefits of bacteriocin production in probiotic LAB however is 
influenced by the producers ability to actively establish itself and produce bacteriocins in 




acidilactici UL5 for example failed to establish itself in the mouse intestinal microbiota as 
the strain was not detectable in faecal samples two days after administration. This 
Pediococcus strain was originally isolated from fermented sausage and therefore may simply 
not have been well adapted to survive and establish in the GI tract of the host (Dabour et 
al., 2009).  
 
Medical applications of bacteriocins 
With the increasing prevalence of antibiotic resistant pathogens, bacteriocins represent 
a potential novel treatment for the control of these pathogens due to their potency and low 
toxicity. Much of the work which has been done in this field has involved the use of animal 
models, thus more clinical human research must be completed to determine the actual 
efficacy of bacteriocins in clinical applications. Nonetheless, the results of trials using model 
systems are promising. Intravenous injections of nisin, for example, was shown to be more 
effective than vancomycin treatment in Str. pneumoniae infected mouse models (Goldstein 
et al., 1998). Due to its inhibitory activity against Helicobacter pylori nisin can be used in the 
treatment of peptic ulcers and has been commercialized for treatments of gastric 
Helicobacter infections (Dicks et al., 2011). The stability and activity of nisin at low pH makes 
this a potentially useful antimicrobial for the treatment of this gut pathogen. The narrow 
spectrum of inhibition of pediocin-like bacteriocins could also be useful in the treatment of 
listeriosis which is extremely dangerous to pregnant women and immunocompromised 
individuals. Intra-gastric administration of pediocin PA-1 in mice was shown to reduce 
Listeria levels and slow pathogen translocation to other organs whilst having no effect on 




Bacteriocins can also be used in oral and respiratory health, for example a nisin-
containing mouthwash was found to reduce gingivitis in beagle dogs (Howell et al., 1993). 
Nisin F was also shown to be effective against S. aureus infections in the respiratory tracts of 
immunosuppressed rats, a remedy which could be beneficial in the treatment of respiratory 
diseases in immunocompromised and cystic fibrosis patients (De Kwaadsteniet et al., 2009). 
Bacteriocins also have potentially useful roles in skin care by modulating the skin 
microbiome and inhibiting pathogens. The bacteriocins ESL5 produced by E. faecalsi SL-5 
displayed antimicrobial activity against Propionibacterium acnes, a key factor in the 
pathogenesis of acne vulgaris. The incorporation of the concentrated bacteriocin into a 
topical lotion was shown to significantly reduce inflammatory lesions in treated patients in 
comparison to a placebo (Kang et al., 2009).  
One of the issues associated with the use of bacteriocins in medical applications is that 
they can be degraded proteolytically in the body, thus reducing their effectiveness (Rink et 
al., 2010). Encapsulation of the bacteriocins and the use of drug delivery systems may 
circumvent this, allowing bacteriocins to be delivered directly to the area of interest in the 
host (Leserman et al., 1980). Encapsulation of bacteriocins may allow for their slow and 
extended release resulting in prolonged antimicrobial activity whilst also protecting the 
peptide from degradation in the body (Langer and Folkman, 1976). 
A similar concept can be used in a clinical setting and the incorporation of bacteriocins 
into nanofibers and materials has numerous potential uses. Electrospinning is one such 
method whereby bacteriocins such as nisin can be incorporated into the core of nanofibres. 
The use of such nisin-eluting nanofibres in wound dressings has been shown to significantly 




This represents a potentially useful medical barrier against the acquisition of skin infections 
(Heunis et al., 2013). The incorporation of these antimicrobials into dressings and fibres 
extends the potential use of bacteriocins in the medical field.  
 
 
Veterinary applications of bacteriocins 
Bacteriocins also display potentially useful benefits for animal care. One such application 
is the use of bacteriocins to treat mastitis in lactating animals. Mastitis is the inflammation 
of the mammary gland as a result of the infection with pathogenic microbes. A study by Cao 
et al. used an intramammary infusion of nisin to treat mastitis in dairy cows; the results for 
the nisin treatment had a clinical cure rate similar to that of gentamycin treatment. Nisin, 
however, is a food grade product with very few associated issues if it enters the food chain, 
as opposed to antibiotics such as gentamycin (Cao et al., 2007). A nisin based teat sealer 
was shown to reduce S. aureus and E. coli levels by 3.9 log and 4.22 log respectively after a 
one-minute exposure to the formula, a result comparable to conventional chemical 
treatments. The nisin formula however displayed a lower potential for skin irritation in 
comparison to the chemical treatments (Sears et al., 1992). A lacticin 3147 containing 
fermentate was used as a teat dip for mastitis prevention in dairy cows. Here teats were 
first coated with a pathogen before being treated with the teat dip for ten minutes, the 
lacticin 3147 containing fermentate was shown to reduce Staphylococcus, Str. dysgalactiae 




The antimicrobial activity of bacteriocins may also be useful for the treatment of GI tract 
infections in a range of animals. A bacteriocin OR-7 from Lb. salivarius was shown to reduce 
the colonization of chickens by Campylobacter jejuni. The purified bacteriocin was 
encapsulated and incorporated into chicken feed, chicks were then challenged with 
Campylobacter jejuni strains. Bacteriocin treatment was shown to greatly reduce pathogen 
colonization (Stern et al., 2006). An in vitro model of swine intestinal fermentations 
displayed the potential of pediocin A to inhibit the growth of pathogenic clostridia in the 
intestine, again representing an alternative to the use of traditional antibiotics in animal 
husbandry (Casadei et al., 2009).  
Bacteriocins also represent an alternative to the addition of subclinical levels of 
antibiotics to animal feed as growth promoters. Dietary nisin was shown to increase feed 
conversion and body weight gain in broiler chickens. While the exact mechanism of action is 
unclear, nisin was shown to modulate the gut microbial ecology, thus the authors 
postulated that it may be a result of improved nutrient absorption and utilization or due to 
an improved immune response to pathogenic Eimeria parasites (Józefiak et al., 2013). 
Similarly the addition of pediocin A to the feed of chickens challenged with Clostridium 
perfringens improved their growth and feed conversion rates (Grilli et al., 2009). 
Reutericyclin  
Reutericyclin is an antimicrobial N-acylated tetrameric acid produced by a number of Lb. 
reuteri strains (Gänzle, 2004). Reutericyclin is produced by the combined activity of a non-
ribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) encoded within the Lb. 
reuteri genome. It is unique in the fact that is one of the very few functional NRPS/PKS 




dissipates the transmembrane ΔpH of sensitive cells by translocating protons across the 
cytoplasmic membrane (Gänzle, 2004). It is active against a range of Gram-positive bacteria 
including pathogens such as Clostridium difficile and MRSA (Cherian et al., 2014). 
Reutericyclin producing Lb. reuteri strains have a number of potential uses in both food 
production and as potential probiotics due to the antimicrobial activity of the compound. 
Reutericyclin production in sourdough has been shown to help Lb. reuteri persist in the 
environment and remains active against sensitive strains in the dough (Gänzle and Vogel, 
2003). This suggests that such producing strains may have potential as starter cultures for 
food preservation (Gänzle and Vogel, 2003). As a potential probiotic trait, a reutericyclin 
producing strain was found to subtly alter the fecal microbiota of weanling pigs, however no 
effect on clostridial toxins in host faeces was observed after treatment (Yang et al., 2015).  
Antimicrobial metabolites   
In certain cases, metabolic waste products and intermediates produced by LAB during 
fermentation can themselves display antimicrobial activity. These antimicrobial metabolites 
can play an important role in food preservation by limiting the growth of spoilage and 
pathogenic microbes (Ross et al., 2002). The composition and characteristics of these 
antimicrobials will be further discussed below.  
Organic Acids  
Organic acids are a by-product of LAB metabolism, however in several cases these have 
been shown to possess antimicrobial activity. The primary acids produced by LAB are lactic 
acid and acetic acid, however others such as formic acid can also be produced (Lindgren and 




internal pH of sensitive cells. In the uncharged form these acids are lipid permeable and 
thus can freely diffuse into the cell’s cytoplasm (Hirshfield et al., 2003). Once in the 
cytoplasm they can dissociate causing an accumulation of anions, lowering the cells internal 
pH (pHi) (Salmond et al., 1984). This can affect numerous processes in the cells and can lead 
to internal enzyme denaturation. The increased anion concentration within the cell can also 
lead to an increase in the transportation of potassium ions into the cell (Roe et al., 2002). 
This influx of ions increases the turgor pressure within the cell, and in order to balance this, 
glutamate is then transported out of the cells which results in the disruption of the cells’ 
osmolarity and thus inhibits cell growth (Warnecke and Gill, 2005). A drop in pH can also 
induce changes in the fatty acid composition of the cells membrane (Cotter and Hill, 2003). 
The inhibition of cells by weak acids is not however solely due to lowering the cells pHi, as 
different acids can have specific effects on cells; for instance the treatment of E. coli cells 
with formate or acetate leads to distinctive transcriptional responses between the two 
acids. Acetate was shown to induce the production of proteins found in the RpoS regulon 
which is an important controller of the bacterial stress response, while formate caused 
reduced steady state expression of these genes (Kirkpatrick et al., 2001). Acetic, lactic and 
citric acids were also shown to display different levels of antimicrobial activity against L. 
monocytogenes even when cells had identical pHi values (Young and Foegeding, 1993). Such 
differences may be explained by the distinctive anion pools within the cells after treatments 
with each acid, the particular lipophilicity of each acid may also affect cells differently as was 
shown in yeast cells (Hirshfield et al., 2003, Capozzi et al., 2009).  
Lactic acid is the primary organic acid produced by LAB and, as with other organic acids, 




exposure to lactic acid, Bacillus cereus displayed an altered expression of 196 genes which 
are not associated with the general response to acidic shock, again indicating a more 
specific mode of action for this molecule. Rather, it was shown to alter the metabolism of 
these cells by controlling the expression of genes involved in amino acid metabolism (Mols 
et al., 2010). In addition lactic acid may also induce oxidative stress within cells (Mols et al., 
2010, Mols and Abee, 2011, Abbott et al., 2009).  
Acetic acid was also found to have a large impact on gene expression in Bacillus cereus, 
altering the regulation of 1430 genes, affecting a variety of pathways involved in 
oligopeptide and amino acid transport and metabolism which is similar to the response seen 
for lactic acid. Acetic acid also altered carbohydrate transport and metabolism in cells, with 
genes involved in glucose, fructose, lichenan and trehalose transport and metabolism being 
down-regulated (Mols et al., 2010). As with lactic acid, acetic acid may also inhibit cells by 
causing oxidative stress (Mols et al., 2010, Mols and Abee, 2011) 
Applications 
Organic acids can be used in a variety of applications, and due to their broad spectrum 
of activity and their ‘generally regarded as safe’ (GRAS) status they are particularly suited to 
the food industry (Chai et al., 2016). Solutions containing organic acids are used in the meat 
processing industry in the US and Canada for carcass decontamination (Loretz et al., 2011). 
They may also be added to juices and beverages where they can serve as biopreservatives 
and as acidity regulators (Quitmann et al., 2013). The neutralization of these organic acids 
can produce salts which are useful due to their wide spectrum of activity against a range of 
pathogens and food spoilage microbes such as E. coli O157, MRSA and Pseudomonas 




organic acids in particular can be used to improve the shelf life of products such as meat, 
poultry and fish and to control the growth of pathogens (Sallam, 2007, Maca et al., 1997). 
Levels up to 4.8% by weight of formulation of sodium and potassium lactate are permitted 
in food to inhibit microbes (Juneja and Thippareddi, 2004). These may also be useful if 
incorporated into food packaging whereby a controlled release may prolong a product’s 
shelf life by inhibiting spoilage microorganisms (Wang et al., 2015). Often these salts may 
have benefits beyond their antimicrobial activity, sodium lactate for example can also act as 
a humectant and emulsifier (Brewer et al., 1991). Organic acids may also be highly useful in 
animal feed systems as reducing the microbial load of feedstuffs there is an increase in 
nutrients available to the host. The production of these acids may also reduce the 
production of ammonia by spoilage microbes and also reduce the pH of the digesta (Dibner 
and Buttin, 2002).  
The combination of treatment with organic acids and other compounds can greatly 
enhance the antimicrobial activity of both and can lead to potential novel treatments for 
food preservation. The combination of lactic acid with the phenolic compound carvacrol has 
been shown to have synergistic antimicrobial activity against Shigella sonnei in infected 
lettuce leaves (Chai et al., 2016). The combination of organic acids and transition metals was 
also found to be highly synergistic with an up to a 1000 fold increase in antimicrobial activity 
whilst greatly also improving the effective range of activity against many pathogenic 
bacteria. Here the organic acids form complexes with these transition metals, increasing the 
permeability of the metals which leads to an increase in their intracellular concentration. 
The addition of organic acids to copper sprays currently used in plant and crop treatment 




antimicrobial activity between different organic acids and UV-A radiation has also been 
reported even when used at sub-lethal levels (de Oliveira et al., 2017). 
The production of these acids by LAB is in itself an important commercial trait for food 
fermentations. It is the production of lactic acid and other organic acids which helps in the 
preservation of fermented foods (Leroy and De Vuyst, 2004). While acids have important 
functional roles in the fermentation of many products (i.e. separation of curds and whey in 
cheese manufacture), these acids also reduce the growth of spoilage microbes by lowering 
the pH of the food to a prohibitive level. LAB are involved in the fermentation of a wide 
range of food, such as fermented meats (salami), fermented vegetables (kimchii, 
sauerkraut) and fermented dairy products (kefir, yoghurt). Thus, fermentation by LAB 
provides a cheap and cost effective method for food preservation whilst also often 
enhancing flavour and nutritional qualities (Ezeji and Ojimelukwe, 1993).   
Reuterin  
Reuterin is an antimicrobial compound which is an intermediate in the metabolism of 
glycerol in certain species. The name is derived from its most notable producer, Lb. reuteri, 
however several other Lactobacillus species have also been shown to produce this 
compound, as well as cells from other genera such as certain strains of Klebsiella (Martin et 
al., 2005, Sauvageot et al., 2000, Schütz and Radler, 1984, Slininger et al., 1983). Reuterin is 
composed of a mixture of 3-hydroxypropionaldehyde (3-HPA), its dimer and its hydrated 
form (Vollenweider and Lacroix, 2004). 3-HPA is an intermediate in the breakdown of 
glycerol to 1, 3-propanediol. Glycerol is first converted to 3-HPA by the adenosylcobalamin-
dependent glycerol dehydratase (GDHt), 3-HPA can then be further broken down into 1, 3-




particularly useful producer of reuterin due to its ability to tolerate larger concentrations of 
the compound compared to other producing species (Vollenweider and Lacroix, 2004). 
Reuterin inhibits sensitive cells by inducing oxidative stress as the reactive aldehyde in 
reuterin reacts with thiol groups of small molecules and proteins which can lead to their 
inactivation (Schaefer et al., 2010). Reuterin has a broad spectrum of activity, inhibiting a 
wide range of both Gram-positive and Gram-negative bacteria along with yeasts, moulds 
and protozoa (Cleusix et al., 2007). 
Applications 
Due to its broad spectrum of activity, reuterin may potentially be a useful antimicrobial. 
Reuterin treated mice infected with Trypanosoma brucei brucei displayed a 61% reduction 
in parasitemia levels and had an increased survival rate after a 7 day treatment (Yunmbam 
and Roberts, 1993). Due to its low potential toxicity in the body along with its inhibitory 
spectrum against food borne pathogens and spoilage bacteria, reuterin could also be used 
in combination with other treatments as a potential food preservative (Fernández-Cruz et 
al., 2016). When added to a Spanish curdled milk product reuterin alone displayed little 
antimicrobial activity against L. monocytogenes or S. aureus, however when used together 
with nisin and the lactoperoxidase system there was synergistic inhibition of these 
pathogens (Arqués et al., 2008). Reuterin-producing Lb. reuteri strains may also serve as 
potential probiotics. Lb. reuteri itself has been shown to survive gastric transit and has the 
ability to colonise the intestine (Vollenweider and Lacroix, 2004). Models of the colonic 
epithelium have shown that reuterin production improves the protection offered by Lb. 
reuteri against the adherence, invasion and intracellular survival of Salmonella 




glycerol in the human intestine remains unclear, however, a Lb. reuteri strain was shown to 
produce reuterin in the gut of gnotobiotic mice following a cecal glycerol injection (Morita 
et al., 2008). 
 
Hydrogen Peroxide  
Several LAB have also been found to produce hydrogen peroxide in the presence of 
oxygen (Hertzberger et al., 2014, Schellenberg et al., 2012, Hütt et al., 2016). The exact 
mode of action for the antimicrobial activity of H2O2 is not completely understood; however 
it is most likely a combination of DNA damage, protein oxidation and membrane disruption 
of the target cell (Tamarit et al., 1998, Imlay et al., 1988). This can be due to the production 
of reactive hydroxyl radicals formed by Fenton’s reaction (Linley et al., 2012). These 
hydroxyl radicals cause breaks in DNA due to their reaction with the methyl groups of 
thymine (Engevik and Versalovic, 2017, Di Mascio et al., 1989). The small molecular size of 
the molecule allows it to easily enter the cells where it can react with internal proteins and 
DNA, the activity of H2O2 can also be affected by whether the compound is in liquid or 
gaseous form (Finnegan et al., 2010). H2O2 is thought to be more effective against Gram-
positive than Gram-negative bacteria and anaerobic strains are thought to be more sensitive 
to the compound as they lack the peroxidases and catalases encoded by aerobic bacteria 
which allows them to break down H2O2 (McDonnell and Russell, 1999). The activity of H2O2 
can also be enhanced synergistically by acting together with the lactic acid produced by 
these bacteria (Atassi and Servin, 2010). Here, the membrane damage induced by lactic acid 
may make cells more susceptible and sensitive to the activity of H2O2 (Engevik and 





The antimicrobial activity associated with H2O2 production makes it a potentially useful 
probiotic trait and its importance can be especially seen in the vaginal microbiota. H2O2 
producing lactobacilli have been associated with protection against the acquisition of 
bacterial vaginosis and their absence is associated with a greater risk of acquiring HIV-1 
infection (Hawes et al., 1996, Martin Jr et al., 1999). H2O2 production may also support 
colonization of the vagina by producing strains (Vallor et al., 2001). Whilst H2O2 production 
has been associated with colonisation, it has been shown that the levels produced by such 
strains may not be sufficient to inhibit the growth of vaginal pathogens and that lactic acid 
may be playing a greater antimicrobial role (O'Hanlon et al., 2010, O'Hanlon et al., 2011, 
Gong et al., 2014). Rather than acting as an antimicrobial H2O2 may have a more important 
immunomodulatory role in the vagina, lowering the levels of pro-inflammatory cytokines. 
This may explain the positive correlation between H2O2 producing lactobacilli and reduced 
bacterial vaginosis levels (Mitchell et al., 2015). 
Ethanol 
Ethanol is another antimicrobial product resulting from the metabolic reactions of 
certain LAB. Alcohols such as ethanol are commonly used as disinfectants due to their broad 
spectrum of activity, inhibiting bacterial cells, fungi and viruses. Ethanol is thought to 
damage cell membranes and denature proteins which disrupts crucial cell processes 
(McDonnell and Russell, 1999). Whilst ethanol at high concentrations displays potent 
antimicrobial activity, the levels produced by cells in vivo are unlikely to reach high enough 
concentrations to act as an effective antimicrobial (Sissons et al., 1996, Elshaghabee et al., 




combined with other antimicrobial such as lactic acid which is also produced by these 
strains (Oh and Marshall, 1993). 
 
Diacetyl 
Diacetyl is a metabolic product from LAB which has also been shown to display 
antimicrobial activity. Diacetyl is an alternative minor product of the metabolism of some of 
these strains and can be formed by the spontaneous oxidation of acetolactate, an 
intermediate in the conversion of pyruvate to acetoin (Gänzle, 2015, Cocaign-Bousquet et 
al., 1996). The formation of diacetyl by LAB can be beneficial for fermented foods and other 
products due to its butter-like aroma, diacetyl has also been found to display antimicrobial 
activity against a range of bacteria. Whilst its activity is not as strong as other antimicrobials 
(Olasupo et al., 2003), it can inhibit the growth of Gram-negative bacteria which are typically 
unaffected by bacteriocins from LAB such as pediocin PA-1 or nisin (Kang and Fung, 1999, 
Gao et al., 1999). Gram positive strains tend to be less sensitive to diacetyl activity (Lanciotti 
et al., 2003). The concentration of diacetyl which is normally found in fermented foods is 
much lower than that required for antimicrobial activity and is unlikely to play a large role in 
bacterial inhibition in the environment (Clark and Winter, 2015, Helander et al., 1997). 
Continued exposure to diacetyl in an industrial setting has also been associated with lung 
disease which makes the molecule less attractive as an additive (Clark and Winter, 2015, 





Antimicrobials produced by LAB could potentially represent an untapped resource in 
regards to food processing and medical applications. With increasing concerns over food 
safety and the increase of multidrug resistant superbugs there is an urgent need for novel 
treatments. In this respect, bacteriocins, in particular, offer much potential. Many studies 
have focused on nisin, outlining its efficacy against important pathogens; it is also approved 
as a food additive and is extensively used in certain food processing industries. As we have 
seen, LAB produce a plethora of bacteriocins with potential to follow the same route as nisin 
for food safety and medicinal applications.  
Another advantage of bacteriocins, over other antimicrobials, is that they can be easily 
altered through genetic manipulation owing to their gene-encoded nature (Field et al., 
2015).  Modification of the nisin peptide for example has already led to the identification of 
mutants with enhanced antimicrobial activity (Healy et al., 2013). This may allow scientists 
to overcome some of the deficiencies associated with bacteriocins such as their degradation 
and stability in food matrices and the body. The narrow spectrum of activity of certain 
bacteriocins also allows pathogens to be targeted more directly with less collateral damage 
to the rest of the microbiota (Rea et al., 2010). 
Whilst production of purified antimicrobial compounds from LAB could prove to be 
economically unfeasible, LAB themselves serve as antimicrobial micro-factories, producing a 
range of antimicrobial compounds in situ. This feature of LAB is particularly suited to their 
role as starter cultures in food fermentations and as probiotics in the realms of host health.  
To date, much of the research into bacteriocins and other antimicrobials from LAB 
has focused on the food industry but the antibiotic resistance crisis has placed an urgent 




importance of our microbiota clearly indicates that such therapies must impart minimal 
damage to the host’s microbiota. In this regard, LAB antimicrobials offer a potential option 
in the development of narrow-spectrum antimicrobial compounds which impart their 
pathogen-inhibiting effects with minimal consequences for the mammalian host.  
Future research should now focus on expanding the LAB antimicrobial repository 
beyond the handful which have made it into the commercial and medical realms with an 
emphasis on progressing these molecules towards intelligently-designed studies which 
provide evidence of their safety and efficacy in practical situations and towards clinical and 





Figures and Tables 
Figure 1. LAB produce a variety of antimicrobials which can inhibit and kill sensitive 
microbes. Compounds such as lactic acid and diacetyl are metabolic waste products which 
can also act as antimicrobials. Bacteriocins are antimicrobial peptides which may be 







Figure 2. LAB can be utilised in food biopreservatoin in several ways. (a) LAB can be used as 
starter cultures in the production of fermented foods, whereby the in situ production of 
bacteriocins and other antimicrobials inhibits the growth of spoilage microbes. (b) 
Bacteriocins from LAB cultures can also be concentrated into purified and semi-purified 






Table 1. Notable bacteriocins produced by LAB  
Class I Producer Notable Targets Reference 
Lantibiotics    
Nisin Lc. lactis subsp. lactis L. monocytogenes, S. aureus, Str. 
pyogenes 
(Rogers and Whittier, 
1928) 
Mutacin B-Ny266 Str. mutans Ny266 Enterococcus sp., Staphylococcus 
sp., Propioniibacterium acnes 
(Mota-Meira et al., 1997) 
Lacticin 3147 Lactococcus lactis 
DPC3147 
L. monocytogenes,  E. faecalis, S. 
aureus 
(Ryan et al., 1996) 
TOMM    
Streptolysin Str. pyogenes Erythrocytes, leukocytes, platelets (Todd, 1938) 
Lactocillin Lb. gasseri JV-V03 Gardnerella vaginalis, 
Corynebacterium aurimucosum, E. 
faecalis 
(Donia et al., 2014) 
Glycocins    
Glycocin F Lb. plantarum KW30 Enterococcus sp., Streptococcus sp., 
Bacillus sp. 
(Kelly et al., 1996) 
 
Class II 
   
Class IIa     
Pediocin PA-1 P. acidilactici PAC-1.0 L. monocytogenes, Lactobacillus 
sp., Clostridium tyrobutyricum 
(Henderson et al., 1992) 
Enterocin A E. faecium CTC492 L. monocytogenes, E. faecalis, 
Cl.tyrobutyricum 
(Aymerich et al., 1996) 
Class IIb    
ABP-118 Lb. salivarius subsp. 
salivarius UCC118 
Bacillus coagulans, L. 
monocytogenes, L. innocua 
(Flynn et al., 2002) 
Plantaricin S Lb. plantarum LPCO10 Propionibacterium sp., Cl. 
tyrobutyricum, E. faecalis 
(Jimenez-Diaz et al., 
1993) 
Class IIc    
Carnocyclin A Carnobacterium 
maltaromaticum UAL307 
S. aureus, L. monocytogenes, E. 
faecalis 
(Martin-Visscher et al., 
2008) 
Acidocin B Lb. acidophilus M46 L. monocytogenes, Cl. sporogenes, 
Brochothrix thermosphacta 
(Leer et al., 1995) 
Class IId    
Bactofencin A Lb. salivarius DPC6502 S. aureus, L. monocytogenes (O'Shea et al., 2013) 
Lactococcin 972 Lactococcus lactis subsp. 
lactis IPLA 972 
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Bacteriocins represent a rather underutilised class of antimicrobials, despite often displaying 
activity against many drug resistant pathogens. Lantibiotics are a post-translationally modified class 
of bacteriocins, characterised by the presence of lanthionine and methyllanthionine bridges. In this 
study, a novel two-component lantibiotic was isolated and characterised. Formicin was isolated from 
Bacillus paralicheniformis APC 1576, an antimicrobial producing strain originally isolated from the 
intestine of a mackerel. Genome sequencing allowed for the detection of the formicin operon, and 
from this the formicin structural genes were identified, along with those involved in lantibiotic 
modification, transport and immunity. The identified bacteriocin was subsequently purified from the 
bacterial supernatant. Despite the degree of conservation seen amongst the entire class of two-
component lantibiotics, the formicin peptides are unique in many respects. The formicin α peptide is 
far less hydrophobic than any of the equivalent lantibiotics, and with a charge of plus two it is one of 
the most positively charged α peptides. The β peptide is unique in that it is the only such peptide 
with a negative charge due to the presence of an aspartic acid residue in the C-terminus, possibly 
indicating a slight variation to the mode of action of the bacteriocin. Formicin also displays a broad 
spectrum of inhibition against Gram positive strains, inhibiting many clinically relevant pathogens 
such as Staphylococcus aureus, Clostridium difficile and Listeria monocytogenes. The range of 
inhibition displayed against many important pathogens indicates a potential therapeutic use against 






With the increased prevalence of many drug resistant bacterial strains, the development of 
new antimicrobials is becoming a growing necessity.  One such class of antimicrobials which appear 
to be underrepresented in clinical applications are bacteriocins (Cotter et al., 2013). Unlike 
traditional antibiotics, bacteriocins are gene encoded and ribosomally-synthesised peptides. This 
makes them suitable for genetic manipulation, with the potential for novel and specialised drug 
design (Gillor et al., 2005). The spectrum of inhibition of bacteriocins can range from broad to 
narrow spectrum, the latter of which may allow for highly targeted antibacterial therapies which 
may reduce the collateral damage associated with the use of broad spectrum antibiotics (Rea et al., 
2011).  
The lantibiotics (lanthionine containing antibiotics) comprise a well-studied class of 
bacteriocins, the most notable of which is nisin (Rogers, 1928) which is commonly used as a food 
preservative. Lantibiotics are classified based on the presence of lanthionine or methyllanthionine 
bridges. In these peptides, serine and threonine residues are post-translationally modified and 
dehydrated to form 2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb) residues. The thiol 
group of a cysteine residue subsequently reacts with the Dha or Dhb residues resulting in the 
formation of lanthionine or methyllanthionine thioether cross-links (Xie and van der Donk, 2004).  
The lantibiotic gene cluster encodes an array of genes required for the modification, 
regulation and transport of the bacteriocin. Lantibiotics are divided into classes depending on the 
mechanism by which they are synthesised. Class I lantibiotics encode the enzymes LanB and LanC 
within the bacteriocin operon, where LanB catalyses the dehydration of the serine and threonine 
residues, whilst LanC catalyses the cyclization of the lanthionine rings. In Class II lantibiotics, LanM 
alone catalyses both dehydration and cyclization of the lantibiotics (Willey and van der Donk, 2007). 
LanR and LanK play key roles in the regulation of lantibiotic production (Lee et al., 2011). Once the 




respectively (Escano et al., 2015). In some cases, LanT can carry out both leader sequence cleavage 
and peptide secretion functions (Furgerson Ihnken et al., 2008). Immunity to lantibiotics can be 
afforded by immunity proteins such as the lipoprotein LanI which likely binds the secreted 
lantibiotic, and the ABC transporter LanFEG which transports bacteriocin peptides from the 
membrane to the extracellular medium. Here LanF binds and hydrolyses ATP which provides the 
energy required for the transport of the bacteriocin through the LanEG membrane complex (Stein et 
al., 2005, Takala et al., 2004, Alkhatib et al., 2012). For a review on this class of bacteriocins see 
(Willey and van der Donk, 2007). 
Within the lantibiotic class of bacteriocins exists a small subgroup of two-component 
lantibiotics. Such bacteriocins are produced by an array of genera, including Staphylococcus and 
Lactobacillus (Navaratna et al., 1998, Holo et al., 2001). Interestingly, of the few two-component 
lantibiotics which have been described, two of these bacteriocins identified prior to this study are 
produced by Bacillus species. Bacilli species are known to produce a vast range of antimicrobials, 
whether antibiotics (e.g. gramicidin, bacitracin) or bacteriocins (e.g. thuricin CD, mersacidin) (Katz 
and Demain, 1977, Rea et al., 2010, Chatterjee et al., 1992). The currently identified two-component 
lantibiotics include lacticin 3147 (Lactococcus lactis) (Ryan et al., 1996), lichenicidin (Bacillus 
licheniformis) (Begley et al., 2009, Dischinger et al., 2009), haloduracin (Bacillus halodurans) 
(McClerren et al., 2006), enterocin W (Enterococcus faecalis) (Sawa et al., 2012), plantaricin W 
(Lactobacillus plantarum) (Holo et al., 2001), BHT (Streptococcus rattus) (Hyink et al., 2005), Smb 
(Streptococcus mutans) (Yonezawa and Kuramitsu, 2005) and staphylococcin C55 (Staphylococcus 
aureus) (Navaratna et al., 1998). In this subclass of bacteriocins, the two peptides produced tend to 
act synergistically and usually display negligible antimicrobial activity on their own.  
The mode of action of lacticin 3147 identifies a likely model for the mode of action of 
similarly structured lantibiotics. The α peptide of lacticin 3147 (Ltnα) resembles the globular 
lantibiotic mersacidin, mirroring its activity by binding to lipid II which acts as an important docking 




which the β peptide (Ltnβ) can then bind. Ltnβ resembles an elongated lantibiotic, which, once 
recruited by Ltnα, inserts itself into the target membrane, inducing pore formation, which results in 
cell death. Here the cooperative activity of both peptides is necessary for optimal antimicrobial 
activity as the stability of the total bacteriocin-lipid II complex is important for both pore formation 
and the inhibition of cell wall biosynthesis (Martin et al., 2004, Wiedemann et al., 2006).  
 In this study we extend the class of two-component lantibiotics by identifying a novel 
bacteriocin known as formicin which is produced by a marine isolate, Bacillus paralicheniformis APC 
1576. Whilst this lantibiotic resembles the previously described two-component lantibiotics, it 






Isolation of B. paralicheniformis APC 1576 
B. paralicheniformis APC 1576 was isolated from the intestinal microbiota of a freshly caught 
mackerel. In an initial screen for bacteriocin production the strain was found to inhibit L. delbrueckii 
subsp. bulgaricus LMG 6901 in an overlay assay (Fig. 1(a)). In addition, cell free supernatants (CFS) 
also inhibited L. delbrueckii subsp. bulgaricus LMG 6901 in a well diffusion assay indicating that the 
antimicrobial substance was secreted by the cells into the media (Fig. 1(b)). Colony MS was used to 
determine the molecular masses of the peptides produced by the cell, however, the detected 
peptide masses (Fig. 1(c)) failed to match any previously characterised bacteriocin, including 
lichenicidin, a bacteriocin produced by B. licheniformis  (Begley et al., 2009). Moreover, more than 
one source of antimicrobial activity was found following purification of the antimicrobial peptides. 
MALDI-TOF MS identified a molecule with a mass of 1422.54 Da, which displayed activity against L. 
delbrueckii subsp. bulgaricus LMG 6901 once purified; this mass correlates closely with that of 
bacitracin which is encoded on the genome. The production of more than one antimicrobial from 
Bacillus species is not unexpected. Therefore, in order to identify all potential antimicrobials with 
activity against L. delbrueckii subsp. bulgaricus LMG 6901 the genome of B. paralicheniformis APC 
1576 was sequenced. 
Identification of a Novel Two-Component Lantibiotic Operon 
Once the draft genome was obtained, the sequence was analysed with BAGEL3 and antiSMASH 
to identify the antimicrobials encoded. Gene clusters encoding the antibiotics bacitracin, surfactin 
and fengycin were found within the genome. The strain likely produces at least one of these 
antimicrobials, as antifungal activity was also observed against Aspergillus niger in overlay assays 
(data not shown).  
A novel lantibiotic operon was also identified within the genome of the strain (Fig. 2). This 




Two putative lantibiotic-encoding structural genes were identified on this operon. ORF1 (frcA1) 
encodes a 66 amino acid peptide and ORF3 (frcA2) encodes a 71 amino acid peptide. Analysis of the 
prepropeptides (including the bacteriocin leader sequence) of these lantibiotics shows the formicin 
A1 prepropeptide displayed 47.8% amino acid identity to the unmodified haloduracin A1 equivalent 
and 35.9% identity to the lantibiotic mersacidin. As the putative bacteriocin appears to be a two-
component bacteriocin, two lantibiotic modification enzymes should be present. The order of the 
genes in the operon would suggest that ORF2 (frcM1) is the modification enzyme associated with 
frcA1. Upon analysis, this ORF displayed 38.7% identity to the haloduracin HalM1 modification 
enzyme. The second lantibiotic gene, ORF3 (frcA2), appears to resemble the elongated β peptides of 
the other two-component lantibiotics which are involved in membrane insertion (Wiedemann et al., 
2006). Upon analysis, formicin A2 revealed 42.4% identity with the unmodified lichenicidin LchA2 
prepropeptide. ORF4 (frcM2) encodes the modification enzyme which follows this structural 
peptide, and displayed 33.6% identity to the lichenicidin LchM2 modification enzyme. 
 ORF5 located downstream of LchM2 is predicted to encode a lantibiotic transporter, 
displaying 52.5% identity to the haloduracin transporter, HalT. In addition to its function in 
bacteriocin transport, a sequence encoding a C39 peptidase domain (cd02425) can also be found 
within the gene, this is likely involved in the cleavage of the leader sequence from the 
prebacteriocin. BLAST analysis of ORF6 identified the gene as encoding a hypothetical protein; the 
sequence, however, did show 28.4% identity to LanY encoded within the lichenicidin operon (Begley 
et al., 2009). ORFs 7, 8 and 9 all encode ABC transporter related peptides, as do ORFs 11, 12 and 13. 
These are likely to be involved in bacteriocin immunity. ORF7 and ORF11 both encode domains 
resembling that of the ABC-binding cassette domain of the bacitracin-resistance transporter 
(cd03268) and displayed 44.5% identity to each other. Instead of the common Q-loop motif found in 
the nucleotide binding domains of such transporters, both these proteins instead encode an E-loop 
motif which is indicative of lantibiotic immunity proteins (Okuda et al., 2010, Alkhatib et al., 2012). 




these gene clusters may suggest a dual mechanism of bacteriocin immunity. Immunity to the 
lichenicidin bacteriocin is thought to follow a similar mechanism, with two transporters being 
encoded, with one showing homology to the bacitracin transporter (Dischinger et al., 2009). Such 
mechanisms, however, do not confer a general immunity against all two-component lantibiotics, as 
both the producers of lichenicidin (B. licheniformis ATCC 14580) and lacticin 3147 (Lactococcus 
lactis subsp. lactis DPC 3147) displayed sensitivity to formicin (Table 1). 
ORF10 (frcR), which splits the transporter clusters, encodes a LanR equivalent transcriptional 
regulator. This gene encodes helix-turn-helix XRE-family domains, crucial for binding DNA and 
regulating gene expression. This LanR type protein displayed 49.4% and 60.3% identity to the 
regulators found within the lichenicidin and haloduracin operons, respectively. ORF14 (frcP) encodes 
a lanthionine specific protease displaying 29.8% identity to LicP found in the lichenicidin operon. As 
in lichenicidin, the LanT-like ORF (frcT) likely cleaves the N-terminal glycine leader sequence from 
both propeptides upon transport, whilst the LanP-like protease (frcP) possibly cleaves the six newly 
exposed N-terminal amino acids from the β peptide to generate the mature bacteriocin (Tang et al., 
2015). The final ORF found in the gene cluster encodes a DNA damage inducible protein. 
Bacteriocin Structure Prediction and Analysis 
The spectrum of activity and characteristics of the bacteriocin could not be determined from the 
crude bacteriocin supernatant alone due to the interference from the other antimicrobials produced 
by the strain. Thus, to determine the activity of formicin, it was necessary purify the bacteriocin from 
the cell free supernatant. Using the predicted masses of the lantibiotic structural peptides identified 
from genomic data it was possible to determine if the formicin peptides were present in active 
HPLC-derived fractions using MALDI-TOF MS.  
From the purified peptides, masses of 3254.34 Da and 2472.06 Da were detected for the α 
and β peptides, respectively. The predicted mass of the Frcα peptide based on the amino acid 




masses  correlates with the loss of three water residues which is most likely associated with the 
formation of lanthionine and methyllanthionine bridges, and also the possible formation of one 
disulphide bond, resulting in a predicted mass of 3254.80 Da. Due to the similarities between the 
two, the structure of Halα was used as a basis for the prediction of the structure of Frcα.  Based on 
the Halα template the formation of a lanthionine bridge may occur between Ser-7 and Cys-17, while 
methyllanthionine bridges could form between Thr-18 and Cys-23, and Thr-20 and Cys-27, whilst 
Ser-26 remains unaltered. In addition, a disulphide bridge is also likely to form between Cys-1 and 
Cys-8 (Fig. 3).  
The second mass determined by MALDI-TOF MS relates to the β peptide of the bacteriocin. 
Due to the presence of the extra LanP serine protease encoded in the bacteriocin operon and the 
similarity formicin displays to haloduracin and lichenicidin it is likely that the first six amino acids 
following the lantibiotic leader sequence are also cleaved from the formicin peptide. Once these 
amino acids are discounted the predicted mass of the peptide is 2614.95 Da, a difference of 142.89 
Da from the mass detected by MALDI-TOF MS. This mass difference corresponds closely with the 
loss of 144 Da which would be associated with 8 dehydration reactions. Using the β peptides of 
lichenicidin and lacticin 3147 as templates, we predicted that the peptide is most likely to form 
bridges between Thr-1 and Cys-8, Thr-13 and Cys-17, Ser-19 and Cys-22, and Thr-23 and Cys-26. This 
would result in Thr-2, Ser-4, Ser-5 and Thr-10 being dehydrated to their respective Dha and Dhb 
residues, whilst Ser-24 remains unaltered (Fig. 3). 
The purified peptides were screened against a range of indicator organisms to determine the 
spectrum of inhibition (Table 1). Purified formicin inhibited 29 of the 35 indicator strains screened, 
exhibiting a broad spectrum of activity against a range of bacterial genera including lactobacilli and 
enterococci, and notable pathogens such as Staphylococcus aureus, Listeria monocytogenes, 
Clostridium difficile and Bacillus subtilis. The Frcα peptide alone at a concentration of 50 µM also 
displayed antimicrobial activity against a number of indicators, whilst Frcβ alone displayed no 




In terms of thermostability, the bacteriocin retained a high degree of activity after 
treatment at 100˚C for thirty minutes, displaying a reduction in the size of the zone of inhibition 
of approximately 28%. Activity was, however, lost after treatment for fifteen minutes at 121˚C. 
The bacteriocin was also found to be susceptible to digestion by α-chymotrypsin and proteinase 
K, indicating its proteinaceous nature. 
Homology between Bacteriocins 
The previously described two-component lantibiotics all display a degree of homology with 
certain conserved residues found throughout. As a result, sequence comparisons of these structural 
peptides were carried out with formicin to determine if this conservation extended to the new 
bacteriocin (Fig. 4). The results indicate that formicin complies with the conservation that is seen 
amongst the other bacteriocins. The mersacidin like α peptides display the greatest levels of 
conservation, this reflects the shared mode of action in specifically binding to lipid II. This homology, 
especially in the lanthionine and methyllanthionine bridge forming regions, confers a structural 
similarity in each of the peptides. The broader role of the β peptides in membrane insertion is 
reflected in a greater degree of divergence in the composition of these peptides. The regions of 
conservation which are seen amongst the β peptides extend to Frcβ also, with the C-terminus of the 
peptides showing a relatively conserved pattern of lanthionine and methyllanthionine bridge 
formation. The N-terminus of the β peptides display a much lower degree of conservation, despite 
this, these N-terminus regions are rich in hydrophobic amino acids which likely play an important 






Formicin represents a novel member of the class of two-component lantibiotics. This class of 
bacteriocins are themselves unusual given the lipid II binding and pore forming activities of the 
bacteriocin are performed by two separate peptides, whilst certain lantibiotics such as nisin and 
subtilin have the ability to carry out both functions on a single peptide. It is unclear as to whether 
these two-component lantibiotics have evolved due to a divergence of a nisin like lantibiotic into 
two separate genes after a duplication event or whether they have come about due to the 
convergence of a mersacidin like lipid II binding lantibiotic and a pore forming lantibiotic. If the latter 
is the case, it is interesting as to how such different peptides would have evolved to depend on each 
other for antibacterial activity, and in some cases lose the activity each would have shown on its 
own. 
Sequencing of B. paralicheniformis APC 1576, allowed for the elucidation of the formicin 
bacteriocin operon (Fig. 2). Analysis of the bacteriocin operon identified two lantibiotic structural 
genes (frcA1 and frcA2) and two modification enzymes (frcM1 and frcM2) which convert the 
formicin structural peptides to the mature lantibiotics. Transport and leader cleavage is likely to be 
carried out by frcT, whilst frcP may act as a further protease, cleaving 6 N-terminal amino acids from 
Frcβ. ORFs 7, 8, 9 and 11, 12, 13 all predict to encode ABC transporters which are likely to comprise 
the strain’s immunity mechanism, protecting itself from attack by its own bacteriocin. 
 Comparative analysis of the bacteriocin structural genes allow for the homology between 
bacteriocins to be determined (Fig. 4). In the case of both Frcα and Frcβ, the closest homologs are 
the haloduracin α and β mature peptides, displaying 71% and 39% identity respectively. Such 
homology reflects the close relationship of the two producers as both belong to the Bacillus genus. 
The differences between the formicin and lichenicidin peptides are surprisingly large, given that both 
are produced from related species, with the α peptides displaying 46% identity and the β peptides 




layout of the formicin operon itself differs from that of the previously characterised two-component 
lantibiotics, transcription of the formicin operon would appear to be unidirectional whereby the 
genes for the structural peptides are separated by those encoding the LanM modification enzymes, 
an arrangement which seems to be unique to formicin. Both the haloduracin and lichenicidin 
structural genes (Figure 2) would likely be transcribed in opposite directions, possibly indicating that 
gene inversion may have taken place. Such differences again display the evolutionary divergence 
seen between this class of bacteriocins. 
Analysis of the primary structure of these peptides indicates that some key differences exist 
between the formicin peptides and other members of the class, despite such strong regions of 
homology found throughout. The α peptide of formicin, for example, contains only five hydrophobic 
amino acids, whilst others in the class contain an average of nine. Whilst hydrophobic residues are 
crucial for membrane activity in certain bacteriocins, it has been suggested that it is the charged 
residues of these lantibiotics which control binding to lipid II as opposed to hydrophobic 
interactions. This indicates that binding of formicin to lipid II is not compromised despite its lower 
hydrophobicity, a fact which is supported by the activity of the α peptide independent of the β 
peptide (Hsu et al., 2003, Fimland et al., 2006). As with the α peptides from enterocin W and 
plantaricin W, the α peptide of formicin contains six charged amino acids, with an overall positive 
charge of plus two, rendering them amongst the most highly charged in the class. These charged 
residues not only affect the structure of the peptide but the higher positive charge may lead to an 
increased affinity for the anionic bacterial membrane. The formicin β peptide differs most when 
compared to other lantibiotic β peptides with regards to charge. As is common in this class, the N-
terminal tails of the β peptides are composed largely of hydrophobic residues, crucial for membrane 
insertion and pore formation. Whilst the previously described β peptides all contain a positively 
charged C-terminus, containing Lys and Arg residues, formicin is unique in that it encodes a 
negatively charged β peptide. The lone charged residue found in the peptide is the penultimate C-




between the α and β peptides (Wiedemann et al., 2006), thus this negative residue may suggest an 
increased affinity for the positively charged α peptide, possibly representing a stronger complex 
compared to previously described pairs. 
The tertiary structure of these peptides has an important functional role in the antimicrobial 
activity of these lantibiotics. Analysis of the N-terminus of Frcα suggests the formation of a 
disulphide bridge between Cys-1 and Cys-8. Whilst this has been shown to be inessential for 
antimicrobial activity, it may reduce the degradation of the peptide once secreted (Cooper et al., 
2008). Of the lantibiotic rings believed to be formed in Frcα, only the C ring is thought to be 
essential, with alterations abolishing all activity completely in both haloduracin and lacticin 3147 
(Cooper et al., 2008, Cotter et al., 2006). The B ring found in these α peptides, has been shown to be 
unnecessary, which is unusual given the high degree of conservation amongst such bacteriocins, 
including mersacidin. Disruption of the A ring in haloduracin has been shown to reduce, but not 
eliminate activity, thus showing this region is important but not essential for the antibacterial 
activity of the bacteriocin (Cooper et al., 2008). As per analysis of the haloduracin β peptide, the A 
ring of the peptide has been found to be dispensable, whilst loss of the C and D rings led to a 
reduction in activity but not total elimination. Disruption of the B ring could not be achieved without 






 In this study, formicin, a novel member of the class of two-component lantibiotics has been 
identified. Key regions of homology, primarily those involved in lanthionine and methyllanthionine 
bridge formation, seen throughout this class have been shown to be extended to formicin. Such 
homology is expected to confer a similar mode of action to all lantibiotics in this class, with the α 
peptide of the bacteriocin binding to lipid II and subsequently recruiting the β peptide for membrane 
insertion and pore formation. Whilst formicin likely conforms to such mechanisms, there are certain 
key variations which differentiate it from the rest of the class. The reduction of hydrophobicity of 
Frcα, and the unusual negative charge of Frcβ make formicin a unique member of the two-
component lantibiotics. Further studies are required to determine the effects of such changes on the 
activity of the bacteriocins, as it is recognised that charge and hydrophobicity play a central role in 
the activity of these lantibiotics, and in bacteriocins in general. Formicin itself displays a broad range 
of inhibition, inhibiting several clinically relevant Gram-positive pathogens, such as C. difficile, S. 
aureus and L. monocytogenes. With the continued progression of antibiotic resistance in pathogenic 
bacteria, the discovery of novel therapies against such agents is a priority and since the bacteriocin is 
produced by a species long associated with biotechnology applications, a straightforward route 
towards large scale processing of the readily purified peptides is anticipated. Thus formicin 






Material and Methods 
Isolation of Bacteria from Fish Samples 
Marine fish were caught off the coast of Ireland and stored on ice prior to analysis. The 
intestinal contents of the fish and a sample of the skin and gills were aseptically removed. Samples 
were suspended in maximum recovery diluent (MRD) (Oxoid Ltd., Basingstoke, Hampshire, United 
Kingdom), serial dilutions were then plated on brain heart infusion (BHI) agar (Merck, Darmstadt, 
Germany), and marine media 2216 (Difco Laboratories, Detroit, MI) and incubated aerobically at 
30˚C for three days. Colonies were isolated from these plates and analysed for antimicrobial activity 
using deferred antagonism assays, whereby spots of the bacterial cultures were overlaid with 10 ml 
de Man, Rogosa and Sharpe (MRS) agar (Difco Laboratories, Detroit, MI) seeded with 25 μl of a 
Lactobacillus delbrueckii subsp. bulgaricus LMG 6901 overnight culture. Colonies which displayed 
significant zones of inhibition were further characterised.  
In this study, the strain of interest, B. paralicheniformis APC 1576, was isolated from the 
intestinal tract of a mackerel (Scomber scombrus) and grown on BHI aerobically at 37˚C. The strain 
was identified by 16S rRNA sequencing using the UniF (5’ -AGAGTTTGATCCTGGCTCAGG- 3’) and UniR 
(5’ -ACGGCAACCTTGTTACGAGT- 3’) primers to amplify the sequence. PCR products were cleaned 
using an illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare, Buckinghamshire, UK) 
and subsequent sequencing was completed by Cogenics (Essex, UK).  
Colony Mass Spectrometry 
Colony matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) (Axima TOF2 MALDI-TOF mass spectrometer, Shimadzu Biotech, Manchester, UK) was used to 
determine the molecular mass of the peptides produced as follows: cells were first mixed in a 70% 2-
propanol 0.1% TFA (IPA) and vortexed, the sample was separated by centrifugation and the 




matrix solution, 0.5 µl of the supernatant from the cell extract was then placed on the target and a 
final layer of matrix solution was added. Positive-ion reflectron mode was used to identify the 
peptide masses. The masses detected were then compared to those of known bacteriocins.  
Draft Genome Sequencing 
Genomic DNA was extracted using the GenElute bacterial genomic kit (Sigma-Aldrich, Wicklow, 
Ireland) and the Nextera XT DNA kit (Illumina, San Diego, CA, USA) was used for library preparation. 
The DNA was quantified using a Qubit® 2.0 fluorometer. Sequencing was performed using Illumina’s 
MiSeq platform using paired-end 2 x 300 base pair reads in the Teagasc Sequencing Centre, Teagasc 
Food Research Centre Moorepark.  Reads were assembled de novo, using SPADES (version 3.1.1), 
resulting in 70 contigs. Open reading frames (ORFs) were identified and annotated using Prokka 
(version 1.1).  Further manual annotation was implemented with ARTEMIS and Artemis Comparison 
Tool (ACT). Genomic data is available from GenBank/EMBL under accession no. LXPD00000000 
Bacteriocin Identification 
The bacteriocin mining tool BAGEL3 was used to identify the bacteriocin operons encoded in the 
genome (van Heel et al., 2013). BAGEL3 scans small ORFs to identify potential bacteriocin encoding 
genes. The surrounding genes are then analysed for other bacteriocin related components such as 
transporters and immunity proteins, thus allowing the entire bacteriocin operon to be identified (de 
Jong et al., 2006). The program antiSMASH was also used to identify antibiotic and secondary 
metabolite encoding genes within the genome, as these compounds are often associated with the 
Bacillus genus (Medema et al., 2011). Sequence alignments of the bacteriocin were performed using 
the Clustal Omega software. 
Bacteriocin Purification 
Cultures of B. paralicheniformis APC 1576 were grown statically overnight in 400 ml volumes of 




of Amberlite XAD-16 beads (Sigma-Aldrich, Wicklow, Ireland). The column was washed with 250 ml 
of 35% ethanol and antimicrobial activity eluted with 250ml of IPA. The IPA was removed via rotary 
evaporation and the sample was then applied to a 10g, 60ml Strata C18-E solid-phase extraction (SPE) 
column (Phenomenex, Cheshire, UK). The SPE column was washed with 90ml of 35% ethanol and 
90ml of IPA. The IPA was once again removed via rotary evaporation from the eluent and the sample 
applied to a semi prep Proteo Jupiter HPLC column (10 x 250 mm, 90Å, 4µm) running a 27.5-65% 
acetonitrile 0.1% TFA gradient where buffer A was 0.1% TFA and buffer B was 90% acetonitrile 0.1% 
TFA. Fractions were collected at 1 minute intervals and were subsequently analysed with MALDI-TOF 
MS and agar well diffusion assays as described below using L. delbrueckii subsp. bulgaricus LMG 
6901 as the target organism to identify active fractions containing peptides of interest. 
Antimicrobial Assays 
The antimicrobial activity of the isolated peptides was analysed using well diffusion assays 
against a range of indicator organisms (Table 1). Briefly, this involved seeding 20 mls of the 
appropriate agar with 50µl of an overnight indicator culture, the agar was allowed to cool and 7 mm 
wide wells were then bored in the agar. The purified bacteriocin peptides were dried to a powder 
and diluted separately in potassium phosphate buffer pH 6.8 to a concentration of 50μM. The 
combination of these peptides in a 1:1 ratio thus gave a total bacteriocin concentration of 25μM for 
each peptide. Fifty microliters of this solution was then placed in wells in the indicator plate, these 
were subsequently incubated overnight under the appropriate growth conditions as outlined in 
Table 1. 
Peptide Stability 
The stability of the bacteriocin was determined using purified peptides. To determine the active 
temperature range of the lantibiotic, 25μM aliquots of the bacteriocin were treated at 60˚C, 70˚C, 
80˚C, 90˚C and 100˚C for 30 minutes, a sample was also treated at 121˚C for 15 minutes. These 




well diffusion assays as previously described. To determine the susceptibility of the bacteriocin to 
proteases, 5 μM aliquots of the α and β peptides were treated separately with proteinase K and α-
chymotrypsin each at a concentration of 10 mg/ml (Sigma-Aldrich, Wicklow, Ireland). Samples were 
incubated at 37˚C for three hours followed by treatment at 100˚C for ten minutes to inactivate these 
proteases. Both bacteriocin peptides were then combined post treatment to give a final total 
concentration of 2.5µM, these were then screened against L. delbrueckii subsp. bulgarcus LMG 6901 





Figures and Tables 
Figure 1. Formicin identification and activity. (a) Deferred antagonism assay against L. delbrueckii 
subsp. bulgaricus LMG 6901 identified B. licheniformis APC 1576 as an antimicrobial producer. (b) 
Antibacterial activity of the B. licheniformis APC 1576 cell free supernatant against L. delbrueckii 
subsp. bulgaricus LMG 6901 in a well diffusion assay. (c) Colony MALDI-TOF MS displaying the 
masses of the peptides produced by B. licheniformis APC 1576, allowing identification of the 
antimicrobials produced (3255.92 Da = Frc α (formicin); Frcβ is not seen using colony MALDI-TOF 







Figure 2. Formicin Operon. Visualisation of the formicin, lichenicidin and haloduracin bacteriocin 
gene clusters. Clear bacteriocin homologs are identified using the accepted nomenclature for 
describing lantibiotics. For formicin, frcA1 and frcA2 encode the putative bacteriocins, frcM1 and 
frcM2 encode the accompanying modification enzymes and frcT and frcP are involved in bacteriocin 
transport and leader cleavage. Similar nomenclature is used for lichenicidin (lic) and haloduracin 







Figure 3. Lantibiotic Structure Prediction. The structures of the formicin α and β peptides were 
predicted using the Halα and Licβ peptides, respectively, as templates. The conservation of key 
amino acids suggests a structural homology between the peptides. The rings formed from 
lanthionine and methyllanthionine bridges are labelled alphabetically, with the N-terminal ring of 
Frcα excluded as it is predicted to be formed via a disulphide bond. The bacteriocin prepropeptides 







Figure 4. Sequence Alignment of Formicin Structural Peptides. Using Clustal Omega, the formicin 
peptides FrcA1 (a) and FrcA2 (b) were aligned against the previously described two-component 
bacteriocins. The percentage amino acid identities of each peptide with the formicin peptides are 
shown. The conservation score between the peptides were calculated with Clustal Omega for the 
alignments containing less than 25% gaps, * represent a score of 10.  The sequences in bold 
represent the six amino acids cleaved from the N-terminus of these peptides by LanP proteases. 
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Table 1. Growth conditions of indicator strains and inhibition spectrum of formicin pure 
peptides following well diffusion assays (- = No activity, + = 0.5-1.5mm inhibition zone, ++ = 2-









Lactobacillus delbrueckii subsp. bulgaricus LMG 6901 37 Anaerobic MRS +++ 
L. delbrueckii subsp. lactis LMG 7942 37 Anaerobic MRS +++ 
L. amylovorus LMG 9496 37 Anaerobic MRS + 
L. fermentum LMG 6902 37 Anaerobic MRS ++ 
L. agilis LMG 9186 37 Anaerobic MRS ++ 
L. casei LMG 6904 37 Anaerobic MRS ++ 
L. amylophilus DSM 20533 37 Anaerobic MRS +++ 
L. acidophilus LMG 9433 37 Anaerobic MRS - 
L. buchneri DSM 20057 37 Anaerobic MRS - 
Enterococcus faecium DPC 4898 37 Anaerobic MRS ++ 
E. faecalis LMG7397 37 Anaerobic MRS ++ 
E. saccharolyticus DPC 4902 37 Anaerobic MRS ++ 
E. mundtii LMG 10748 37 Anaerobic MRS + 
Lactococcus lactis HP 30 Aerobic LM17 +++ 
L. lactis subsp. lactis DPC 3147 30 Aerobic LM17 +++ 
Micrococcus luteus DPC 6275 30 Aerobic BHI +++ 
Listeria innocua DPC 3572 37 Aerobic BHI ++ 
L. monocytogenes DPC 5788 37 Aerobic BHI + 
L. monocytogenes DPC 6893 37 Aerobic BHI + 
L. monocytogenes DPC 6894 37 Aerobic BHI + 
Bacillus cereus DPC 6087 37 Aerobic BHI + 
B. subtilis DPC 6551 37 Aerobic BHI ++ 
B. subtilis LMG 8198 37 Aerobic BHI + 
B. licheniformis DSM 13 37 Aerobic BHI ++ 
Pseudomonas aeruginosa APC 2064 37 Aerobic BHI - 
Staphylococcus chromogenes  APC 82 37 Aerobic BHI - 
S. aureus C55 37 Aerobic BHI - 
S. aureus R963 37 Aerobic BHI + 
Streptococcus mutans APC 1076 37 Aerobic BHI +++ 
Clostridium indolis DPC 6345 37 Anaerobic RCM ++ 
C. histolyticum DPC 6344 37 Anaerobic RCM ++ 
C. sporogenes DPC 6341 37 Anaerobic RCM ++ 
C. difficile  ATCC 1382 37 Anaerobic RCM + 
C. perfringens LMG 11264 37 Anaerobic RCM ++ 
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Abstract 
Lactobacilli constitute a large genus of Gram-positive lactic acid bacteria which have widespread 
roles, ranging from gut commensals to starters in fermented foods. A combination of in silico and 
laboratory-based screening allowed us to determine the overall bacteriocin producing potential of 
representative strains of each species of the genus. The genomes of 175 lactobacilli and 38 
associated species were screened for the presence of antimicrobial producing genes and combined 
with screening for antimicrobial activity against a range of indicators. There also appears to be a link 
between the strains environment and bacteriocin production, with those from the animal and 
human microbiota encoding over twice as many bacteriocins as those from other sources.  Five 
novel bacteriocins were identified belonging to differing bacteriocin classes, including two-peptide 
bacteriocins (muricidin and acidocin X) and circular bacteriocins (paracyclicin). In addition, there was 
a clear clustering of helveticin type bacteriolysins in the Lactobacillus acidophilus group of species. 
This combined in silico and in vitro approach to screening has demonstrated the true diversity and 
complexity of bacteriocins across the genus. It also highlights their biological importance in terms of 







Bacteriocins are ribosomally-synthesised antimicrobial peptides which generally act by inducing 
pore formation or inhibiting cell wall synthesis in target cells (Cotter et al., 2005).  Some bacteriocins, 
such as nisin, have found widespread applicability as bio preservatives in food systems where they 
have been used for decades.  Moreover, bacteriocin production can also be a key probiotic trait 
(Dobson et al., 2012, Walsh et al., 2008), and bacteriocins have been suggested as potential 
alternatives to antibiotics in the future (Cotter et al., 2013). The Lactobacillus genus has a long 
association with bacteriocin production, with numerous bacteriocins isolated from such species 
(O'Shea et al., 2013, Holo et al., 2001). Originally bacteriocin producers were isolated from 
functional screens against selected target strains, but many studies now rely on prior in silico 
screening, using tools such as BAGEL (Begley et al., 2009, McClerren et al., 2006). BAGEL scans the 
bacterial genome for putative bacteriocin open reading frames (ORFs) and also analyses surrounding 
ORFs to search for possible biosynthetic genes, immunity genes and transporters (de Jong et al., 
2010). Whilst the areas of interest identified by BAGEL represent potential bacteriocin operons, this 
does not always translate into functional bacteriocin production for many reasons including 
problems with mutation, regulation or target specificity. 
There are varying accounts on the extent of bacteriocin production in the environment. While 
numerous accounts assume ubiquity in production (Gillor et al., 2008, Inglis et al., 2013), a definitive 
analysis has yet to focus on clarifying the actual extent of bacteriocin production. In this study, we 
elucidate the bacteriocinogenic potential of representative species of the Lactobacillus genus and 
some related genera; i.e. the Lactobacillus Genus Complex. Previously Sun et al. (Sun et al., 2015) 
analysed the genomes of 175 Lactobacillus species and 38 closely related species, carrying out a 
screen for putative bacteriocin operons using the BAGEL bacteriocin mining tool. Despite no longer 
formally being considered as bacteriocins, large (>30kDa) helveticin-like antimicrobial proteins were 




encoding putative bacteriocin operons for in vitro production using well diffusion assays (WDAs) and 
MALDI TOF MS. Well diffusion assays were used to detect antimicrobial production whilst MALDI 
TOF MS and SDS PAGE were used to identify the masses of the bacteriocins. Peptide masses 
identified by MS were correlated with the theoretical masses of bacteriocins identified by BAGEL to 
confirm the identity of the anti-microbial. We reinforced the BAGEL results with BLAST searches for 
key lantibiotic and sactibiotic enzymes using specific sequences employed in previous studies against 
this new dataset of Lactobacillus genomes (Begley et al., 2009, Marsh et al., 2010, Goto et al., 2010). 







Distribution of Bacteriocin Operons 
Several studies have completed bacteriocin screens on diverse and unrelated species of bacteria 
(Begley et al., 2009, Walsh et al., 2015, Murphy et al., 2011). The aim of this study was to focus 
primarily on the lactobacilli and investigate the distribution of bacteriocin genes across this single 
large important genus. From the information identified by BAGEL, we used a phylogenetic tree to 
visualise the distribution of bacteriocin operons within the genus (Figure 1). Historically the 
Lactobacillus genus has a long association with bacteriocin production. While this study focuses on 
the type strain of each Lactobacillus species, Table 1 identifies those bacteriocins which have been 
previously identified and characterised from all strains in the Lactobacillus Genus Complex. In all, 66 
bacteriocins have been characterised from lactobacilli previously, which would suggest a high degree 
of production within the genus. It is notable that the production of these unique bacteriocins is, in 
fact, restricted to 16 different species.  
Visualisation of the distribution of bacteriocins throughout the Lactobacillus Genus Complex 
shows that there is a clear clustering of helveticin-like operons amongst the L. acidophilus branch of 
species, indicating that such genes have been retained from a common ancestor (Figure 1). Despite 
being previously classified as class III bacteriocins, these proteins are now termed bacteriolysins and 
are considered a distinct group of antimicrobials. Whilst these proteins are ribosomally synthesised, 
they are much larger than classical Gram positive bacteriocins (approx.30 kDa) and are heat labile. 
Helveticin J is the only previously characterised bacteriolysin from lactobacilli (Joerger and 
Klaenhammer, 1986), but here we show that these genes are actually highly prevalent across the 
genus, with 43 potential homologs identified from 23 strains (for alignment results see 
Supplementary Figure 1). Of the 18 strains in the L. acidophilus group, 36 helveticin homologs were 
distributed amongst 16 of these strains. While certain strains can encode up to four helveticin 




high degree of homology (in some cases greater than 99%) between some structural genes encoded 
by different strains does indicate that horizontal gene transfer of helveticin homologs has occurred; 
such a mechanism may also explain the presence of these genes in the six strains outside of the L. 
acidophilus group (Figure 1). 
The environment from which these strains have been isolated also seems to correlate with their 
bacteriocinogenic potential (Supplementary Table 1). For example, of the strains isolated from an 
animal or human origin 37.5% were identified as encoding a complete bacteriocin or helveticin like 
operon in BAGEL or BLAST screens (21 of 56 strains). This figure for strains isolated from non-animal 
source (food, plants, environmental and alcohol/wine products) displays an over two-fold reduction 
at 16.67% (25 of 150 strains). This result suggests that the bacteriocin production may prove to be a 
competitive advantage for strains from complex environments such as the microbiota of humans 
and animals. 
Diversity of Bacteriocins Identified 
Bacteriocins are a diverse and varied group of antimicrobials, which use different systems for 
bacteriocin modification, transport and immunity. In silico analysis allows us to determine which 
types of bacteriocins the lactobacilli can synthesise. To analyse the diversity of the bacteriocins 
encoded by lactobacilli, an in silico screen was first carried out on the genome of each strain 
followed by in vitro screening of each bacteriocin encoding strain to identify antimicrobial activity 
against a range of indicators (Table 2). MALDI TOF MS and SDS PAGE allowed us to determine the 
mass and subsequently the identity of the bacteriocins produced by the strains (Supplementary 
Figure 2). The bacteriocin classification scheme devised by Cotter et al. (Cotter et al., 2005, Cotter et 







 Class I bacteriocins are comprised of ribosomally synthesised, post-translationally modified 
bacteriocins (RiPPs)(Cotter et al., 2013). Originally restricted to lantibiotics, this class has now been 
extended to include other post-translationally modified bacteriocins such as sactibiotics.  
Lantibiotics 
Lantibiotics are a group of bacteriocins characterised by the presence of lanthionine and 
methyllanthionine bridges. Here, serine and threonine residues are converted to 2,3-
didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb), respectively, which then react with the 
thiol group found in cysteine residues, forming lanthionine or methyllanthionine thioether cross-
links (McAuliffe et al., 2001). Currently three lantibiotics have been attributed to the Lactobacillus 
genus; lactocin S (Mortvedt et al., 1991), plantaricin C (Gonzalez et al., 1994) and the two peptide 
lantibiotic plantaricin W (Holo et al., 2001). 
The BAGEL screen of the Lactobacillus dataset identified three further lactobacilli encoding 
lantibiotic structural peptides (Table 3). Of these, potential production was only identified in L. 
taiwanensis DSM 21401 which encodes a type I lantipeptide (a lantibiotic which doesn’t display 
antimicrobial activity), characterised by the presence of LanB and LanC modification enzymes. What 
is unusual about this peptide is the fact the structural gene is small compared to other lantipeptides, 
with the mature peptide predicted to contain only 14 amino acids. Despite a lack of demonstrated 
antibacterial activity against the range of indicators tested, MALDI TOF MS did identify a mass which 
correlates with the predicted mass of the mature lantipeptide. The lack of antimicrobial activity may 
simply imply that the indicator organisms tested were not sensitive, or that the putative lantipeptide 
has a signalling rather than a bacteriocidal role. 
A further type I lantibiotic operon was identified by BAGEL in the strain L. amylovorus DSM 
20531. This strain appears to encode a complete lantibiotic operon which contains the required 




homolog but a LanB homolog was absent from the operon which is necessary for initial dehydration 
of serine and threonine residues. The production of either of these bacteriocins was not detected in 
vitro. 
Lantibiotic operons were also identified in some of the other genera studied. Pediococcus 
damnosus DSM 20331 was found to encode and produce a class II lantibiotic. This strain has 
previously been found to produce the partially characterised lantibiotic pediocin PD-1 (Bauer et al., 
2005). From genomic data used in this study, the sequence of the pediocin PD-1 gene has now been 
elucidated, showing a high similarity to the lantibiotic plantaricin C (PlnC) (Turner et al., 1999). Due 
to the similarity between the two bacteriocins, pediocin PD-1 likely shares a common mode of action 
with PlnC whose activity has been shown to be as a result of the combination of pore formation and 
inhibition of lipid II synthesis (Wiedemann et al., 2006). P. claussenii DSM 14800 was also shown to 
encode pediocin PD-1, however, this strain failed to display bacteriocin production. The 
Carnobacterium maltaromaticum strains DSM 20722 and DSM 20730 were also both found to 
encode the two-component lantibiotic carnolysin, however the in vitro production of this bacteriocin 
was not seen in either strain (Tulini et al., 2014). 
To supplement the results of BAGEL searches, previous in silico lantibiotic screens were repeated 
on the new Lactobacillus dataset. We used the modification enzymes NisC, LtnM1 and VenL as 
drivers in the BLAST search for novel lantibiotics (Marsh et al., 2010, Begley et al., 2009, Goto et al., 
2010). L. gallinarum DSM 10532, L. crispatus DSM 20584 and P. cellicola DSM 17757 were all found 
to harbour a NisC homolog, despite not being identified by BAGEL. However, upon examination of 
the surrounding genes, no potential structural genes were identified. Strains identified in BLAST 
searches as encoding LanM homologs had also been identified by BAGEL. No homolog of the novel 






The sactibiotics are a growing class of bacteriocins characterised by the presence of unusual 
sulphur to α-carbon linkages. These modifications are carried out by radical S-adenosylmethionine 
(SAM) proteins which catalyse the formation of these thioether bonds (Fluhe et al., 2012, Mathur et 
al., 2015). To analyse the prevalence of potential sactibiotic operons within the lactobacilli, the 
sequences for the radical SAMs associated with a two-component sactibiotic thuricin CD (TrnC and 
TrnD) were used as drivers in a BLAST analysis of the genomes available(Rea et al., 2010, Murphy et 
al., 2011). Only two radical SAMs were found resembling those associated with thuricin CD.  L. mali 
DSM 20444 was found to encode one such SAM, however, analysis of the operon failed to identify a 
potential structural gene. Kandleria vitulina DSM 20405 appears to encode a complete sactibiotic 
operon, encompassing a structural gene, transporter and associated radical SAM, however, no 
biological activity could be attributed to this strain with the panel of indicators tested. BAGEL further 
identified two potential sactibiotic related radical SAM proteins in C. maltaromaticum DSM 20342 
and DSM 20722 but no potential structural genes for these enzymes were apparent.  
TOMMs 
Thiazole/oxazole modified microcins (TOMMs) are a class of RiPPs which are now included with 
the class I bacteriocins. These peptides undergo extensive post-translational modification, where 
cysteine, serine and threonine residues are converted into the corresponding heterocycles; thiazole, 
oxazole and methyloxazole, respectively (Molloy et al., 2011). TOMMs exist in gene clusters, with 
components encoding several factors involved in transport, modification and immunity. Using 
streptolysin as an example, the modification of the structural peptide is the result of the activity of 
the SagBCD enzyme complex, encompassing a cyclodehydratase (SagC), a dehydrogenase (SagB) and 
a docking protein (SagD) (Lee et al., 2008). Whilst SagBCD clusters are described as being relatively 
widespread amongst prokaryotes, no TOMM has yet been identified from a Lactobacillus species 
(Lee et al., 2008). In our study L. crispatus DSM 20584, L. intestinalis DSM 6629 and Oenococcus 




Whilst the operons in O. kitaharae DSM 17330 and L. intestinalis DSM 6629 appear to be complete, 
the L. crispatus DSM 20584 TOMM operon appears to lack a structural gene, however, the structural 
gene for similar operons has been found to be some distance from the SagBCD homologs previously 
(Haft, 2009). Of these three strains, L. crispatus DSM 20584 was the only one found to display 
antimicrobial activity; the source of this activity, however, remains unclear. 
Class II 
 Class II bacteriocins are small heat stable peptides which are not subject to extensive post 
translational modification, most of which act to permeabilize the membrane of target cells (Cotter et 
al., 2005).  This class of bacteriocins is further subdivided based on the structure and activity of the 
peptides. 
Class IIa 
 Class IIa or ‘pediocin-like’ bacteriocins display a narrow range of antimicrobial activity, 
particularly displaying strong anti-listerial activity. Such bacteriocins encompass a highly conserved 
YGNGV/L N-terminal motif followed by cysteine residues which can form a disulphide bridge. Unlike 
the N-terminus, the C-terminus is less conserved and is likely involved in membrane insertion and 
pore formation (Fimland et al., 2005). These bacteriocins likely act by using the mannose-
phosphotransferase system on sensitive cells as a receptor (Ramnath et al., 2000). 
Despite having a long association with this class of bacteriocins, surprisingly only 3 
Lactobacillus strains were found to encode what appear to be complete class IIa bacteriocin 
operons, containing structural, immunity and transport genes (Table 4a). Of these, L. hordei DSM 
19519 displayed bacteriocin production against six of the indicators tested. From MALDI TOF MS and 
BAGEL results, the production of coagulin was confirmed. This 44 amino acid bacteriocin was 
originally isolated from Bacillus coagulans and closely resembles the bacteriocin pediocin PA-1, 
differing by a single amino acid due to a N41T substitution (Hyronimus et al., 1998, Le Marrec et al., 




encoding a structural peptide displaying 74% amino acid identity to plantaricin 423. Production of 
this bacteriocin however was not seen. 
Numerous lactobacilli identified in this study were found to carry partial pediocin-like 
operons, often containing the bacteriocin structural gene and associated immunity protein but 
lacking the appropriate transporters (Table 4b). One potential explanation is that when a strain 
acquired the gene for pediocin resistance that the neighbouring small bacteriocin structural gene 
was also transferred, whilst the larger transporters were not. 
Although not included in the Lactobacillaceae family, several Carnobacterium strains were 
included in the preceding genomic study (Sun et al., 2015). Numerous bacteriocins have been 
attributed to this genus previously (Quadri et al., 1994, Tulini et al., 2014). While the source of 
antimicrobial activity from C. maltaromaticum DSM20342 is unclear, C. maltaromaticum DSM 20722 
was found to produce the class IIa bacteriocin cbnB2 and cbnBM1, the class IId bacteriocin cbnX was 
also produced by the strain (Tulini et al., 2014). CbnB2 contains an N2Y mutation which was also 
previously seen by Tulini et al. (Tulini et al., 2014).  
Class IIb 
The class IIb bacteriocins are comprised of unmodified two peptide bacteriocins, whose activity 
is dependent on the synergistic activity of both peptides which interact to form a single antimicrobial 
unit (Nissen-Meyer et al., 2010). These bacteriocins are likely to act by forming membrane spanning 
pores which result in the leakage of small molecules from the cell. Such bacteriocins tend to contain 
conserved GxxxG or AxxxA motifs which are responsible for close helix interactions between each 
bacteriocin peptide (Nissen-Meyer et al., 2010).  A wide range of class IIb bacteriocins were 
identified by BAGEL in this study (Table 5). 
L. murinus DSM 20452 was one of the strains which demonstrated bacteriocin production. 




(muricidin). Both peptides of muricidin display homology to the class IIa bacteriocin plantaricin S, 
with the α peptide displaying 41% amino acid identity to pln Sα and the β peptide 48% to pln Sβ. The 
β peptide found here however lacks the AxxxA motif found in pln Sβ, a sequence which has been 
shown to be important for helix-helix interactions in pln S (Soliman et al., 2011). 
Another two-peptide bacteriocin (acidocin X) was also identified from L. acidophilus DSM 20079. 
Correlation between the bacteriocins identified by BAGEL and MALDI TOF MS results led to the 
identification of two, bacteriocin like, peptides. The first of these was a 35 amino acid peptide 
displaying 53% identity with the enterocin X β peptide. The second peptide was not identified in 
BAGEL and was found by manual analysis of the bacteriocin operon, this displays 25% identity to the 
enterocin X α peptide.  
Class IIc 
Class IIc bacteriocins are also known as circular bacteriocins due to the covalent linkage of the N- 
and C-termini. The compact circular structure of these bacteriocins can contribute to their 
temperature and pH stability (Gabrielsen et al., 2014). These circular bacteriocins permeabilize the 
target cell membrane, resulting in a loss of membrane potential which leads to cell death (Van 
Belkum et al., 2011). Despite having similar modes of action, this class of bacteriocins are further 
broken down into two subgroups, based on the isoelectric point of the peptides and the 
conservation seen amongst the groups (Acedo et al., 2015). Currently, there are two examples of 
class IIc bacteriocins produced from lactobacilli, both of which belong to subgroup II. Originally 
identified as two separate class IIc bacteriocins, Gassericin A (L. gasseri LA39) and reutericin 6 (L. 
reuteri LA6) have now been shown to be identical (Kawai et al., 2001, Arakawa et al., 2010). Acidocin 
B (L. acidophilus M46), originally thought to be linear, has also been recently reclassified as a circular 
bacteriocin. Leuconostoc mesenteroides TK41401 has also been shown to produce leucocyclicin Q, a 




From the analysis carried out in this study, L. paracasei subsp. paracasei DSM 5622 was found to 
produce a potential class IIc bacteriocin (paracyclicin), with a structural gene displaying 64% amino 
acid identity to butyrivibriocin AR10 (Kalmokoff et al., 2003). The operon contains a putative ABC 
permease, ATPase and a protein belonging to the DUF 95 protein family, all of which have been 
associated with the gene clusters of circular bacteriocins (Gabrielsen et al., 2014). Upon purification 
of the bacterial supernatant, a mass of 5905.75 Da was identified as the causative agent of 
antimicrobial activity. This mass correlates closely with the predicted mass of the mature bacteriocin 
structural peptide which is calculated as 5906.87 Da. It is clear that paracyclicin belongs to the 
subgroup II circular bacteriocins, due to a high level of conservation found within the group (Table 
6). Despite this conservation, this novel bacteriocin does display variation in certain conserved 
regions which is not seen in the rest of the class. L. nodensis DSM 19682 was also found to encode 
one such potential bacteriocin, however, no antimicrobial activity was observed with this strain. 
Class IId 
Class IId bacteriocins are single peptide, linear bacteriocins which do not display homology to 
the pediocin like bacteriocins (Cotter et al., 2013). This class of bacteriocins displays a high degree of 
diversity and numerous class IId bacteriocins have been characterised from lactobacilli previously 
(Table 1). In silico analysis of the Lactobacillus dataset identified numerous novel structural genes 
(Table 7) with several shown to be produced. 
L. paralimentarius DSM 13961 was one such strain displaying the production of a class IId 
bacteriocin (paralimenterocin). The paralimenterocin structural gene identified encodes a 44 amino 
acid single peptide bacteriocin whose closest homolog appears to be the relatively uncharacterised 
bacteriocin BacSJ2-8 to which it has 77% identity (Kojic et al., 2010). The mode of action of both of 
these bacteriocins remains unclear. 
L. equicursoris DSM 19284 is also highly likely to produce a novel class IId bacteriocin 




not identify an associated mass. In silico BAGEL analysis identified three putative bacteriocin 
operons, two of which encoded larger bacteriolysins of approximately 30kDa, the remaining operon 
encodes a homolog of lactococcin 972. SDS PAGE analysis of the concentrated culture supernatant 
identified a mass between the 5kDa and 10kDa markers which displayed antimicrobial activity once 
overlaid with L. delbrueckii subsp. bulgaricus LMG 6901 (Supplementary Figure 2). This mass 
correlates well with the predicted mass (approximately 7kDa) of the lactococcin 972 homolog 
‘equicursorin’. Lactococcin 972 is unique with respect to its activity in comparison to other class II 
bacteriocins. These bacteriocins do not induce pore formation in the cells but instead act by binding 
to lipid II and inhibiting septum formation. Lactococcin 972 is also unusual in that it’s biologically 
active form is as a homodimer (Martinez et al., 2000, Martinez et al., 2008). Given that only two such 
bacteriocins have been identified, it was surprising that four further lactococcin 972-like operons 
were identified in genomic dataset screened in this study (Table 7 (b)). An in silico screen carried out 
by Letzel et al. (Letzel et al., 2014) identified 9 further Lactococcin 972 operons in anaerobic 
bacteria, thus due to the expansion of this group, these bacteriocins may warrant a separate 
classification, given their unique mode of action when compared to other class II bacteriocins.  
Bacteriolysins (Formerly Class III Bacteriocins) 
In the Lactobacillus dataset, a number of homologs of the bacteriolysin helveticin (Joerger and 
Klaenhammer, 1986) were found to be encoded, with several displaying in vitro antimicrobial 
activity. The approximate size of these proteins was determined using SDS PAGE overlay assays, as 
MALDI TOF MS wasn’t used to determine the size of these larger proteins. Several strains encoded 
numerous helveticin homologs, however, SDS PAGE overlays were not able to identify which of 
these homologs was actually produced as all had masses of approximately 37 kDa (Supplementary 
Figure 3).  
 L. intestinalis DSM 6629 was shown to produce one of these helveticin homologs, with four 




helveticin J. L. kitasatonis DSM 16761 also produced a helveticin like peptide, the strain encodes two 
such proteins displaying 35% and 41% identity to helveticin J. Two L. amylovorus strains (DSM 16698 
and DSM 20531) were shown to produce a helveticin homolog. L amylovovrus DSM 16698 encodes 
four of such proteins, whilst L. amylovorus DSM 20531 encodes three. Both share a single identical 
helveticin homolog but it is unclear whether this is the protein produced by both strains. L. kalixensis 
DSM 16043 also produces a helveticin-like protein, with 3 homologs encoded within the genome 
displaying, 34%, 49% and 50% amino acid identity to helveticin J. 
BAGEL also identified a helveticin homolog (77% identity to helveticin J) from L. crispatus 
DSM20584. Interestingly, analysis of the results of a previous exoproteomic study identified the 
secretion of this protein (Johnson et al., 2016). The antimicrobial activity of the strain in this study 
was determined to be due to a small peptide by an SDS PAGE overlay assay, this is most likely a 






This study gives the first complete assessment of bacteriocin production across the Lactobacillus 
Genus Complex, combining both in silico and laboratory based screening methods. This combination 
of approaches allows for a more representative estimation of bacteriocin production to be 
calculated. Well-diffusion assays and MALDI TOF MS allows for the confirmation of in vitro 
bacteriocin production by cells. Bacteriocin production however can be a highly regulated process, 
with strains requiring specific conditions and environments to induce production of these 
antimicrobials (Diep et al., 2000, Maldonado-Barragan et al., 2013). Such regulations would make it 
extremely difficult to identify the bacteriocins found here using in silico screens if we were to rely on 
in vitro screening methods alone. Thus, the use of BAGEL and BLAST bacteriocin screens allows us to 
identify these bacteriocin operons from the Lactobacillus Genus Complex without the shortcomings 
and restrictions of laboratory based screens.  
In silico analysis has allowed us to determine the overall bacteriocinogenic potential of the 
Lactobacillus genus. Of the 213 strains analysed, 51 were identified by BAGEL or in BLAST screens as 
harbouring what appears to be a complete bacteriocin or helveticin like operon, a prevalence of 
23.94%. If we focus on the lactobacilli, of the 175 strains analysed only 25 were found to encode 
bacteriocin operons (14%). If helveticin operons and those of previously characterised bacteriocins 
are included, of the Lactobacillus species analysed 30% were found to encode at least one 
antimicrobial. This figure of 30% is surprisingly high given that lactobacilli are not associated with the 
production of more traditional antibiotics formed by non-ribosomal peptide synthetases (NRPS) and 
polyketide synthases (PKS). Given the extent of bacteriocin production within the genus, the 
production of antimicrobials by these means may be unnecessary, especially given the size of such 
NRPS and PKS operons and the subsequent energy it would take for their production. Thus, 





There was a high degree of novelty within the bacteriocins identified by BAGEL in this study. Of 
all the structural genes identified here, 73% had not previously been characterised. Screening of 
these strains identified five novel functional bacteriocins (muricidin, acidocin X, paracyclicin, 
paralimenterocin and equicursorin) from a range of bacteriocin classes. In addition, five novel 
producers of helveticin-like peptides were also identified. The abundance of homologs of helveticin-
like bacteriolysins encoded by lactobacilli is surprising given how little these proteins have been 
characterised to date. The observation that most strains in the L. acidophilus group encode 
helveticin homologs with significant homology suggests that this trait was derived from a common 
ancestor and then disseminated by horizontal transfer. Apart from narrow spectrum antimicrobial 
activity, no other function has been ascribed to these proteins. The role these proteins play in the 
life cycle of this narrow branch of strains warrants further study.  
The variety and distribution of bacteriocins throughout the genus is interesting when compared 
to the results of other in silico screens which were carried out. Letzel et al. (Letzel et al., 2014) used 
BAGEL and other tools to screen the genomes of 211 anaerobes for bacteriocin encoding genes (no 
lactobacilli were included in the screen, and helveticin like proteins were excluded).  Of these 211 
strains, just over 25% were found to encode a bacteriocin like peptide. Thus despite the differences 
in the make-up of the datasets, there is a similar level of bacteriocin encoding genes found in both 
groups. While the overall levels may be similar, the diversity of the bacteriocins encoded differs 
greatly. Of the bacteriocins encoded in the anaerobic dataset, 78% were found to be class I modified 
bacteriocins, while in the Lactobacillus Genus Complex this value is only 17%. One similarity between 
these sets of results, however, is the presence of lactococcin 972 like bacteriocins. 9 novel homologs 
were identified in the anaerobic bacteria, this result taken with the number of novel homologs 
identified from the lactobacilli suggests that this group of unique bacteriocins merit their own class 




In a bioinformatics screen of Bacillus species for bacteriocin operons (Zhao and Kuipers, 2016), 
the overall level of bacteriocins encoded by such strains was much higher, with 583 putative 
bacteriocin operons encoded in the genomes of 328 strains. 89% of these strains, covering 50 
different species encode a bacteriocin, a much higher level than seen in the anaerobic bacteria and 
the lactobacilli. The diversity of encoded bacteriocins again differs to that of the lactobacilli with 66% 
of operons identified here encoding class I bacteriocins. This difference suggests that there is not an 
even distribution in the types of bacteriocins across genera, with the lactobacilli in particular relying 
on the production of class II bacteriocins in comparison to other groups. A similar high prevalence of 
bacteriocin operons can be found in the cyanobacteria, with 145 putative bacteriocin gene clusters 
being identified in 43 of the 58 complete and partial genomes screened (Wang et al., 2011). It must 
be remembered, however, that in both studies these operons were not manually analysed so, in 
reality, overall levels may be lower.  
The inter-species diversity of bacteriocin production can be seen in a screen carried out, 
whereby the genomes of 169 Streptococcus mutans strains were screened by BAGEL for bacteriocin 
operons (Liu et al., 2016). 211 bacteriocin operons were found distributed amongst 157 strains, of 
which 32 were lantibiotic operons. These results show that despite carrying out a comprehensive 
analysis of bacteriocin production in lactobacilli, a high level of diversity within each species can still 
result in novel bacteriocins being identified.  
The environment from which strains are isolated may also influence their bacteriocinogenic 
potential. 37.5% of strains isolated from human and animal microbiomes encoded bacteriocins or 
bacteriolysins, this is over twice the value for strains isolated from food, wine and beer, plants and 
the environment at 16.67%. The microbiota of animals is a complex environment with microbes 
under constant competition for nutrients and resources (Kostic et al., 2013). Bacteriocin production 
can provide a competitive advantage for strains, allowing them inhibit sensitive strains thus reducing 




2012, Walsh et al., 2008, Gillor et al., 2009). This may suggest why a greater proportion of lactobacilli 
from these environments encode bacteriocins. Environments such as fermented foods would 
provide a much narrower niche for the growth of microbes. Less competition here may negate the 
need for these bacteria to expend energy on bacteriocin production. 
Given the association of lactobacilli with probiotics and food production, the knowledge of their 
potential to produce antimicrobials is of great value (Sanders and Klaenhammer, 2001). Bacteriocin 
production may increase their ability to establish themselves in a community such as the gut, or 
provide a natural mechanism to inhibit the growth of food spoilage microorganisms (Walsh et al., 
2008, Yang et al., 2014). Thus bacteriocin production can prove a useful trait for an industrially 
important group of bacteria. Previously, the isolation of bacteriocins from lactobacilli relied on 
intensive laboratory screens of individual cultures. The use of tools such a BAGEL and BLAST 
however now allow for the rapid identification of bacteriocin operons within strains, and with the 





Materials and Methods 
Bacteriocin Identification 
 The bacteriocin mining tool BAGEL2 was used to identify putative bacteriocin operons(de 
Jong et al., 2010) and the genome visualisation tool ARTEMIS was subsequently used for manual 
analysis of the bacterial genomes(Rutherford et al., 2000). To determine the degree of novelty in the 
bacteriocins identified by BAGEL2, BLASTP searches were done for each putative bacteriocin peptide 
against those identified in the BAGEL screen. The levels of identity described in this study are derived 
from Clustal Omega. For bacteriocin analysis using specific “driver” sequences, the BLASTP program 
was used using default parameters. The driver sequences used were NisC (GenBank Accession no. 
CAA79470.1), LtnM1 (GenBank Accession no. NP_047321.1), VenL (GenBank Accession no. 
AEA03262.1), TrnC and TrnD from Bacillus thuringiensis DPC 6431. 
Bacterial Strains 
 The bacterial strains screened for bacteriocin production and the conditions for growth are 
listed in Supplementary Table 2. Anaerocult A gas packs (Merck, Darmstadt, Germany) were used to 
generate anaerobic conditions. 
Bacteriocin Assays 
 Bacteriocin activity was analysed via well diffusion assays against the indicator organisms 
listed in Supplementary Table 3. Briefly, each strain screened was grown in broth under the 
appropriate conditions. The cell free supernatant of each culture was prepared by centrifuging the 
fully grown culture at 4000 RCF for 20 minutes, the pH was adjusted to pH7 using sodium hydroxide 
to negate any antimicrobial activity which may be caused by the acidity of the cell free supernatants. 
Fifty microlitres of an overnight culture of each indicator was then added to 20 ml of the appropriate 




agar.  Fifty microliters of the cell free supernatant of the strains being tested was then placed in a 
well. These indicator plates were refrigerated for two hours prior to incubation. 
Mass Spectrometry (MS) 
 MALDI TOF colony mass spectroscopy was carried out on each of the strains as previously 
described to identify masses of putative bacteriocins (Field et al., 2010). Here colonies were first 
mixed with a 70% propan-2-ol 0.1% TFA solution to elute bacteriocin from the cell. Following 
centrifugation, the subsequent supernatant was spotted on the target pre-coated with CHCA matrix 
solution. A further layer of matrix solution was then added on top of this supernatant. An Axima 
TOF2plus MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) was used to identify 
the peptide masses using positive-ion reflectron mode. 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS PAGE was used for the identification of higher molecular weight antimicrobial proteins 
(bacteriolysins). Cultures were grown overnight in broth and the cell free supernatants were 
prepared as described above. The proteins from the bacterial supernatant were precipitated by 
addition of ammonium sulphate salts up to a concentration of 50%. The precipitate was collected by 
centrifugation and resuspended in water. Supernatants were then incubated with TruPAGETM LDS 
sample buffer (Sigma-Aldrich, Wicklow, Ireland) for 10 minutes at 70˚C. Samples were run on 12% 
acrylamide gels at 30 mA, together with Precision Plus Protein™ Dual Xtra prestained protein 
standards (Bio-Rad, Hertfordshire, UK) which were used to estimate molecular mass with a range of 
2-250kDa. The completed gels were divided in two, one half was stained using the EZBlueTM staining 
reagent (Sigma-Aldrich). The other half was washed with 1% tween-80 (Sigma-Aldrich) for 45 
minutes, followed by three 5 minute washes in distilled water. This gel was overlaid with soft MRS 




6901. The plate was incubated overnight to determine the mass of any antimicrobial proteins 
produced. 
Bacteriocin Purification  
Carnobacteriocins CbnB2, CbnBM1 and CbnX 
Carnobacterium maltaromaticum DSM 20722 was grown overnight in TSA broth, 100 ml of 
the supernatant was passed through a 5g, 20ml Strata C18-E solid-phase extraction (SPE) column 
(Phenomenex, Cheshire, UK). The column was washed with 20ml of 30% ethanol and 20ml of 70% 2-
propanol (IPA) 0.1% TFA. The 70% IPA eluent was concentrated and applied to a Semi Prep Proteo 
Jupiter RP-HPLC column (10 x 250mm, 90Å, 4µm) (Phenomenex, Cheshire, UK) running a 20-55% 
gradient whereby buffer B was 90% acetonitrile. MALDI TOF MS was carried out on fractions to 
identify the presence of the peptides of interest.  
Paracyclicin 
L. paracasei subsp. paracasei DSM 5622 was grown overnight in MRS broth. Culture 
supernatant was passed through a column containing 60g Amberlite XAD beads and washed with 
400ml of 50% ethanol and the antimicrobial peptide eluted with 400ml of 70% IPA 0.1% TFA. The IPA 
was removed and the eluent passed through a 5g, 20ml C18 SPE column pre-equilibrated with 
methanol and water. The column was washed with 30ml of 50% ethanol and activity eluted with 30 
ml of IPA. The IPA was removed from the C18 SPE IPA eluent and the sample applied to a semi 
preparative Vydac C4 Mass Spec (10 x 250 mm, 300Å, 5µ) RP-HPLC column (Grace, Columbia, USA) 
running an acetonitrile and propan-2-ol gradient described as follows: 5-55% buffer B and 0-5% 
buffer C over 25 minutes followed by and 55-19% buffer B and 5-81% buffer C over 60 minutes, 19-
5% buffer B and 81-95% buffer C over 5 minutes where buffer A is Milli Q water containing 0.1% TFA, 
buffer B is 90% acetonitrile 0.1% TFA and buffer C is 90% propan-2-ol 0.1% TFA. Eluent was 




using well diffusion assays against L. delbrueckii subsp. bulgaricus LMG 6901. MALDI TOF MS was 





Figures and Tables 
 
Figure 1. Distribution of complete bacteriocin operons amongst the Lactobacillus Genus Complex 





Table 1. Bacteriocins characterised from species within the Lactobacillus Genus Complex 
 
Bacteriocin Subclass Producing strain Origin Reference 
Class I      
Plantaricin W (α and β) II 
Lactobacillus plantarum LMG 
2379 
Wine 
(Holo et al., 2001) 
Plantaricin C II L. plantarum LL441 Cabrales cheese 
(Gonzalez et al., 1994) 
Lactocin Sa II L. sakei L45 Sausages 
(Mortvedt et al., 1991) 




(Green et al., 1997) 
Glycocin F Glycocin L. plantarum KW30 Fermented corn 
(Venugopal et al., 2011) 
Class II      
Acidocin A IIa L. acidophilus TK9201 Fermented milk (starter) (Kanatani et al., 1995) 
Curvaticin L442 IIa L. curvatus L442 Greek fermented sausage (Xiraphi et al., 2006) 
Curvaticin 13  IIa L. curvatus SB13 Sausages (Sudirman et al., 1993) 
Sakacin P (variant)b IIa L. curvatus LTH1174 Fermented meat (Cocolin and Rantsiou, 2007) 
Plantaricin BM-1 IIa L. plantarum BM-1 Fermented meat (Zhang et al., 2013) 
Plantaricin C19 IIa L. plantarum C19 Fermented cucumber (Atrih et al., 2001) 
Plantaricin 423 IIa L. plantarum 423 Sorghum (beer) (Van Reenen et al., 2003) 
Sakacin Pc IIa L. sakei LTH673 Cured meat (Tichaczek et al., 1994) 
Sakacin Ad IIa L. sakei Lb706 Meat (Holck et al., 1992) 
Sakacin Ge IIa L. sakei 2512 Food origin (Simon et al., 2002) 
Sakacin Xf IIa L. sakei 5 Malt (Vaughan et al., 2003) 
Bavaricin A IIa L. sakei MI1401 Sourdough (Larsen and Norrung, 1993) 
Bavaricin MN IIa L. sakei MN Meat (bovine) (Kaiser and Montville, 1996) 
Bacteriocin L-1077 IIa L. salivarius L-1077 Intestine (broilers) (Svetoch et al., 2011) 
Leucocin Agh IIa Leuconostoc geldium UAL 187  Vacuum-packed meat (Hastings et al., 1991) 
Leucocin C IIa Leuc. mesenteroides TA33a Spoiled vacuum-packed meat (Papathanasopoulos et al., 1997) 
Leucocin 10Ch IIa Leuc. mesenteroides 10 Malted barley (Vaughan et al., 2001) 
Leucocin 683Y IIa Leuc. mesenteroides 683 Malted barley (Vaughan et al., 2001) 
Mesentericin Y105 IIa 
Leuc. mesenteroides subsp. 
mesenteroides Y105 
Goats milk 
(Hechard et al., 1992) 
Pediocin PA-1 (ACH)i IIa P. acidilactici PAC1.0 Meat (Gonzalez and Kunka, 1987) 
Pediocin SA-1 IIa P. acidilactici NRRL B5627 Meat (Anastasiadou et al., 2008b) 
Penocin A IIa P. pentosaceus ATCC 25745 Plants (Diep et al., 2006) 
Pediocin SM-1 IIa P. pentosaceus Mees 1934 Meat (Anastasiadou et al., 2008a) 




(Papagianni and Papamichael, 
2011) 
Lactobin Aj IIb L. amylovorus LMG P-13139 Corn liquor (Contreras et al., 1997) 
Brevicin 174 (breB and breC) IIb L. brevis 174A Iyokan (fruit) (Noda et al., 2015) 
Lactocin 705 (Lac705α and 
Lac705β) 
IIb L. casei CRL 705 Meat 
(Vignolo et al., 1996) 
Acidocin LF221 (LF221A and 
LF221B)k 
IIb L. gasseri LF221 Faeces (child) 
(Majhenič et al., 2004) 
Gasericin T (GatA and GatX) IIb L. gasseri SBT2055 Faeces (human) (Kawai et al., 2000) 
Lactacin F (LafA and LafX)l IIb L. johnsonii VPI11088 Intestine (human) (Fremaux et al., 1993) 
Sakacin T (SakTα and SakTβ)m IIb L. sakei CTC372 Sausages (Aymerich et al., 2000) 
Plantaricin E/F (PlnE and PlnF) IIb L. plantarum C11 Fermented cucumber (Diep et al., 1996) 
Plantaricin J/K (PlnJ and PlnK) IIb L. plantarum C11 Fermented cucumber (Diep et al., 1996) 
Plantaricin S (Plsα and Plsβ)n IIb L. plantarum LPCO10 Green olives (Stephens et al., 1998) 




Table 1. Continued     
Bacteriocin Subclass Producing strain Origin Reference 
     
Plantaricin NC8 (PLNC8α and 
PLNC8β) 
IIb L. plantarum NC8 Ensilage 
(Maldonado et al., 2003) 
Salivaricin ABP-118 (Abp118α 
and Abp118β) 
IIb L. salivarius UCC118 Intestine (human probiotic) 
(Flynn et al., 2002) 
Salivaricin CLR 1328 (Salα and 
Salβ) 
IIb L. salivarius CLR1328 Vagina (human) 
(Vera Pingitore et al., 2009) 
Salivaricin P (Sln1 and Sln2) IIb L. salivarius DPC6005 Intestine (pig) (Barrett et al., 2007) 
Salivaricin T (SalTα and SalTβ) IIb L. salivarius DPC6488 Intestine (neonate) (O'Shea et al., 2011) 
Acidocin B IIc L. acidophilus M46 Food origin (Leer et al., 1995) 
Gassericin Ao IIc L. gasseri LA39 Faeces (child) (Kawai et al., 1998) 
Leucocyclicin Q IIc Leuc. mesenteroides TK41401 Japanese pickles (Masuda et al., 2011) 
Acidocin 8912 IId L. acidophilus TK8912 Dairy origin (Tahara et al., 1992) 
Brevicin 27 IId L. brevis SB27 Sausages (Benoit et al., 1997) 
Lactocin MXJ 32A IId L. coryniformis MXJ 32 Fermented vegetables (Lu et al., 2014) 
Curvalicin BAP2 IId L. curvatus CWBI-B28 Meat (Ghalfi et al., 2010) 
Curvaticin FS47  IId L. curvatus FS47 Meat (Garver and Muriana, 1994) 
Sakacin Q (variant)p IId L. curvatus LTH1174 Fermented meat (Cocolin and Rantsiou, 2007) 
Bacteriocin SJ2-8 IId L. paracasei BGSJ2-8 Home-made cheese (Lozo et al., 2007) 
Paracin C IId L. paracasei CICC 20241 Probiotic (Pei et al., 2013) 
Plantaricin 1.25 α IId L. plantarum TMW1.25 Fermented sausages (Remiger et al., 1999) 
Plantaricin 1.25 β IId L. plantarum TMW1.25 Fermented sausages (Remiger et al., 1999) 
Plantaricin 149 IId L. plantarum NRIC 149 Pineapple (Kato et al., 1994) 
Plantaricin 163 IId L. plantarum 163 Fermented vegetables (Hu et al., 2013) 
Plantaricin A IId L. plantarum C11 Fermented cucumber (Nissen-Meyer et al., 1993) 
Plantaricin ASM1 IId L. plantarum A-1 Corn bread (Hata et al., 2010) 
Plantaricin JLA-9 IId L. plantarum JLA-9 
Suan-Tsai (Chinese fermented 
cabbage) 
(Zhao et al., 2016) 
Plantaricin ST31 IId L. plantarum ST31 Sourdough (Todorov et al., 1999) 
Sakacin Qq IId L. sakei LTH673 Fermented dry sausage (Mathiesen et al., 2005) 
Salivaricin L IId L. salivarius DPC6488 Intestine (neonate) (O'Shea et al., 2011) 
Plantaricin Y IId L. plantarum 510 Koshu vineyard (Chen et al., 2014) 
Rhamnosin A IId L. rhamnosus 68 Intestinal microbiota (human) (Dimitrijevic et al., 2009) 
Bactofencin A IId L. salivarius DPC6502 Intestine (porcine) (O'Shea et al., 2013) 
Bacteriocin LS2 IId L. salivarius BGHO1 Oral (human) 
(Busarcevic and Dalgalarrondo, 
2012) 
Leucocin B IId Leuc. mesenteroides TA33a Spoiled vacuum-packed meat (Papathanasopoulos et al., 1997) 
Mesentericin 52Br IId Leuc. mesenteroides FR52 Raw Milk (Revol‐Junelles et al., 1996) 
Leucocin N IId 
Leuc. pseudomesenteroides QU 
15 
Nukadoko 
(Sawa et al., 2010) 
Leucocin Q IId 
Leuc. pseudomesenteroides QU 
15 
Nukadoko 
(Sawa et al., 2010) 
Weissellicin 110 IId Weissella cibaria 110 Plaa-Som (Srionnual et al., 2007) 
Weissellicin L IId W. hellenica 4-7 Sian-sianzih (Leong et al., 2013) 
Weissellicin M IId W. hellenica QU 13 Pickel barrel (Masuda et al., 2011) 
Weissellicin Y IId W. hellenica QU 13 Pickel barrel (Masuda et al., 2011) 
Lactacin Bs - L. acidophilus N2 Food origin 
(Barefoot and Klaenhammer, 
1983) 




     
Table 1. Continued     
Bacteriocin Subclass Producing strain Origin Reference 
     
Curvalicin BAP3 - L. curvatus CWBI-B28 Meat (Ghalfi et al., 2010) 
Gassericin E - L. gasseri EV1461 Healthy vagina (human) 
(Maldonado-Barragan et al., 
2016) 
Plantacin B - L. plantarum NCDO1193 Dairy origin (West and Warner, 1988) 
Plantaricin F - L. plantarum BF001 Spoiled cat fish filets (Fricourt et al., 1994) 
Plantaricn T - L. plantarum LPCO10 Green olives (Jimenez-Diaz et al., 1993) 
Bacteriocin SMXD51 - L. salivarius SMXD51 Faeces (chicken) (Messaoudi et al., 2012) 
Salivaricin B - L. salivarius M7 Food origin (Ten Brink et al., 1994) 
Bacteriolysin      
Helveticin J   L. helveticus NCDO481 Dairy origin 
(Joerger and Klaenhammer, 
1986) 
 
Characterised bacteriocins with identicle amino acid sequences: 
a
Sakacina M/lactocin S from L. sakei 148 
(Sobrino et al., 1992, Skaugen et al., 1997). 
b
Varient of sakacin P from L. curvatus L442 (Cocolin and Rantsiou, 
2007). 
c
Sakacin 674 from L. sakei 674 (Holck et al., 1994). 
d
Curvacin A from L. curvatus LTH1174 (Tichaczek et 
al., 1993) and sakacin K from L. sakei CTC 494 (Hugas et al., 1995). 
e
Bacteriocin R1333 from Lb. sakei R1333 
(Todorov et al., 2011). 
f
Sakacin X from L. curvatus 2711 (Hequet et al., 2007) and L. curvatus CRL705 (Hebert et 
al., 2012). 
g
Leucocin A-TA33a from Leuonostoc mesenteroides TA33a (Papathanasopoulos et al., 1997) and 
Leucocin B-Ta11a from Leuc. carnosum Ta11a (Felix et al., 1994). 
h
Leucocin A-4010 and Lecucocin B-4010 from 
Leuc. carnosum 4010 (Budde et al., 2003).  
i
Also produced by L. plantarum WHE92 (Ennahar et al., 1996). 
j
Amilovorin L471 from L. amylovorus DCE471 (De Vuyst et al., 2004). 
k
Gassericin K7 (K7A y K7B) from L. gasseri 
K7 (Peternel et al., 2010). 
l
Lactacin F from L. acidophilus 30SC (Oh et al., 2011).
m
Sakacin T (SakTα and SakTβ) 
from L. sakei 5 (Vaughan et al., 2003),  L. curvatus 2711 (Hequet et al., 2007) and  L. curvatus CRL705 (Hebert 
et al., 2012). 
n
Also produced by L. pentosus B96 (Hurtado et al., 2011).  
p
Reutericin 6 from L. reuteri LA6 (Kawai 
et al., 2001).
p
Varient of sakacin Q from L. curvatus L442 (Cocolin and Rantsiou, 2007) and L. curvatus CRL705 
(Hebert et al., 2012). 
q
Sakacin Q from L. sakei Lb674 (Mathiesen et al., 2005) and sakacin Q from L. curvatus 
CRL705 (Hebert et al., 2012).
  r
Mesentericin B105 from Leuc. mesenteroides subsp. mesenteroides Y105 
(Héchard et al., 1999).  
s
Acidocin J1132 from L. acidophilus JCM1132 (Tahara et al., 1996). The - symbol 





Table 2. Spectrum of inhibition of bacteriocin producing strains against a range of indicator strains 
  



























L. paralimentarius 13961 
   
++ +++ ++ 
 
+ +++ 
L. murinus 20452 + 
        




+++ +++ +++ 
L. intestinalis 6629 +++ 
 
+ 
      
L. paracasei subsp. 
paracasei 
5622 + + 
       
L. acidophilus 20079 ++ ++ + 
    
+ 
 
L. agilis 20509 
      
+ 
  
L. crispatus 20584 ++ + + 
      
L. equicursoris 19284 ++ 
        
L. pentosus 20314 + 
        
L. kalixensis 16043 + 
        
L. amylovorus 20531 + 
        
L. kitasatonis 16761 ++ 
        
P. damnosus 20331 +++ 
        
C. maltaromaticum 20342 + + 
       
C. maltaromaticum 20722 ++ + 




Activity of pH neutralised cell free supernatants from bacteriocin producers in agar well diffusion 
assay. Inhibition of indicators is described in radius (mm) of the zone of inhibition in WDA, scores are 





Table 3. Potential Lantibiotic/Lantipeptide Structural Peptides 
Species Strain Potential Unmodified Lantibiotic/Lantipeptide Sequence 
L. taiwanensis DSM 21401 TSTGCCNGPSKLQG 
L. amylovorus DSM 20531 AKSYSAYSSCSCVNPPCPIATMD 
L. gastricus DSM 16045 GTETAQSTPAISRVTLSIARKSSAKCISWISFSAGGLNSYKSKC 
P. damnosus 






Table 4 (a). Structural Genes for Complete Class IIa Operons 
Species Strain Structural Peptide Homolog (%Amino Acid Identity) 
L. hordei DSM 19519 KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGTHKC Coagulin (100%) 
  
KYYGNGVSCTKKHGCKVNWGQAFTCSVNRFANFGHGNC Plantaricin 423 (74%) 
L. acidipiscis DSM 15836 KYYGNGLHIPKHGKPYINWGQAIQSIGKISYHGWVNGITSGAAGVGRH Hiracin JM79 (44%) 
L. futsaii JCM 17355 KYYGNGVSCGKHTCKVNWGQAWNESVNRWGNSWVNGLTGLRQH Plantaricin 423 (57%) 
C. maltaromaticum DSM 20722 AISYGNGVYCNKEKCWVNKAENKQAITGIVIGGWASSLAGMGH Carnobacteriocin cbn BM1 (100%) 
  
VYYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP Carnobacteriocin cbn B2 (98%) 
(b) Structural Genes for Incomplete Class IIa Operons 
Species Strain Structural Peptide Homolog (%Amino Acid Identity) 
L. agilis DSM 20509 SRYYGNGITCGKHKCTVNWGQAWTCGVNRLANFGHGNC Plantaricin 423 (73%) 
L. aquaticus DSM 21051 KNYGNGVYCTKKHGYKVDWGQAWSIIGNNSAANSTTRGAAGWKSK Avicin A (74%) 
L. rennini DSM 20253 KYYGNGVSCSKHSCSVDWGKALTCTINNGAMAWTTGGHQGNHKC Pediocin Ach/PA-1 (89%) 
L. ruminis DSM 20403 KYYGNGVYCGKHKCRVDWGQAWGCSVNRWGAAVGTGGKATIGHC Pediocin Ach/PA-1 (55%) 
P. pentosaceus DSM 20336 KYYGNGLYCGKHSCSVDWGKATTCIINNGAMAWATGGHQGTHKC Pediocin Ach/PA-1 (93%) 






Table 5. Potential Class IIb Structural Genes 
Species Strain Structural Peptide 
L. murinus DSM 20452 
YNRLAGQIGHYTGKAVIVGATVLGIASLF Produced 
in vitro (Muricidin) KRGLGYHIVDAVVSFGKGFLDAF 
YDIEKALWGGYGYQLGWRNKWNLSHRYFKI 
GVPGWYYGMLWKIGVSGYKHRKDIMNGFDRGFNNYPK 
L. acidophilus DSM 20079 
SNNIFWTRVGVGWAAEARCMIKPSLGNWTTKAVSCGAKGLYAAVRG Produced 
in vitro (Acidocin X) VAPIVYPIAGYVMKQMFEHSDQIIKGFKRGWKKYK 
L. taiwanensis DSM 21401 
NRWGDTVLSAASGAGTGIKACKSFGPWGMAICGSNRRLFWLYS 
RNNWQTNVGGAVGSAMIGATVGGTICGPACAVAGAHYLPILWTGVTAATGGFGKIRK 
L. crispatus DSM 20584 
NRWTNAYSAALGCAVPGVKYGKKLGGVWGAVIGGVGGAAVCGLAGYVRKG 
SKGKGRNNWAGNTIGIVSSAATGAALGSAICGPGCGFVGAHWGAVGWTAVASFSGAFGKIRK 
L. nantensis DSM 16982 
SFKGFVQGFINGLTGKKH 
KGPWNYKTGYNLGKWISKRF 
L. apodemi DSM 16634 
YDIEKALWKGYGYQLGWRSKWNLSHRYFKI 
GVPGWYYSMLWKIGVSGYKHRKDIMSGFDKGFNNYPK 












L. paraplantarum DSM 10667 
FNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR 
VFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG 























Table 6. Alignment of Class IIc Subgroup II Bacteriocins 
Bacteriocin Structural Peptide 
Gassericin A IYWIADQFGIHLATGTARKLLDAMASGASLGTAFAAILGVTLPAWALAAAGALGATAA 
Acidocin B IYWIADQFGIHLATGTARKLLDAVASGASLGTAFAAILGVTLPAWALAAAGALGATAA 
Butyrivibriocin AR10  IYFIADKMGIQLAPAWYQDIVNWVSAGGTLTTGFAIIVGVTVPAWIAEAAAAFGIASA 
L. paracesei subsp. 
paracasei DSM 5622 
(Paracyclicin) 
IYFIANKLGIHLAPGWYQDMVNYVSAGGSLAGAFSVVAGVTLPAWIVPIATAFGAVSA 
L. nodensis DSM 19682 -IWIAGLFGIHLDNSLESKLVSGILNGGSAAGVFAAMLGITLPAWAAAAATAMGATAA 
   :**  :**:*  .   .::. :  *.:    *: : *:*:***    * *:* .:* 
 
* = Positions with a single conserved residue 
:  = Conservation between groups with strongly similar properties, scoring > 0.5 in the Gonnet PAM 
250 matrix 






Table 7. Potential Class IId Structural proteins 
Species Strain Structural Protein 
L. paralimentarius DSM 13961 NFFGGSNGYSWRDKKGHWHYTVTSGVSSTVAQIIGNGWGSAGAPGVGQR 
L. pentosus DSM 20314 KSNTYSLQMGSVVRTATKIFKKMEW 
L. hokkaidonensis DSM 26202 VTLSVATHSKNGLKKFFKWVRKL 
L. xiangfangensis LMG 26013 KLVKLYTAEPYTFYRDTRTKKIVMRQTTGYSAHLQHVIADGWVRSAHL 
L. paracasei DSM 5622 DSIRDVSPTFNKIRRWFDGLFK  
L. murinus DSM 20452 YDIEKALWGGYGYQLGWRNKWNLSHRYFKI 
Leuc. kimchii IMSNU 11154 KSFWSWASDASSWLSGPQQPNSPLLKKKR 
Leuc. geldium KCTC 3527 KRVYIPNGNGAWLDSNTGKGGVDWNVAVPALGSIMVNGWAQNGPLAHLHP 
(b)  Potential Class IId Lactococcin 972 Homologs 
Species Strain Structural Protein 
L. equicursoris 
(equicursorin) DSM 19284 GGTWNYGVGSKYVWSYYSHNSKTHKASVEGKYYVTSGWIKEKTQARASAAKAAAGNQSYYDVK 
L. amylophilus DSM 20533 GGTWNYGVGLTGTFGYSDYLHNSKTHSASVGRTKSDCNKVTKTKGVWAQSKYTKIPPTGLNYWWSVS 
L. graminis DSM 20719 GGTWYSGFSGTKVYSQYYHGSKKHSATAKNGWGAGVRNTQKAGIWAYSSVNSTLTGNKTYWAVY 
L. hamsteri DSM 5661 GGVWNYGVGKKYVWSYYSHHRLTHKSSVEGKYYSSSGWVSPGTEARASAEKAQHGNKSYFDVE 








Supplementary Table 1. Source of Strains    
Species Name StrainID Source 
Antimicrobial 
Encoded 
Lactobacillus agilis DSM-20509 Environment 
 Lactobacillus aquaticus DSM-21051 Environment 
 Lactobacillus concavus DSM-17758 Environment 
 Lactobacillus coryniformis torquens DSM-20004 Environment 
 Lactobacillus paracollinoides DSM-15502 Environment 
 Lactobacillus sharpeae DSM-20505 Environment 
 Weissella kandleri DSM-20593 Environment 
 Carnobacterium divergens DSM-20623 Food 
 Carnobacterium maltaromaticum DSM-20342 Food 
 Carnobacterium maltaromaticum DSM-20722 Food Yes 
Lactobacillus acetotolerans DSM-20749 Food 
 Lactobacillus acidifarinae DSM-19394 Food 
 Lactobacillus acidipiscis DSM-15836 Food Yes 
Lactobacillus acidipiscis DSM-15353 Food 
 Lactobacillus algidus DSM-15638 Food 
 Lactobacillus alimentarius DSM-20249 Food 
 Lactobacillus bifermentans DSM-20003 Food 
 Lactobacillus capillatus DSM-19910 Food 
 Lactobacillus casei DSM-20011 Food 
 Lactobacillus collinoides DSM-20515 Food 
 Lactobacillus crustorum LMG-23699 Food 
 Lactobacillus crustorum JCM-15951 Food 
 Lactobacillus curvatus DSM-20019 Food 
 Lactobacillus delbrueckii bulgaricus DSM-20081 Food 
 Lactobacillus delbrueckii delbrueckii DSM-20074 Food 
 Lactobacillus delbrueckii indicus DSM-15996 Food 
 Lactobacillus delbrueckii lactis DSM-20072 Food 
 Lactobacillus farciminis DSM-20184 Food 
 Lactobacillus frumenti DSM-13145 Food 
 Lactobacillus fuchuensis DSM-14340 Food 
 Lactobacillus futsaii JCM-17355 Food Yes 
Lactobacillus hammesii DSM-16381 Food 
 Lactobacillus harbinensis DSM-16991 Food 
 Lactobacillus helveticus CGMCC-1.1877 Food Yes 
Lactobacillus kefiranofaciens kefiranofaciens DSM-5016 Food 
 Lactobacillus kefiranofaciens kefirgranum DSM-10550 Food Yes 
Lactobacillus kefiri DSM-20587 Food 
 Lactobacillus kimchicus JCM-15530 Food 
 Lactobacillus kimchiensis DSM-24716 Food 
 Lactobacillus kisonensis DSM-19906 Food 
 Lactobacillus koreensis JCM-16448 Food 
 Lactobacillus mindensis DSM-14500 Food 




Supplementary Table 1. Continued    
Lactobacillus namurensis DSM-19117 Food 
 Lactobacillus nantensis DSM-16982 Food Yes 
Lactobacillus nodensis DSM-19682 Food Yes 
Lactobacillus odoratitofui DSM-19909 Food 
 Lactobacillus otakiensis DSM-19908 Food 
 Lactobacillus panis DSM-6035 Food 
 Lactobacillus parabrevis LMG-11984 Food 
 Lactobacillus parabrevis ATCC-53295 Food 
 Lactobacillus paracasei tolerans DSM-20258 Food 
 Lactobacillus parakefiri DSM-10551 Food 
 Lactobacillus paralimentarius DSM-13238 Food 
 Lactobacillus paralimentarius DSM-13961 Food Yes 
Lactobacillus perolens DSM-12744 Food 
 Lactobacillus plantarum plantarum CGMCC-1.2437 Food Yes 
Lactobacillus pontis DSM-8475 Food 
 Lactobacillus rapi DSM-19907 Food 
 Lactobacillus rossiae DSM-15814 Food 
 Lactobacillus sakei carnosus DSM-15831 Food 
 Lactobacillus sanfranciscensis DSM-20451 Food 
 Lactobacillus secaliphilus DSM-17896 Food 
 Lactobacillus selangorensis DSM-13344 Food 
 Lactobacillus selangorensis ATCC-BAA-66 Food 
 Lactobacillus senmaizukei DSM-21775 Food 
 Lactobacillus siliginis DSM-22696 Food 
 Lactobacillus spicheri DSM-15429 Food 
 Lactobacillus suebicus DSM-5007 Food 
 Lactobacillus sunkii DSM-19904 Food 
 Lactobacillus tucceti DSM-20183 Food 
 Lactobacillus versmoldensis DSM-14857 Food 
 Lactobacillus xiangfangensis LMG-26013 Food 
 Lactobacillus zymae DSM-19395 Food 
 Lactococcus lactis LMG-7760 Food 
 Leuconostoc argentinum KCTC-3773 Food Yes 
Leuconostoc carnosum JB16 Food 
 Leuconostoc citreum KM20 Food 
 Leuconostoc fallax KCTC-3537 Food Yes 
Leuconostoc gasicomitatum LMG-18811 Food 
 Leuconostoc gelidum KCTC-3527 Food Yes 
Leuconostoc kimchii IMSNU-11154 Food 
 Leuconostoc mesenteroides ATCC-8293 Food 
 Leuconostoc pseudomesenteroides 4882 Food 
 Pediococcus argentinicus DSM-23026 Food 
 
Weissella halotolerans DSM-20190 Food 
 Weissella minor DSM-20014 Food 





Supplementary Table 1. Continued    
Atopobium minutum DSM-20586 Human/Animal  
Atopobium rimae DSM-7090 Human/Animal 
 Carnobacterium maltaromaticum DSM-20730 Human/Animal Yes 
Kandleria vitulina DSM-20405 Human/Animal Yes 
Lactobacillus acidophilus DSM-20079 Human/Animal Yes 
Lactobacillus amylophilus DSM-20533 Human/Animal Yes 
Lactobacillus amylotrophicus DSM-20534 Human/Animal 
 Lactobacillus amylovorus DSM-20531 Human/Animal Yes 
Lactobacillus amylovorus DSM-16698 Human/Animal Yes 
Lactobacillus animalis DSM-20602 Human/Animal 
 Lactobacillus antri DSM-16041 Human/Animal 
 Lactobacillus apodemi DSM-16634 Human/Animal Yes 
Lactobacillus aviarius araffinosus DSM-20653 Human/Animal 
 Lactobacillus aviarius aviarius DSM-20655 Human/Animal 
 Lactobacillus brantae DSM-23927 Human/Animal 
 Lactobacillus brevis DSM-20054 Human/Animal 
 Lactobacillus ceti DSM-22408 Human/Animal 
 Lactobacillus coleohominis DSM-14060 Human/Animal 
 Lactobacillus crispatus DSM-20584 Human/Animal Yes 
Lactobacillus equi DSM-15833 Human/Animal 
 Lactobacillus equicursoris DSM-19284 Human/Animal Yes 
Lactobacillus equigenerosi DSM-18793 Human/Animal 
 Lactobacillus fermentum DSM-20055 Human/Animal 
 Lactobacillus gallinarum DSM-10532 Human/Animal Yes 
Lactobacillus gasseri ATCC-33323 Human/Animal 
 Lactobacillus gastricus DSM-16045 Human/Animal Yes 
Lactobacillus gigeriorum DSM-23908 Human/Animal Yes 
Lactobacillus hamsteri DSM-5661 Human/Animal Yes 
Lactobacillus hayakitensis DSM-18933 Human/Animal 
 Lactobacillus hominis DSM-23910 Human/Animal Yes 
Lactobacillus iners DSM-13335 Human/Animal 
 Lactobacillus ingluviei DSM-15946 Human/Animal 
 Lactobacillus ingluviei DSM-14792 Human/Animal 
 Lactobacillus intestinalis DSM-6629 Human/Animal Yes 
Lactobacillus jensenii DSM-20557 Human/Animal 
 Lactobacillus johnsonii ATCC-33200 Human/Animal Yes 
Lactobacillus kalixensis DSM-16043 Human/Animal Yes 
Lactobacillus kitasatonis DSM-16761 Human/Animal Yes 
Lactobacillus mucosae DSM-13345 Human/Animal 
 Lactobacillus murinus DSM-20452 Human/Animal Yes 
Lactobacillus oligofermentans DSM-15707 Human/Animal 
 Lactobacillus oris DSM-4864 Human/Animal 
 Lactobacillus pantheris DSM-15945 Human/Animal 
 Lactobacillus parabuchneri DSM-5707 Human/Animal Yes 
Lactobacillus psittaci DSM-15354 Human/Animal 




Supplementary Table 1. Continued    
Lactobacillus reuteri DSM-20016 Human/Animal  
Lactobacillus ruminis DSM-20403 Human/Animal 
 Lactobacillus saerimneri DSM-16049 Human/Animal 
 Lactobacillus salivarius DSM-20555 Human/Animal 
 Lactobacillus saniviri DSM-24301 Human/Animal 
 Lactobacillus senioris DSM-24302 Human/Animal 
 Lactobacillus ultunensis DSM-16047 Human/Animal Yes 
Lactobacillus vaccinostercus DSM-20634 Human/Animal 
 Lactobacillus vaginalis DSM-5837 Human/Animal 
 Olsenella uli DSM-7084 Human/Animal 
 Fructobacillus fructosus DSM-20349 Plant 
 Lactobacillus buchneri DSM-20057 Plant 
 Lactobacillus cacaonum DSM-21116 Plant 
 Lactobacillus camelliae DSM-22697 Plant 
 Lactobacillus coryniformis coryniformis DSM-20001 Plant 
 Lactobacillus dextrinicus DSM-20335 Plant 
 Lactobacillus diolivorans DSM-14421 Plant 
 Lactobacillus fabifermentans DSM-21115 Plant 
 Lactobacillus floricola DSM-23037 Plant 
 Lactobacillus florum DSM-22689 Plant 
 Lactobacillus ghanensis DSM-18630 Plant 
 Lactobacillus graminis DSM-20719 Plant Yes 
Lactobacillus hokkaidonensis DSM-26202 Plant Yes 
Lactobacillus hordei DSM-19519 Plant Yes 
Lactobacillus manihotivorans DSM-13343 Plant 
 Lactobacillus nasuensis JCM-17158 Plant 
 Lactobacillus ozensis DSM-23829 Plant 
 Lactobacillus plantarum DSM-13273 Plant Yes 
Lactobacillus plantarum argentoratensis DSM-16365 Plant 
 Lactobacillus pobuzihii NBRC-103219 Plant 
 Lactobacillus pobuzihii.Chen KCTC-13174 Plant 
 Lactobacillus sucicola DSM-21376 Plant 
 Lactobacillus taiwanensis DSM-21401 Plant Yes 
Lactobacillus thailandensis DSM-22698 Plant 
 Lactobacillus uvarum DSM-19971 Plant 
 Lactobacillus vini DSM-20605 Plant 
 Pediococcus lolii DSM-19927 Plant 
 Pediococcus parvulus DSM-20332 Plant 
 Pediococcus stilesii DSM-18001 Plant 
 Weissella confusa DSM-20196 Plant 
 Lactobacillus fructivorans DSM-20203 Unknown 
 Lactobacillus paracasei paracasei DSM-5622 Unknown Yes 
Lactobacillus pasteurii DSM-23907 Unknown Yes 
Lactobacillus pentosus DSM-20314 Unknown Yes 
Lactobacillus rhamnosus DSM-20021 Unknown Yes 





Supplementary Table 1. Continued    
Pediococcus acidilactici AS1-2696 Unknown  
Lactobacillus amylolyticus DSM-11664 Wine/Alcohol Products Yes 
Lactobacillus composti DSM-18527 Wine/Alcohol Products 
 Lactobacillus delbrueckii jakobsenii DSM-26046 Wine/Alcohol Products 
 Lactobacillus farraginis DSM-18382 Wine/Alcohol Products Yes 
Lactobacillus fructivorans ATCC-27394 Wine/Alcohol Products 
 Lactobacillus fructivorans DSM-20350 Wine/Alcohol Products 
 Lactobacillus helveticus LMG-22464 Wine/Alcohol Products Yes 
Lactobacillus hilgardii DSM-20176 Wine/Alcohol Products 
 Lactobacillus homohiochii DSM-20571 Wine/Alcohol Products 
 Lactobacillus kunkeei DSM-12361 Wine/Alcohol Products 
 Lactobacillus lindneri DSM-20690 Wine/Alcohol Products 
 Lactobacillus malefermentans DSM-5705 Wine/Alcohol Products 
 Lactobacillus mali DSM-20444 Wine/Alcohol Products 
 Lactobacillus mali ATCC-27304 Wine/Alcohol Products 
 Lactobacillus nagelii DSM-13675 Wine/Alcohol Products 
 Lactobacillus oeni DSM-19972 Wine/Alcohol Products 
 Lactobacillus parabuchneri DSM-15352 Wine/Alcohol Products 
 Lactobacillus parafarraginis DSM-18390 Wine/Alcohol Products Yes 
Lactobacillus paralimentarius DSM-19674 Wine/Alcohol Products 
 Lactobacillus paraplantarum DSM-10667 Wine/Alcohol Products Yes 
Lactobacillus paucivorans DSM-22467 Wine/Alcohol Products 
 Lactobacillus sakei sakei DSM-20017 Wine/Alcohol Products 
 Lactobacillus satsumensis DSM-16230 Wine/Alcohol Products 
 Lactobacillus similis DSM-23365 Wine/Alcohol Products 
 Lactobacillus zeae DSM-20178 Wine/Alcohol Products Yes 
Oenococcus kitaharae DSM-17330 Wine/Alcohol Products 
 Oenococcus oeni ATCC-BAA-1163 Wine/Alcohol Products Yes 
Pediococcus cellicola DSM-17757 Wine/Alcohol Products 
 Pediococcus claussenii DSM-14800 Wine/Alcohol Products Yes 
Pediococcus damnosus DSM-20331 Wine/Alcohol Products Yes 
Pediococcus ethanolidurans DSM-22301 Wine/Alcohol Products 
 Pediococcus inopinatus DSM-20285 Wine/Alcohol Products 









Supplementary Table 2. Bacterial strains screened for bacteriocin production 
Species Strain Growth Medium  Condition Temp (˚C) 
Carnobacterium maltaromaticum DSM 20342 TSA Aerobic 30 
Carnobacterium maltaromaticum DSM 20722 TSA Aerobic 30 
Carnobacterium maltaromaticum DSM 20730 TSA Aerobic 30 
Lactobacillus acidipiscis DSM 15836 MRS + Vitamin soln.  Anaerobic 30 
Lactobacillus acidophilus DSM 20079 mMRS Anaerobic 37 
Lactobacillus agilis DSM 20509 mMRS Anaerobic 38 
Lactobacillus amylophilus DSM 20533 MRS Aerobic 30 
Lactobacillus amylovorus DSM 16698 MRS Anaerobic 37 
Lactobacillus amylovorus DSM 20531 MRS Anaerobic 37 
Lactobacillus apodemi DSM 16634 MRS Anaerobic 37 
Lactobacillus aquaticus DSM 21051 MRS Anaerobic 37 
Lactobacillus buchneri DSM 20057 MRS Aerobic 37 
Lactobacillus casei DSM 20011 MRS Aerobic 30 
Lactobacillus composti DSM 18527 MRS Anaerobic 30 
Lactobacillus coryniformis subsp. coryniformis DSM 20001 MRS Aerobic 30 
Lactobacillus coryniformis subsp. torquens DSM 20004 MRS Aerobic 30 
Lactobacillus crispatus DSM 20584 mMRS Anaerobic 37 
Lactobacillus equicursoris DSM 19284 MRS Anaerobic 37 
Lactobacillus fabifermentans DSM 21115 MRS Anaerobic 30 
Lactobacillus fuchuensis DSM 14340 MRS Aerobic 20 
Lactobacillus futsaii JCM 17355 MRS Aerobic 30 
Lactobacillus gastricus DSM 16045 MRS Anaerobic 37 
Lactobacillus graminis DSM 16045 MRS Aerobic 30 
Lactobacillus hamsteri DSM 5661 MRS Anaerobic 37 
Lactobacillus harbinensis DSM 16991 MRS Anaerobic 37 
Lactobacillus helveticus CGMCC 1.1877 MRS Anaerobic 37 
Lactobacillus helveticus LMG 22464 MRS Anaerobic 37 
Lactobacillus hokkaidonensis DSM 26202 MRS Anaerobic 25 
Lactobacillus hordei DSM 19519 MRS Anaerobic 30 
Lactobacillus intestinalis DSM 6629 MRS Aerobic 37 
Lactobacillus johnsoni DSM 10533 MRS Anaerobic 37 
Lactobacillus kalixensis DSM 16043 MRS Aerobic 37 





Supplementary Table 2. Continued 
Species Strain Growth Medium  Condition Temp (˚C) 
Lactobacillus kimchiensis DSM 24716 MRS Anaerobic 25 
Lactobacillus kitasatonis DSM 16761 MRS Anaerobic 37 
Lactobacillus mali DSM 20444 MRS Aerobic 30 
Lactobacillus mindensis DSM 14500 MRS Anaerobic 30 
Lactobacillus murinus DSM 20452 MRS Aerobic 37 
Lactobacillus nantensis DSM 16982 
mMRS + 1% maltose + 
0.5% YE  
Aerobic 30 
Lactobacillus nodensis DSM 19682 MRS Anaerobic 30 
Lactobacillus otakiensis DSM 19908 MRS Anaerobic 30 
Lactobacillus parabuchneri DSM 5707 MRS Aerobic 30 
Lactobacillus paracasei subsp. paracasei DSM 5622 MRS Aerobic 30 
Lactobacillus paracasei subsp. tolerans DSM 20258 MRS Aerobic 30 
Lactobacillus parafarraginis DSM 18390 MRS Anaerobic 30 
Lactobacillus paralimentarius DSM 13961 MRS Aerobic 30 
Lactobacillus paralimentarius DSM 13238 MRS Aerobic 30 
Lactobacillus paraplantarum DSM 10667 MRS Aerobic 30 
Lactobacillus pasteurii DSM 23907 MRS Anaerobic 37 
Lactobacillus pentosus DSM 20314 MRS Aerobic 30 
Lactobacillus plantarum DSM 13273 MRS Aerobic 37 
Lactobacillus plantarum subsp. argentoratensis DSM 16365 MRS Anaerobic 30 
Lactobacillus plantarum subsp. plantarum DSM 20174 MRS Aerobic 30 
Lactobacillus rennini DSM 20253 MRS + CAA Aerobic 30 
Lactobacillus reuteri DSM 20016  MRS Aerobic 37 
Lactobacillus rhamnosus DSM 20021 MRS Aerobic 37 
Lactobacillus rossiae DSM 15814 MRS + 1% maltose + 1% YE  Anaerobic 30 
Lactobacillus ruminis DSM 20403 MRS Anaerobic 37 
Lactobacillus similis DSM 23365 MRS Anaerobic 37 
Lactobacillus taiwanensis DSM 21401 MRS Anaerobic 37 
Lactobacillus xiangfangensis LMG 26013 MRS Aerobic 30 
Lactobacillus zeae DSM 20178 MRS Aerobic 37 
Leuconostoc fallax DSM 20189 MRS Aerobic 30 
Leuconostoc gasicomitatum LMG 18811 MRS Anaerobic 22 
Leuconostoc gelidum subsp. gelidum DSM 5578 MRS Anaerobic 25 






Supplementary Table 2. Continued 
Species Strain Growth Medium  Condition Temp (˚C) 
Oenococcus kitaharae DSM 17330 mMRS + 10% tomato juice Anaerobic 30 
Oenococcus oeni ATCC-BAA 1163 MRS Anaerobic 37 
Pediococcus cellicola DSM 17757 MRS Anaerobic 30 
Pediococcus claussenii DSM 14800 MRS pH 5.7 Aerobic 30 
Pediococcus damnosus DSM 20331 mMRS pH 5.7 Anaerobic 26 
Pediococcus ethanolidurans DSM 22301 MRS Anaerobic 37 
Pediococcus pentosaceus DSM 20336 MRS Aerobic 30 




Supplementary Table 3. Indicator Strains 
Species Strain Growth Medium Conditions Temp (˚C) 
Enterococcus faecium LMG 11423 MRS Anaerobic 37 
E. mundtii LMG 10748 MRS Anaerobic 37 
E. saccharolyticus LMG 11427 MRS Anaerobic 37 
Lactobacillus acidophilus LMG 9433 MRS Anaerobic 37 
L. agilis LMG 9186 MRS Anaerobic 37 
L. amylovorus LMG 9496 MRS Anaerobic 37 
L. casei LMG 6904 mMRS Anaerobic 37 
L. crispatus LMG 9479 MRS Anaerobic 37 
L. delbrueckii subsp. bulgaricus LMG 6901 MRS Anaerobic 37 
L. delbrueckii subsp. lactis LMG 7942 MRS Anaerobic 37 
L. fermentum LMG 6902 MRS Anaerobic 37 
L. johnsonii DSM 10533 MRS Anaerobic 37 
L. plantarum LMG 6907 MRS Anaerobic 37 
L. rhamnosus GG MRS Anaerobic 37 
Listeria innocua DPC 3572 BHI Aerobic 37 
Micrococcus luteus DPC 6275 BHI Aerobic 30 
Staphylococcus aureus DPC 5246 BHI Aerobic 37 






Supplementary Figure 1. Divergence and percentage identity of helveticin homologs encoded by 





Supplementary Figure 2. Colony MALDI TOF MS and SDS PAGE profiles of the peptides produced by 






Figure 3. An SDS PAGE gel overlayed with the indicator L. delbrueckii subsp. bulgaricus shows the 
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Chapter 4: Reincarnation of Bacteriocins 
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Bacteria commonly produce narrow spectrum bacteriocins as a means of inhibiting closely 
related species competing for similar resources in an environment. The increasing availability of 
genomic data means that it is becoming easier to identify bacteriocins encoded within genomes. 
Often, however, the presence of bacteriocin genes in a strain does not always translate into 
biological antimicrobial activity.  For example, when analysing the Lactobacillus pangenome we 
identified strains encoding ten pediocin-like bacteriocin structural genes which failed to display 
inhibitory activity. Nine of these bacteriocins were novel whilst one was identified as the previously 
characterised bacteriocin ‘penocin A’.  The composition of these bacteriocin operons varied between 
strains, often with key components missing which are required for bacteriocin production, such as 
dedicated bacteriocin transporters and accessory proteins. In an effort to functionally express these 
bacteriocins, the structural genes for the ten pediocin homologs were cloned alongside the 
dedicated pediocin PA-1 transporter in both Escherichia coli and Lactobacillus paracasei 
heterologous hosts. Each bacteriocin was cloned with its native leader sequence and as a fusion 
protein with the pediocin PA-1 leader sequence. Several of these bacteriocins displayed a broader 
spectrum of inhibition than the original pediocin PA-1. We show how potentially valuable 
bacteriocins can easily be ‘reincarnated’ from in silico data and produced in vitro despite often 
lacking the necessary accompanying machinery.  Moreover, the study demonstrates how genomic 
datasets such as the Lactobacillus pangenome harbour a potential “arsenal” of antimicrobial activity 






Bacteria exist in complex communities, under constant competition from other strains and 
species for nutrients and space. The production of antimicrobial peptides known as bacteriocins has 
been shown to be one means by which such strains can gain a competitive advantage (Kommineni et 
al., 2015). Bacteriocins can be broad spectrum, inhibiting a variety of bacteria, or narrow spectrum 
where they inhibit primarily closely related species. As closely related species are more likely to 
occupy the same environmental niche as the producer, these bacteriocin genes could offer a 
potentially useful armoury of antimicrobials in helping the producer establish itself in such a niche.  
The increasing availability of genomic data has changed the way we identify and study 
bacteriocins in communities. Bioinformatic screening tools such as BAGEL (de Jong et al., 2010) and 
antiSMASH (Weber et al., 2015) can now process vast amounts of genomic data to search for 
antimicrobial operons and genes (Walsh et al., 2015, Letzel et al., 2014). This allows us to identify 
previously uncharacterised bacteriocins and antibiotics, and to understand the extent of which 
strains encode these natural weapons for targeting competitors. In many of these cases however, 
the bacteriocin genes appear to be inactive antimicrobial relics which are unlikely to play an active 
role given the degradation of the surrounding accessory genes. Mutations within genes, loss of key 
genes within operons and tight transcriptional regulation can all prevent cells from producing these 
antimicrobials. This means that many such strains harbour potentially useful bacteriocins that are 
destined to remain uncharacterised due to a lack of in vitro production. One method to overcome 
this issue is to clone the antimicrobial operon into a host where expression can be controlled. This 
allows for the natural bacteriocin regulation to be circumvented and/or gene loss to be overcome, 
thus ensuring production of otherwise unavailable antimicrobials for further characterisation and 
potential exploitation. 
In this study we focused on the expression of potential class IIa bacteriocins from members of 




modifications, structure and mode of action. Class II bacteriocins are not subject to extensive post-
translational modification and the class IIa bacteriocins are single peptides with a highly conserved 
‘YGNGV’ N-terminal sequence. These bacteriocins (also known as ‘pediocin-like’ bacteriocins) are 
relatively narrow spectrum and display high levels of activity against Listeria species (Cotter et al., 
2005). They bind to the mannose phosphotransferase transport system in sensitive strains and 
subsequently induce pore formation which leads to cell death (Zhou et al., 2016). The effective 
production of these bacteriocins depends on the production of several other associated proteins 
(Fimland et al., 2005). For example, an associated ABC transporter must be produced by cells in 
order to transport the bacteriocin outside  the cell, and an immunity protein is also required  to  
protect the producing strain from being killed by its own bacteriocin (Drider et al., 2006). Certain 
class IIa bacteriocins also require an accessory protein for correct disulphide bond formation 
(Oppegard et al., 2015). These operons may also have a three-component regulatory system which 
regulates expression of the bacteriocin. Here, when the concentration of an inducer peptide 
encoded within the operon reaches a certain level it signals a transmembrane histidine kinase which 
in turn activates a response regulator which initiates transcription of the bacteriocin operon 
(Ennahar et al., 2000). 
The Lactobacillus Genus Complex analysed in this study encompasses the Lactobacillus, 
Pediococcus, Leuconostoc, Weissella, Fructobacillus and Oenococcus genera and numerous pediocin-
like bacteriocins have been associated with this grouping (Collins et al., 2017). Previously Sun et al. 
(Sun et al., 2015) sequenced the genomes of 213 strains belonging to this complex, these were then 
subject to both in silico and in vitro bacteriocin screening (Collins et al., 2017). Numerous strains 
from that study were found to encode bacteriocin operons but did not show in vitro bacteriocin 
production. Several of these strains encoded complete operons for pediocin-like bacteriocins, whilst 
more had incomplete operons harbouring just structural and immunity genes. Whereas regulatory 
issues may prevent expression of bacteriocins in strains harbouring complete operons, those 




strains encode intact bacteriocin and immunity genes whilst lacking the machinery needed to 
actually produce and secrete these antimicrobials. One potential explanation for this is that these 
strains may have maintained the bacteriocin immunity gene under selective pressure from these 
antimicrobials. The neighbouring bacteriocin encoding gene is small and may have simply been 
maintained due its proximity to the immunity gene, the much larger transport machinery may then 
have been lost.  
In this study we use an expression systems derived by Mesa Pereira et al. (Mesa-Pereira et al., 
2017) to reincarnate these bacteriocins, allowing for in vitro production.  It was found that for 
production of pediocin PA-1, only the structural gene and the transporter were necessary for 
bacteriocin production and secretion. As some of our putative novel bacteriocins lacked an 
associated transporter, the pediocin PA-1 transporter was used in each case. Bacteriocin peptides 
were detected by mass spectrometry and activity was identified by screening against a range of 
indicator organisms. The systems used have allowed us to isolate seven novel bacteriocins and 
represents a unique and rapid way of producing bacteriocins. This method allows us to reincarnate 





Identification of ‘Silent’ Pediocin Homologs 
Previous work performed by our group analysed bacteriocin production in 213 Lactobacillus and 
related species (Collins et al., 2017). In silico screening identified the presence of bacteriocin operons 
(or remnants of operons) encoded within the genome of a large number of these strains. Strains 
encoding bacteriocins were then tested for in vitro bacteriocin production but several strains failed 
to display antimicrobial activity (Collins et al., 2017, Sun et al., 2015). This study focused on the class 
IIa bacteriocins; eight strains were found to encode ten of these pediocin-like bacteriocins but failed 
to display any antimicrobial production. Of these ten potential bacteriocins identified, nine were 
novel and one was identified as penocin A, a bacteriocin previously characterised from P. 
pentosaceus ATCC 25745 (Diep et al., 2006) (Table 1) . 
Typically at least four genes are commonly required for the production of a class II bacteriocin; a 
structural gene, a transporter, an immunity gene and a gene encoding an accessory protein (Drider 
et al., 2006). The operons for the ten “silent” class IIa bacteriocins differed in their composition, with 
several lacking the genes for some of the necessary bacteriocin associated components (Figure 1). 
Each of these nine novel bacteriocins were named based on the species which produced them; e.g. 
ruminicin produced by L. ruminus.  Of the operons identified, only those encoding hordeiocin and 
ruminicin were found to encode all four key components for bacteriocin production. The acidicin 
operon also appeared to be complete as the structural peptide doesn’t contain any cysteine residues 
for disulphide bond formation, thus the accessory protein is likely unnecessary. The futcin operon 
was the only other such operon which encoded an ABC transporter for bacteriocin transport and 
leader cleavage. The remaining operons were composed of two to three genes encoding just the 






As there was no identifiable bacteriocin production from these eight strains, it was decided to 
express these novel bacteriocins first in an E. coli host. A modified pETcocoTM-2 vector, pMPB1, 
generated by our group was used for bacteriocin expression (Mesa-Pereira et al., 2017). It was 
previously found that only the structural gene and the ABC transporter are required to express 
pediocin PA-1 using this system. As over half of the bacteriocins identified here lack an associated 
ABC transporter, the pediocin PA-1 transporter PedD was used for the expression of each of these 
bacteriocins. PedD contains an intrinsic domain for cleavage of the bacteriocin leader sequence, and 
as these transporters rely on this leader sequence for peptide processing each of these bacteriocins 
were cloned separately using both their native leader sequence and as a fusion protein containing 
the pediocin PA-1 leader. Recursive PCR was used to generate the genes for each of these fusion 
proteins; genes for the natural bacteriocins and the PedD transporter were amplified by PCR 
(Prodromou and Pearl, 1992). An In-Fusion reaction was then used to assemble and join these PCR 
products to the enzyme-digested pMPB1 vector. For production in L. paracasei NFBC 338, a pNZ44-
derived vector was used; in this case the bacteriocin was cloned as a fusion with the pediocin leader 
along with the PedD transporter. PCR products for these reactions were obtained using positive 
pMPB1 plasmids as a template. In-Fusion reaction was then used to assemble and join these PCR 
products to the enzyme-digested pNZ44 vector. The vectors used are shown in Supplementary Table 
1. 
Production 
E.coli TunerTM (DE3) cells transformed with the newly constructed plasmids were grown in LB 
supplemented with glucose to maintain a low-copy number and bacteriocin expression was induced 
by co-incubation of the clones with 50µM IPTG for three hours. Wells diffusion assays (WDAs) were 
used to identify bacteriocin activity from the bacterial supernatants and cell lysates. Bacteriocins 




the native leader of the bacteriocin sequence was used; with only four of the nine strains displaying 
zones of inhibition against a sensitive indicator (pediocin 20336a has an identical leader to pediocin 
PA-1). For expression in L. paracasei NFBC 338, cells were transformed by electroporation with the 
bacteriocin-containing pNZ44 vectors. Positive transformants were grown overnight and the 
neutralised cell free supernatant was used to identify bacteriocin production in WDAs. 
Of the bacteriocins expressed with the pediocin PA-1 leader sequence in E. coli, eight of the ten 
displayed anti-microbial activity from the cellular supernatant against at least one indicator 
organism (Table 2). Purification of the bacteriocin peptides from the E. coli bacterial supernatant and 
MALDI-TOF mass spectrometry were used to determine the mass of the active peptides. These 
masses correlated closely with the predicted mass of the bacteriocin structural peptide, allowing us 
to identify the bacteriocin produced. This approach confirmed the production of nine of the ten 
bacteriocins, aquaticin was not identified using these methods, potentially due to low levels of 
production by the cells (Supplementary Figure 1). The percentage amino acid identity of these 
bacteriocins in comparison to pediocin ranges from 29.5% to 93.2%. Production levels of 
bacteriocins were shown to vary between the E. coli and L. paracasei expression systems. E. coli 
transformants actually displayed greater or equal bacteriocin activity compared to those produced 
by L. paracasei (Table 3). The only exceptions were the original pediocin PA-1 which was used as a 
control and rennicin B which was produced in very low quantities by the E. coli producer where 
production was only noted after purification of the bacteriocin from the cellular supernatant. 
Interestingly, L. paracasei NFBC 338 failed to produce futcin which was produced by E. coli. 
Spectrum of Activity 
The spectrum of activity was determined using WDAs against 32 indicator strains for 
bacteriocins produced by the E. coli transformants encoding the pediocin leader (Table 2). Despite 
being of the same class of bacteriocins, these novel antimicrobials display a varying spectrum of 




the indicators tested than pediocin PA-1. Aquaticin and rennicin B failed to display antimicrobial 
activity in the crude supernatant from the E. coli heterologous host, whilst acidicin displayed activity 
exclusively against L. mali DSM 20444 in this assay. Many of these bacteriocins, however, can inhibit 
a wide range of Gram-positive bacteria including potential pathogens such as Enterococcus faecalis. 
As with most class IIa bacteriocins, these also display potent anti-listerial activity. Interestingly, L. 
mali DSM 20444 appears to also be an extremely sensitive indicator for testing the activity of class 
IIa bacteriocins here and may prove a safer alternative over the use of Listeria strains to test the 
activity of these bacteriocins.  
Bacteriocin Structures 
Class IIa bacteriocins tend to have a relatively conserved structure. However, some of these 
novel bacteriocins display key differences in the typical conserved regions associated with previously 
characterised class IIa bacteriocins. A three-stranded β-sheet structure can be found at the N-
terminus, this is often stabilised by a conserved disulphide bridge formed between two cysteine 
residues at the N-terminus. Because aquaticin has only a single cysteine residue and acidicin 
completely lacks cysteine residues, these bacteriocins would be unable to produce the conserved 
disulphide bond. The C-terminus is less conserved and can be composed of one or two α-helices and 
an elongated C-terminal tail which can fold back on the α-helix, forming a hairpin-like structure.  A C-
terminal disulphide bond can stabilise this hairpin structure in certain bacteriocins and pediocin 
20336a, rennicin A, rennicin B, hordeiocin, agilicin and ruminicin all have the ability to form this 
disulphide bond (Fimland et al., 2005). 
The N-terminal ‘YGNGV/L’ region is highly conserved in these peptides, interestingly agilicin is 
the only such bacteriocin where the valine or leucine residue in this sequence has been replaced by 
an isoleucine. These peptides also contain a conserved hinge region (VD/NWGXA) which separates 




contains a valine to isoleucine substitution in this motif, a modification only previously seen in 






Due to the growing availability of genomic data and the improvement of software a growing 
number of novel bacteriocins are being identified (Letzel et al., 2014, Zhao and Kuipers, 2016). There 
continues however, to be a disconnect between the identification of these genes and the actual 
production of these bacteriocins in vitro. Whilst metagenomic data provides the ability to detect 
these genes, this is often not correlated to the isolation and characterisation of the producing strain. 
Thus, whilst bacteriocin genes are being discovered at a much greater rate from metagenomic data, 
the isolation of these antimicrobials themselves has proved more difficult. 
One method to bridge the gap between the discovery of bacteriocin genes and their in vitro 
production is to heterologously express these genes in a new host. This could prove particularly 
valuable for strains that are non-culturable or that are extremely difficult to grow in the laboratory. 
Developing and optimising cloning techniques for individual bacteriocins requires time, which can 
make it a laborious task when working with a large number of potential bacteriocin genes identified 
in a genomic screen. The methods used by Mesa-Pereira et al. (Mesa-Pereira et al., 2017) and in this 
study provide a rapid mechanism to express non-lantibiotic bacteriocins such as class IIa and class IId 
bacteriocins. It has been determined that the presence of the bacteriocin structural gene and the 
bacteriocin transporter is sufficient to express these bacteriocins using this system (Mesa-Pereira et 
al., 2017).  This provides a quick and easy method to produce such bacteriocins, even if the original 
operons identified are incomplete. Using this method, it was possible to express novel bacteriocins 
identified from in silico screening of the Lactobacillus Genus Complex, despite many of these lacking 
the obligatory genes required for bacteriocin production by the parent strains. It is unclear as to why 
such strains encode intact bacteriocin and immunity genes whilst lacking the machinery needed to 
actually produce and secrete these antimicrobials. One potential explanation for this is that these 




neighbouring small bacteriocin encoding gene may also have been maintained whilst the larger 
transport machinery was lost.  
The bacteriocin expression system used is based on the pediocin PA-1 operon, using the 
associated transporter PedD to transport the expressed bacteriocin from the cell. Each of the ten 
bacteriocins described here was cloned in an E. coli heterologous host alongside this transporter 
using both its native leader sequence and as a fusion containing the pediocin PA-1 leader as opposed 
to its own. Of the ten bacteriocins studied here, nine were novel. The bacteriocins varied from 93.2% 
to 29.5% amino acid identity to pediocin PA-1. Nine of the ten bacteriocins displayed antimicrobial 
activity (aquaticin activity was not seen and the peptide was not identified after purification and 
MALDI-TOF mass spectrometry); the production of these bacteriocins shows the flexibility in the 
PedD transporter and its ability to secrete several bacteriocins. Production levels of these 
bacteriocins in an E. coli host was greater when they were expressed with the pediocin PA-1 leader 
sequence rather than their own, this is not surprising given that PedD has evolved to cleave the 
pediocin PA-1 leader. Four bacteriocins were produced and secreted using their native leader which 
reflects a degree of redundancy in the specificity of the cleavage domain in the PedD transporter.  
The bacteriocins produced displayed a varying spectrum of activity despite all belonging to the 
class IIa bacteriocins. Pediocin PA-1 is an important commercial additive used in food production in 
the form of powdered fermentates such as ALTA® 2351 (Kerry Bioscience) for the inhibition of 
Listeria species as well as other food spoilage and pathogenic bacteria. The discovery of novel 
bacteriocins here with a greater inhibitory range indicates that alternative bacteriocins may prove to 
be more effective additives in food; it also opens up the possibility for extending the use of these 
bacteriocins for alternative applications such as potential therapeutic uses. Further studies into the 
effect the structure of these bacteriocins can have on bacteriocin activity may also allow for targeted 




The structure of these bacteriocins can be affected by differences in sequences of these 
peptides. The N-terminal β-sheet structure of these bacteriocins can be stabilised by the presence of 
a disulphide bridge, aquaticin and acidicin, however, lack the ability to form such a bond. Sit et al. 
previously found that this disulphide bridge can be removed from class IIa bacteriocins; this reduces 
but does not eliminate the peptides’ inhibitory activity (Sit et al., 2012). This may explain the lower 
levels of activity seen for aquaticin and acidicin. The hydrophobic/amphiphilic C-terminus of these 
peptides is less conserved than the N-terminus. It is involved in membrane insertion, resulting in 
pore formation, and also determines the spectrum of activity of the bacteriocins (Johnsen et al., 
2005). The C-terminus is composed of an α-helix followed by a C-terminal tail which forms a hairpin 
and folds back upon the α-helix. This motif can be stabilised by the presence of a C-terminal 
disulphide bridge which makes the structure less flexible. Class IIa bacteriocins lacking this second 
disulphide bridge tend to be more heat sensitive and can undergo unfolding , making them less 
active at 37˚C (Kaur et al., 2004). Acidicin, futcin, aquaticin and penocin A all lack the ability to form 
this disulphide bridge, which may explain the lower levels of activity seen for these bacteriocins, as 
the majority of the indicator organisms used here are grown at 37˚C. In certain bacteriocins, which 
lack the ability to form this disulphide bridge, the interaction between tryptophan residues found 
just after the hinge region and at the C-terminus can stabilise the hairpin fold (Fimland et al., 2002). 
Penocin A and aquaticin both have terminal tryptophan residues which would compensate for an 
absent disulphide bond. Futcin has a tryptophan residue at position 33 in the mature peptide; 
however this is not predicted to be involved in the stabilisation of the hairpin fold; acidicin lacks a 
stabilising terminal tryptophan residue altogether. This may suggest that such an extended hairpin 
structure does not form in these bacteriocins. Structural differences between these bacteriocins may 
not only affect their inhibitory activity but also may affect the ability of the pediocin transporter to 
secrete these bacteriocins. The bacteriocins which display the greatest divergence form pediocin PA-
1 were, however, shown to be secreted here indicating a level of redundancy in the transporter 




the classes of bacteriocins secreted by this system is supported by the activity of the transporter 
EnkT from E. faecium NKR-5-3 which is involved in the transport of a class IIa bacteriocin, two 
peptides of a class IIb bacteriocin and also an inducer peptide (Sushida et al., 2018). This emphasises 
the potential flexibility of these bacteriocin ABC transporters.   
The novel bacteriocins described here cluster into different groups upon alignment. Pediocin, 
pediocin 20336a, rennicin A and rennicin B display between 84-93% homology to each other. 
Despite being 90.9% identical to pediocin PA-1, rennicin B did not display activity in the crude 
supernatant from the E. coli heterologous host; it did however display equal levels of activity 
compared to rennicin A when expressed in L. paracasei NFBC 338. Two amino acid substitutions in 
rennicin B may explain this as they occur in important structural regions for the bacteriocin. The 
Gly29-Ser29 substitution is found in the C-terminal α-helix of the peptide which is involved in 
membrane insertion. The substitution of a non-polar amino acid for a larger polar one here may 
affect the formation of the helix and membrane insertion. A Gly36-Ser36 substitution occurs in a 
double glycine motif which follows the α-helix. This motif may provide the flexibility for the C-
terminal tail to fold back upon the helix (Fimland et al., 2002), this flexibility may be lost due to the 
substitution with a larger serine residue.  
Hordeiocin, agilicin, futcin and ruminicin to a lesser extent, also cluster together, displaying 
between 60-76% amino acid identity. Hordeiocin, agilicin and ruminicin all display a relatively broad 
spectrum of activity (inhibiting between 18-14 strains), whilst futcin is more narrow spectrum 
(inhibiting nine strains) which again may be due to a lack of a C-terminal stabilising disulphide 
bridge. Penocin A, acidicin and aquaticin lack a high degree of similarity to each other and the other 
bacteriocins produced.   
Through analysis of the data from previous in silico bacteriocin screens there is the potential to 
use these cloning systems to a far greater extent to increase the current repertoire of unmodified 




studies have analysed large amounts of genomic data from other sources to identify novel 
bacteriocins. Zheng et al. (Zheng et al., 2015) screened 700 shotgun metagenomic datasets from the 
Human Microbiome Project for the presence of bacteriocin operons. Of the 4875 putative 
bacteriocin genes found here, there were 3048 potential class II bacteriocins including 50 class IIa 
pediocin homologs, all of which represent potential candidates for use in this expression system. 
Similarly Alvarez-Sieiro et al. screened 238 genomes of lactic acid bacteria using BAGEL3, from this 
they identified 785 putative bacteriocin genes of which 514 encoded potential unmodified 
bacteriocin genes containing 31 class IIa homologs (Alvarez-Sieiro et al., 2016). Other such in silico 
screening studies have identified 209 further unmodified bacteriocin genes (Walsh et al., 2015, Liu et 
al., 2016, Azevedo et al., 2015, Kjos et al., 2011). While duplications and false positives are likely to 
occur in these datasets, even if a small proportion of these genes can be analysed using this 
expression system it represents a significant extension of the class II bacteriocins. 
Thus, whilst in silico genomic studies can lead to the identification of bacteriocins, often this  
research is not carried forward for the characterisation of these antimicrobials. The simple system 
used here outlines how bacteriocin genes identified through in silico screening of the Lactobacillus 
Genus Complex could easily be heterologously expressed. Bacteriocins which otherwise would not 
have been produced by the original strain due to tight regulation of the operon or loss of necessary 
genes were able to be produced and studied. Ten class IIa bacteriocins were studied here, nine of 
which were novel. Nine of these bacteriocins were produced and secreted by the PedD transporter, 
despite showing less than 30% identity to pediocin PA-1, which reflects the permissiveness of the 
transporter in secreting these peptides. These novel bacteriocins notably extend the group of class 
IIa bacteriocins, however these would likely not have been produced and analysed if not for the 
expression systems used here. This has allowed us to reincarnate these bacteriocin relics, and 
provides the capacity to identify and produce a vast range of novel bacteriocins identified by other in 





Materials and Methods 
Strains and Culture Conditions 
Bacterial strains and growth conditions used are displayed in Supplementary Table 2. E. coli 
HST08 StellarTM cells (Takara BIO USA, Inc., Mountain View, CA) were used for normal cloning 
methods, E. coli BL21 TunerTM (DE3) cells (Novagen, EMD Millipore, Billerica, MA) were used for 
expression of the transformed genes. E. coli strains were grown in Luria-Bertani (LB) media 
containing 50µg/ml of ampicillin for plasmid selection. IPTG (Isopropyl β-D-1-thiogalactopyranoside) 
(Fisher Scientific, Dublin, Ireland) was added to the growth media to induce gene expression. L-(+)-
arabinose and D -(+)-glucose (Sigma Aldrich, Arklow, Ireland) were also added to the media to 
control plasmid levels in recombinant cells. L. paracasei NFBC 338 cells were grown in modified MRS 
media containing 0.05% cysteine and 10μg/ml chloramphenicol (Sigma Aldrich, Arklow, Ireland).  
Molecular Cloning and Gene Expression  
Total genomic DNA was extracted from the bacteriocin encoding strains using the GenElute 
Bacterial Genomic DNA Kit (Sigma Aldrich, Arklow, Ireland). Primers were designed for amplification 
of the bacteriocins and transporter genes as outlined in the In-Fusion HD cloning protocol (Takara 
BIO USA, Inc., Mountain View, CA). For amplification of genes containing the bacteriocin along with 
the native leader sequence, the genes were amplified by PCR from the original genomic DNA of the 
host strain using CloneAmp Hifi PCR premix (Takara BIO USA, Inc., Mountain View, CA). Recursive 
PCR was used for the synthesis of fusion genes containing the pediocin PA-1 leader sequence joined 
to the bacteriocin structural gene (Prodromou and Pearl, 1992). In both cases, the fragment 
containing the transporter encoded gene (pedD) was amplified using pMPB1 pedD Fw1 and pMPB1 
pedD Rv1 using P.acidilactici LMG 2351 as a DNA template. The oligonucleotides used in this study 
are listed in Supplementary Table 3. PCR products were purified using the Illustra GFX PCR DNA and 




pMPB1 vector using In-Fusion HD cloning Plus. The pMPB1 vector is based on the commercial 
plasmid pETcocoTM-2 which allows a dual control of expression; at transcriptional level by IPTG 
induction and for amplification at the DNA replication level by L-arabinose (Sektas and Szybalski, 
2002).  
The constructions were transformed into StellarTM competent cells and colonies were selected 
on LB agar plates containing 50µg/ml of ampicillin and 0.2% D-glucose. The transformants were 
confirmed by colony PCR reactions. L-arabinose was used to increase the plasmid copy number in 
cells and plasmid DNA was isolated using the NucleoSpin plasmid kit (Macherey-Nagel, Duren, 
Germany) to be analysed subsequently by double digestion and sequencing. For bacteriocin 
expression, TunerTM (DE3) E. coli cells were transformed with the bacteriocin encoding vectors of 
interest. The transformants were then grown in LB containing 50µg/ml of ampicillin and 0.2% 
glucose which maintains the plasmid in a single copy state. Once cells had grown to an OD600 of 0.5-
0.7, IPTG was added at a concentration of 50 µM to induce expression of the bacteriocin genes. 
For expression in L. paracasei NFBC 338 the pNZ44 plasmid was used which contains the p44 
constitutive promoter. Each bacteriocin was cloned containing the pediocin promoter and the pedD 
transporter, PCR fragments were amplified from positive StellarTM transformants using the pNZ44 
pedA FW and pNZ44 pedD RV oligonucleotides. These were inserted into the linearized NcoI-HindIII 
pNZ44 vector using In-Fusion HD cloning Plus. Constructions were cloned into StellarTM competent 
cells and confirmed as before. For expression, L. paracasei NFBC 338 cells were transformed with the 
bacteriocin-containing plasmids by electroporation. Transformants were grown overnight in MRS 
containing  0.05% cysteine and 10μg/ml of chloramphenicol. 
Bacteriocin Assays 
Bacteriocin activity was determined using WDAs. For TunerTM (DE3) E. coli transformants both 




supernatants were analysed for L. paracasei NFBC 338 cells. Cell supernatants were isolated by 
centrifugation of the liquid cultures at 4000 RCF for 15 minutes, these supernatants were then 
filtered using 0.20 µm membrane filters. For cell lysates, cell pellets were resuspended in 5 ml of 
phosphate-buffered saline (PBS), cells were lysed by sonication using a MSE Soniprep 150 (MSE, 
London, UK). Lysates were subsequently centrifuged at 4000 RCF for 15 minutes and the resulting 
supernatants were filtered using 0.20µm membrane filters. For the indicator plates, 50µl of an 
overnight culture of the indicator strain was added to the appropriate media containing 1% agar. 
Plates were cooled and 7mm wells were bored in the agar. 50μl of the cell supernatants/lysates 
being tested were added to each well and plates were refrigerated for 2 hours prior to incubation 
under the appropriate conditions. WDAs were carried out in triplicate for each bacteriocin. 
Bacteriocin Purification and Mass Spectrometry   
Purification and analysis was carried out for bacteriocins encoding the pediocin PA-1 leader 
sequence from TunerTM (DE3) E. coli transformants. 85ml of each culture supernatant was applied to 
2ml SP sepharose columns (GE Healthcare, UK) pre-equilibrated with 25ml 20mM potassium 
phosphate buffer 25% acetonitrile, pH 2.5. Columns were washed with  20ml 20mM potassium 
phosphate buffer 25% acetonitrile, pH 2.5, the bacteriocins analysed eluted from columns with 25ml 
20mM potassium phosphate buffer 25% acetonitrile containing 2 M KCl, pH 2.5. Eluents were passed 
through a 6ml, 500mg Strata–E C18 SPE column pre-equilibrated (Phenomenex, Cheshire, UK) with 
methanol and water. The column was washed with 6ml 30% ethanol and then 6ml 70% 2-propanol 
0.1 TFA (IPA). MALDI TOF colony mass spectroscopy was carried out on the eluents using an An 
Axima TOF2plus MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) in positive-ion 






















Antimicrobial activity is calculated as the radius of the zone of inhibition from a well diffusion assay 
measured in millimetres. PedA, pediocin PA-1. Acd, acidicin. RenB, rennicin B. Hrd, hordeiocin. Ped 
20336, pediocin 20336a. Aqu, aquaticin. RenA, rennicin A. PenA, penocin A. Fut, futcin. Rum, 





Table 3. Bacteriocin Activity (BU/ml) vs L. innocua DPC3572 
 
E. coli Tuner (DE3) L. paracasei NFBC338 
PedA + ++ 
RenA + + 
Rum +++ +++ 
Agl ++ ++ 
Aqu - - 
RenB - + 
Acd - - 
Ped 20336 + + 
Fut + - 
Hrd +++ ++ 
PenA ++ + 
 
Bacteriocin units per ml (BU/ml) were calculated as the inverse of the highest dilution of bacterial 
supernatant showing activity against L. innocua DPC3572 in a well diffusion assay. + = 0 – 160 BU/ml, 







*MCS, multiple cloning site. Apr, ampicillin resistant. Clr, chloramphenicol resistance. PL, pediocin 





Supplementary Table 2. Bacterial Strains and Growth Conditions 
Species Strain Growth Media Temp. (˚C) Conditions 
Bacteriocin Encoding Strains 
    Lactobacillus acidipiscis DSM 15836 MRS 30 Anaerobic 
L. agilis DSM 20509 MRS 37 Anaerobic 
L. aquaticus DSM 21051 MRS 37 Anaerobic 
L. futsaii JCM 17355 MRS 30 Aerobic 
L. hordei DSM 19519 MRS 30 Anaerobic 
L. rennini DSM 20253 AAM 30 Aerobic 
L. ruminis DSM 20403 MRS 37 Anaerobic 
Pediococcus acidilactici  LMG 2351 MRS 30 Aerobic 
P. pentosaceus DSM 20336 MRS 30 Aerobic 
Host Strains 
    Escherichia coli HST08 Stellar
TM
 LB 37 Aerobic 
E. coli BL21 Turner
TM 
(DE3) LB 37 Aerobic 
L. paracasei NCC 338 mMRS 37 Anaerobic 
Indicator Strains 
    Bacillus cereus  DPC 6087 BHI 37 Aerobic 
Enterococcus faecalis LMG 7397 MRS 37 Anaerobic 
E. faecium DPC 4898 MRS 37 Anaerobic 
E. saccharolyticus DPC 4902 MRS 37 Anaerobic 
E.mundtii LMG 10748 MRS 37 Anaerobic 
L. amylophilus DSM 20509 MRS 30 Aerobic 
L. amylovorus DSM 20531 MRS 37 Anaerobic 
L. apodemi DSM 16654 MRS 37 Anaerobic 
L. bulgaricus LMG 6901 MRS 37 Anaerobic 
L. crustorum JCM 15951 MRS 30 Aerobic 
L. delbrueckii indicus DSM 15996 MRS 37 Anaerobic 
L. delbrueckii lactis LMG 7942 MRS 37 Anaerobic 
L. farraginis DSM 18382 MRS 30 Anaerobic 
L. ingluvei DSM 15946 MRS 37 Anaerobic 
L. intestinalis DSM 6629 MRS 37 Aerobic 
L. kimchicus JCM 15530 MRS 37 Aerobic 
L. mali DSM 20444 MRS 30 Aerobic 
L. nodensis DSM 16982 MRS 30 Anaerobic 
L. paralimentarius DSM 13961 MRS 30 Anaerobic 
L. plantarum DSM 13273 MRS 37 Aerobic 
L. salivarius DPC 6502 MRS 37 Anaerobic 
Leuconostoc fallax DSM 20189 MRS 30 Aerobic 
Listeria innocua DPC 3572 BHI 37 Aerobic 
Li. monocytogenes  DPC 6893 BHI 37 Aerobic 
Li. monocytogenes DPC 6894 BHI 37 Aerobic 
Li. monocytogenes WSL 1416 BHI 37 Aerobic 
Pseudomonas aeruginosa APC 2064 BHI 37 Aerobic 
Pediococcus ethanolidurans DSM 22301 MRS 37 Anaerobic 
P. stilesii DSM 18001 MRS 30 Anaerobic 
P. clausenii DSM 14800 MRS 30 Aerobic 
Staphylococcus aureus C55 BHI 37 Aerobic 





Supplementary Table 3. Primers Used 
Primer Name Sequence 
pMPB1 pedA Fw1   AGAAGGAGATATAAGCATGAAAAAAATTGAAAAATTAACTG 
pedApedD Rv1 CAAAACCATATTAACCAGGTGATTATTGATGCCAGCTCAG  
pMPB1 renA Fw1 AGAAGGAGATATAAGCATGTTAAGTAAAGAAGAGCTAAC   
renApedD Rv1 CAAAACCATATTAACCAGGTGATTAGCATTTATGATTTCC 
pMPB1 penA Fw1 AGAAGGAGATATAAGCATGACTGAAATTAAAGTACTAAACG 
penApedD Rv1 CAAAACCATATTAACCAGGTGATTATCTATGTGCCCAAGGCCCG 
pMPB1 hrdAFw1 AGAAGGAGATATAAGCATGAAGAAAGAAATAGAATTGTCAG 
hrdApedD Rv1 CAAAACCATATTAACCAGGTGATTAACAATTACCATGGCCAAAATTTG 
pMPB1 acdA Fw1 AGAAGGAGATATAAGCCTATCTTTAGAAGAGTCTAGTAG 
acdApedD Rv1 CAAAACCATATTAACCAGGTGATTAATGTCGGCCTACTCCAGCAG 
pMPB1 futA Fw1 AGAAGGAGATATAAGCATGAAAGGGAGATATGTCAATATG 
futApedD Rv1 CAAAACCATATTAACCAGGTGATTAATGTTGGCGTAATCCTGTTAATC 
pMPB1 aglA Fw1 AGAAGGAGATATAAGCATGAGTGATAAAATGGAAAACAAG 
aglApedD Rv1 CAAAACCATATTAACCAGGTGATTAGCAGTTACCATGACCAAAGTTG 
pMPB1 aquA Fw1 AGAAGGAGATATAAGcATGAATGGAGGAAAAAATTATGG 
aquApedD Rv1 CAAAACCATATTAACCAGGTGATTACTTGCTTTTCCATCCTGCAG 
pMPB1 rumA Fw1 AGAAGGAGATATAAGCATGAGACAACTTTCCGAAAAAG 
rumApedD Rv1 CAAAACCATATTAACCAGGTGATTAGCAATGGCCGATTGTAGCC 
pMPB1 pedD Fw1 TCACCTGGTTAATATGGTTTTGTAACCAATGTAAAAGG 
pMPB1 pedD Rv1 GCTCGAGTGCGGCCTAGGCTATTCTTGATTATGAATTAACC  
pNZ44 pedA Fw1 GGAGGCGCTTCCATGAAAAAAATTGAAAAATTAACTG 
pNZ44 pedD Rv1  GGTTCAAAGAAAGCTCTATTCTTGATTATGAATTAACC 
Recursive Primers 
 pMPB1 PedL Fw1 AGAAGGAGATATAAGCATGAAAAAAATTGAAAAATTAACTGAAAAAGAAATGGCCAATATCATTGGTGG 
PLrenA Rv2 CAACCGAGCAAGAATGCTTACTACACGAAACACCATTGCCATAATATTTACCACCAATGATATTGGCC 
PLrenA Fw3 GCATTCTTGCTCGGTTGACTGGGGTAAAGCTTTGACTTGTACCATTAATAATGGTGCAATGGCTTGG 
PLrenApedD Rv4 CCATATTAACCAGGTGATTAGCATTTATGATTTCCTTGGTGACCACCTGTGGTCCAAGCCATTGCACCAT 
PLpenA Rv2 CCACATAGCAAGTCTTTTTACCACAATGCACTCCGTTACCGTAATACTTACCACCAATGATATTGGCC 
PLpenA Fw3 AAAAGACTTGCTATGTGGACTGGGGACAAGCTACAGCTAGCATTGGAAAAATTATAGTGAACGGATGG 
PLpenApedD Rv4 CCATATTAACCAGGTGATTATCTATGTGCCCAAGGCCCGTGTTGTGTCCATCCGTTCACTATAAT 
PLhrdA Rv2 CCATGTTTCTTTGTACAGCTAACTCCATTTCCATAGTATTTCCCACCAATGATATTGGCC 
PLhrdA Fw3 CTGTACAAAGAAACATGGTTGCAAAGTAAATTGGGGACAAGCTTTCACTTGCAGCGTTAATCGT 
PLhrdApedD Rv4 CCATATTAACCAGGTGATTAACAATTACCATGGCCAAAATTTGCAAAACGATTAACGCTGCAAGT 
PLacdA Rv2 CCCCAATTAATATATGGTTTTCCATGTTTAGGAATATGAAGACCATTACCATAGTATTTGCCACCAATGATATTGGCC 
PLacdA Fw3 ACCATATATTAATTGGGGACAAGCTATACAATCAATAGGCAAAATTTCATACCATGGTTGGGTTAATGGT 
PLacdApedD Rv4 CCATATTAACCAGGTGATTAATGTCGGCCTACTCCAGCAGCGCCACTAGTTATACCATTAACCCAACCATG 
PLfutA Rv2 CCAGTTTACTTTACATGTATGTTTTCCACAAGAAACTCCGTTACCGTAGTACTTACCACCAATGATATTGGCC 
PLfutA Fw3 ACATGTAAAGTAAACTGGGGACAAGCCTGGAACGAAAGTGTTAATCGTTGGGGTAATTCATGGGT 
PLfutApedD Rv4 CCATATTAACCAGGTGATTAATGTTGGCGTAATCCTGTTAATCCATTTACCCATGAATTACCCCAA 
PLaglA Rv2 CTTATGTTTGCCACAAGTAATACCGTTACCATAATATCTACTTCCACCAATGATATTGGCC 
PLaglA Fw3 ACTTGTGGCAAACATAAGTGCACAGTTAACTGGGGGCAAGCTTGGACTTGCGGAGTTAAC 
PLaglApedD Rv4 CCATATTAACCAGGTGATTAGCAGTTACCATGACCAAAGTTGGCAAGGCGGTTAACTCCGCAAGTCCA 
PLaquA Rv2 CTACTTTATAACCATGCTTTTTTGTACAGTAGACTCCATTTCCATAATTTTTTCCACCAATGATATTGGCC 
PLaquA Fw3 GCATGGTTATAAAGTAGACTGGGGACAGGCTTGGTCAATTATTGGGAACAATTCGGCAGCGAATTCG 
PLaquApedD Rv4 CCATATTAACCAGGTGATTACTTGCTTTTCCATCCTGCAGCTCCACGAGTTGTCGAATTCGCTGCCGAATT 
PLrumA Rv2 CACGCGGCACTTGTGCTTGCCGCAGTAAACGCCGTTTCCATAATACTTGCCACCAATGATATTGGCC 
PLrumA Fw3 AAGCACAAGTGCCGCGTGGACTGGGGACAGGCATGGGGATGCAGTGTCAACAGATGGGGCGCCGCAGTA 
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As the spread of antibiotic resistance continues, the risks associated with microbial 
infections are becoming of much greater concern. The need for new therapies for the prevention 
and treatment of such infections is clear, but the development of novel antimicrobials and new 
pipelines has dwindled (Burki, 2017). Bacteriocins are one class of antimicrobials which have been 
generally overlooked when it comes to tackling the issue of antibiotic resistance. These 
antimicrobial peptides can exhibit potent inhibitory activity, often against clinically important 
pathogens even at  nanomolar concentrations (Cotter et al., 2013). A narrow spectrum of 
antimicrobial activity for some bacteriocins allows them to target specific pathogens with minimal 
collateral damage to the host microbiome (Rea et al., 2011). The in situ production of bacteriocins 
by probiotic bacteria or members of the host microbiome also forms the basis for treatment and 
prevention of intestinal infections (Corr et al., 2007).  
Whilst the use of alternative antimicrobials such as bacteriocins and organic acids remains 
negligible in medicine, the use of cultures which produce these antimicrobials for the safe 
preservation of foods has been established for millennia (Ross et al., 2002). In particular, the lactic 
acid bacteria (LAB) have a long association with food preservation, having important functional and 
protective roles in the production of fermented foods such as yoghurt, cheese, sauerkraut and 
kimchi. These LAB have been shown to produce a range of metabolites which can lead to the 
inhibition of potential spoilage microbes. Organic acids are a by-product of LAB metabolism which 
lowers the pH of the food source, thus inhibiting the growth of spoilage microbes while also 
modulating the flavour of the food (Rhee et al., 2011). Bacteriocins offer a much more targeted 
approach for enhancing food safety. Bacteriocins can be introduced into fermented foods either by 
in situ production by starter cultures, or else by the exogenous addition of crude fermentates or 
purified bacteriocins (Cotter et al., 2005). Nisin, for example, was awarded generally regarded as 
safe (GRAS) status by the FDA in 1988, and the safe commercial use for decades of this lantibiotic as 
a food preservative demonstrates the potential of such antimicrobials for wide-scale use in industry 




In this study we utilised a variety of mechanisms for the identification and characterisation 
of novel bacteriocins and antimicrobials. Traditionally large microbial screening studies were 
performed against a range of target organisms to identify in vitro antimicrobial activity. As genomic 
sequencing has become more affordable and prevalent, current antimicrobial screens can take an in 
silico-based approach using genomic searches. These genomic screening methods allow for a much 
more targeted approach for the identification of new antimicrobials. It is much less labour intensive 
compared to traditional colony screening, with a much higher success rate. The issue with genomic 
screening, however, is that these homology-based searches depend on the sequences of previously 
characterised antimicrobials, meaning that novel classes of antimicrobials may be overlooked due 
to their lack of similarity to previously characterised genes. Also, antimicrobials identified in large in 
silico screens are often not produced when tested in vitro, which can result a failure to characterise 
these potentially useful molecules. Here, we utilised both in silico and in vitro approaches for the 
identification and characterisation of bacteriocins and discuss their benefits and drawbacks.  
In Chapter 2, traditional colony-based screening was used to isolate an antimicrobial-
producing strain, Bacillus paralicheniformis APC1576. A wide number of colonies were initially 
isolated from the intestine of marine fish, which were then screened against a Lactobacillus 
bulgaricus strain to identify antimicrobial production. The fact that only one strain out of the 
thousands screened was identified as producing a novel bacteriocin demonstrates the low success 
rate of colony-based screening. Once this strain was identified as producing a novel antimicrobial, 
genomic sequencing of the strain was still required to identify the bacteriocin produced, formicin. 
Due to the high level conservation seen amongst the class of two-peptide lantibiotics, the 
bacteriocin genomic screening tool BAGEL easily identified this novel bacteriocin (de Jong et al., 
2010). This study shows how traditional screening methods still have a place for the identification of 
novel antimicrobials, however, the combination of these methods with in silico screening provides a 




In Chapter 3 we adopted this targeted approach, using the genomic data of strains 
composing the Lactobacillus Genus Complex to screen for new bacteriocins and bacteriolysins. The 
BAGEL screening tool was used for the identification of bacteriocins encoded within the genomes of 
these strains (de Jong et al., 2010). Many of these strains have been long investigated for 
bacteriocin production, often due to their association with food preservation. Through in silico 
screening, this study provided an excellent overview of the genetic capacity of these strains to 
produce bacteriocins. We combined this with functional screening for antimicrobial production 
against a range of indicator organisms, this resulted in the identification of five novel bacteriocins. 
While these bacteriocins require further study and characterisation, some do offer potential 
industrial uses. Paralimenterocin, for example, can inhibit the growth of certain enterococci, and as 
the encoding strain was initially isolated from kimchii, it may have a protective role as a starter 
culture in the fermentation of vegetables. The combination of the initial genomic screen followed 
by the functional screen greatly increased the success rate in the identification of these novel 
bacteriocins. This approach is more efficient method for identifying new antimicrobials, cutting 
down the number of cultures to be screened through initial genomic homology-based searches. 
In Chapter 4, we attempted overcame one of the main hurdles associated with genomic-
based screening, which is the failure of many strains to produce the bacteriocins encoded within 
their genomes. Bacteriocin synthesis can be an energetically costly task for many bacteria, thus their 
production is often under tight regulation by the encoding strain (Uzelac et al., 2015). In the case of 
several of the bacteriocins identified here however, many key genes required for the synthesis and 
transport of the peptides were missing from the bacteriocin operon. To overcome the inability of 
such strains to produce a bacteriocin we used a heterologous expression system in which the 
pediocin PA-1 ABC transporter was cloned alongside a range of novel pediocin-like bacteriocins. We 
were able take advantage of the high degree of homology within this pediocin-like bacteriocin 
subclass. Of the novel class IIa bacteriocins identified from the Lactobacillus Genus Complex, their 




associated transporter has the ability to secrete these new bacteriocins from the cells. Whilst this 
system works well for the class IIa bacteriocins, further work is required to determine the 
effectiveness of such an approach using different classes of bacteriocins. The study does show, 
however, how the in silico identification of novel antimicrobials can be translated into biological 
production using the correct expression systems. The benefits of this approach are shown in the 
fact that some of these class IIa bacteriocins expressed heterologously display a greater range of 
antimicrobial activity compared to pediocin PA-1, a commercially used bacteriocin.  
A microbiome-based approach was used in Chapter 5 for the characterisation of microbial 
communities found in the intestinal tracts of deep-sea fish, as well as identifying their potential 
ability for the production of secondary metabolites. Whilst the production of antimicrobials is one 
mechanism by which microbes can influence the microbiome, often it is larger scale environmental 
changes which control which species occupy any given niche. This is seen with the potential 
identification of a link between the diet of the host and the metabolic capabilities of the microbes 
they harbour within their gut. The screen for genes related to the production of secondary 
metabolites shows the potential diversity of natural products which may be synthesised in the 
microbiome of these fish. Given how these bacteria display such adaptions to their environment, 
their apparent lack of resistance towards common antibiotics suggests that any natural products 
encoded within these communities may be highly novel. Studies such as this, however, need to be 
followed up with the heterologous expression of the identified operons, or the isolation of microbes 
from the source which can then be screened for in vitro antimicrobial production. 
Taken together, this thesis outlines several approaches which can be used for the identification 
of novel antimicrobials. Reliance solely on either traditional or in silico screening methods limits the 
possibility of a successful outcome. Traditional wet lab screening is made much more efficient when 
combined with initial genomic screens, the only downside of which is the potential oversight of 




not followed up by the expression and characterisation of the antimicrobial produced, offers little 
benefit when trying to develop new therapies targeting antibiotic resistant microbes. We show that 
when combined correctly, these approaches can lead to the identification of a range of new 
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